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Gamma-aminobutyric acid type B (GABAB) receptor is a G protein coupled 
receptor (GPCR) that mediates decreased neural activity. It has two subunits, GABAB1 
and GABAB2. Previous complementary DNA (cDNA) microa ray data showed strong 
GABAB1 signals from human prefrontal cortex using an intron 4 region probe, and these 
studies indicated that novel intron 4 containing GABAB1 splicing variants exist. We 
cloned GABAB1k, l, m, and n including mouse GABAB1j. Expression of these variants 
are much lower than other major known splicing variants, but GABAB1k, l, m, and n 
levels are similar across brain tissues. GABAB1l and GABAB1m impair GABAB 
receptor induced function. To better define GABAB1 splicing in alcoholic brains, whole 
transcriptome shortgun sequencing (RNA-seq) experiments were proposed. Due to the 
complexity of GABAB1 splicing, we used gene specific libraries as well as whole 
transcriptome libraries to maximize GABAB1 specific splicing junction search. The 
splicing junction search data found that GABAB1 gene is 2 to 3 times longer than the 
 vii  
previous known gene length. Extremely low expression at 5’ end exons was found, and 
GABAB1 exons were grouped based on expression levels. Chronic alcohol altered 
exon/intron expression and splicing junctions more than overall gene expression. 
Decreased exon expression at a GABA binding site, a ransmembrane domain (TM), and 
a microRNA (miRNA) binding site may diminish the normal GABAB1 transcript 
population and compromise signal transduction following chronic alcohol exposure. This 
may explain why GABAB receptor agonists have theraputic benefit in treating 
alcoholism. During the sequence mapping, read pile-ups and gaps were found from whole 
transcriptome libraries in known exons. These may prevent single nucleotide 
polymorphism (SNP) and splicing junction identificat on and gene expression 
calculations. Sequence analysis found sequence biass from their mapped reads. The 
major sequence biases were from RNaseIII RNA fragmentation and T4 polynucleotide 
kinase (T4PNK) reaction. Heat fragmentation and OptiKinase treatment removed the 
read pile-ups and gaps including the sequence biases. The identification of RNaseIII 
target sequences can be incorporated into methods of miRNA gene prediction. These data 
showed the complexity of GABAB1 receptor splicing and the perturbation of splicing by 
chronic alcohol abuse demonstrate the power of RNA-seq to provide new insight into 
gene expression and the role of GABAB receptors in alcoholism. In addition, many other 
important brain genes may have unexplored splicing variants which will be important for 
alcoholism and other psychiatric diseases. Also, new RNA-seq library constructions 
improved the quality of gene expression studies. 
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CHAPTER 1. INTRODUCTION 
 
1.1 ALCOHOL AND ALCOHOLISM 
Alcohol was discovered as a fermented beverage as early as 10,000 B.C. and was 
commonly used in many cultures. Evidence of alcoholic beverage use has been found 
from all over the world, for example Persia, Egypt, China, India, Babylon, Greece, and 
Rome. The geographical and sociological conditions affected the types of alcoholic 
beverages consumed (McGovern, Zhang et al. 2004; McGovern, Mirzoian et al. 2009; 
McGovern, Christofidou-Solomidou et al. 2010). 
Historically, doctors promoted alcoholic beverage drinking for health benefits and 
most recently for cardiovascular disease protection. Though there is the evidence of 
cardiovascular benefit from 1 - 2 drinks per day, the benefit is controversial (Sellman, 
Connor et al. 2009; Sinkiewicz and Weglarz 2009). However, there is a strong correlation 
between high level of alcohol usage and cardiovascul r disease, chronic pancreatitis, 
alcoholic liver disease, cancer, central nervous system (CNS) damage, and peripheral 
nervous system (PNS) damage. Long-tern alcohol usage in excessive amounts can 
damage nearly all organs in the body (Muller, Koch et al. 1985; Testino 2008). 
Excessive alcohol intake is one of the leading causes of death in the world today. 
One study showed that alcohol can be linked to one in very 25 deaths worldwide 
(Lopez, Mathers et al. 2006). In the United States, deaths resulting from alcohol abuse 
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reached about 100,000 (McGinnis and Foege 1993), and excessive alcohol usage is 
currently the third leading cause of death. About $200 billion is spent per year to treat 
alcohol abuse (Gordis 2000). 
There is no cure for alcohol addiction. Currently, here are a few drugs that have 
been approved for the treatment of alcoholism in the U.S., e.g. disulfiram, acamprosate, 
and naltrexone (Bouza, Angeles et al. 2004; Kenna, McGeary et al. 2004). Ondansetron, 
aripiprazole, topiramate, and baclofen also showed promising effects for chronic alcohol 
use (Bouza, Angeles et al. 2004; Johnson 2004; Kenna, McGeary et al. 2004; Enserink 
2011). However, the treatments are not successful for all patients, and molecular 
mechanisms of alcoholism are still undefined. 
 
1.2 ALCOHOL AND BRAIN DAMAGE 
The brain is one of the most sensitive organs to the toxic effects of chronic 
alcohol consumption. Excessive alcohol use can result in brain development impairment, 
lesion introducing dementia, cognitive disorder, and depression (Olegard, Sabel et al. 
1979; Neiman 1998; Pierucci-Lagha and Derouesne 2003; Heffernan 2008; Fergusson, 
Boden et al. 2009). Drinking during pregnancy can also impair brain development and 
cause fetal alcohol syndrome (FAS). Children with FAS have distinct facial features and 
small brains. The smaller brains have fewer neurons and lead to learning and behavior 
problems (Olegard, Sabel et al. 1979). 
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A severe consequence of long term heavy alcohol consumption is also associated 
with brain lesions. This brain damage is linked to a direct toxic effect of alcohol, alcohol 
withdrawal, and nutrient deficiency (Neiman 1998). Brain imaging studies showed 
significant loss of volume in alcoholic brains. Brain white matter was significantly 
correlated with the amount of alcohol consumption (Jensen and Pakkenberg 1993; Kril 
and Halliday 1999). One postmortem human brain study showed the reduction of 
neuronal area in several cortical brain regions, e.g. frontal cortex, motor cortex, and 
cingulate cortex (Kril and Harper 1989). 
Chronic alcohol consumption damages prefrontal cortex more than the other brain 
region. Selective neuronal loss in the prefrontal cortex was found in alcoholics (Kril and 
Harper 1989). Chronic alcohol induced cognitive disorder, such as planning ability 
especially in speed and flexibility, suggested prefrontal cortex damage (Flatscher-Bader, 
van der Brug et al. 2005; Yizhar, Fenno et al. 2011). The prefrontal cortex is involved in 
psychopathology (Alexander and Brown 2011; Yizhar, Fenno et al. 2011) and is 
connected to and regulates mesolimbic dopaminergic pathway. This pathway is involved 
in reward and is the primary site of the pharmacological action of alcohol and drugs of 
abuse. It projects from ventral tegmental area (VTA) to nucleus accumbens (NAc), 
amygdala, and prefrontal cortex. Alcohol and other drugs activate the mesolimbic 
dopaminergic pathway, and prefrontal cortex and theamygdala send excitatory 




Figure 1.1 Mesolimbic dopaminergic pathway. 
This mesolimbic dopaminergic pathway projects from VTA (ventral tegmental area) to 
NAc (nucleus accumbens) and prefrontal cortex. Green lines indicate connections in the 




1.3 GENE EXPRESSION CHANGES IN ALCOHOLIC PREFRONTAL CORTEX 
Genetic and environmental factors almost equally contribute to the development 
of alcoholism (Chao and Nestler 2004). Gene expression can be regulated by alcohol 
treatment in neuronal cells (Wilke, Sganga et al. 1994). Previous microarray studies 
showed gene expression changes in postmortem prefrontal cortex of alcoholics (Liu, 
Lewohl et al. 2004; Flatscher-Bader, van der Brug et al. 2005). As previously mentioned, 
prefrontal cortex regulates the mesolimbic dopaminergic pathway that is involved in 
reward. Therefore, gene expression changes in alcoholi  prefrontal cortex are of interest 
to better understand alcohol addiction. Previous microarray studies compared gene 
expression in alcoholic and non-alcoholic prefrontal cortices. One study detected 533 
alcohol responsive genes (Liu, Lewohl et al. 2006). Among the 533 genes, 27 were 
selected as candidate genes because they were previously identified as alcohol responsive 
genes in other microarray studies (Lavoie and Butterworth 1995; Lewohl, Wang et al. 
2000; Mayfield, Lewohl et al. 2002; Sokolov, Jiang et al. 2003; Flatscher-Bader, van der 
Brug et al. 2005). These genes were divided into 12 functional groups. Among the 
functional groups that were identified, cell adhesion, myelination, neural disease, and 
neurogenesis groups have more than three genes among the 27 genes. Alcoholism was 
more related to the neural disease group than the other groups. The neural disease group 
had Calpain 3, GABAB1, Transferrin, and Transketolase (Liu, Lewohl et al. 2006). 
Transketolase and GABAB1 were previously implicated in chronic alcoholism by other 
studies. 
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Among the candidate genes from the microarray studies, the GABAB receptor 
was of interest because several GABAB agonists are effective in alcohol withdrawal 
syndrome and promotion of alcohol abstinence and are cu rently being used for treating 
alcoholics (Krupitsky, Burakov et al. 1993; Addolorato, Leggio et al. 2006). Thus, 
GABAB1 was selected as a research target. 
 
1.4 GABAB RECEPTOR 
GABA and glycine are the major inhibitory neurotransmitters in vertebrate CNS. 
Both neurotransmitters bind to their respective receptors to activate chloride-sensitive 
channels. GABA receptors are also critical drug tarets for anticonvulsants, sedatives and 
anesthetics (Figure 1.2A). GABAA and glycine receptors (GlyR) are highly homologous; 
however, GABAA receptors are abundant in the cortex and cerebellum while GlyRs 
predominate in the spinal cord and brain stem (Langosch, 1995; Legendre, 2001). 
Another type of GABA receptor, the GABAB receptor, is highly expressed in brain and 
also expressed in heart, small intestine, uterus and the other tissues at lower levels 
(Calver, Medhurst et al. 2000). 
1.4.1 GABAB receptor function 
The GABAB receptor is a GPCR which decreases neural activity. The 
intracellular domain of GABAB1 dimerizes with GABAB2. GABA binds to the 
extracellular domain of GABAB1 and transfers signals through G proteins. G protein α 
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subunits are linked with adenylyl cyclase (AC), and G protein βγ subunits alter 
presynaptic Ca2+ channels and postsynaptic K+ channels. The GABAB receptor decreases 
the activity of AC and decreases neurotransmitter rel ase by inhibiting Ca2+ influx 
through presynaptic Ca2+ channels. At postsynaptic neurons, it activates postsynaptic K+ 
channels, and outward K+ current induces hyperpolarization and K+ equilibrium potential. 
Therefore, it prevents Na+ channel opening and action potential firing (Couve, Moss et al. 




Figure 1.2 GABA and GABAB receptor function. 
A. The chemical structure of GABA. B. The function of GABAB receptor. The 
intracellular domain of GABAB1 dimerizes with GABAB2. It inhibits AC and 
presynaptic Ca2+ channel. It enhances postsynaptic K+ channel. Thus, GABAB receptor 
decreases neural excitability. (modified from Couve et al, 2000) 
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1.4.2 GABAB1 splicing variants 
GABAB1 has two major splicing variants (GABAB1a and b) in human CNS. 
GABAB1a is the longest splicing variant and has 23 exons (Figure 1.3A). GABAB1b is 
an N-terminal truncated form of GABAB1a, and its alternative N-terminal is from intron 
5 of GABAB1a. GABAB1a and b are the most widely studied. GABAB1a appears to be 
mainly presynaptic and coupled with Ca2+ channels. GABAB1b might be a postsynaptic 
receptor and linked with K+ channels. However, their localization and functions are not 
clear (Couve, Moss et al. 2000; Billinton, Ige et al. 2001). GABAB1c has no exon 4 of 
GABAB1a, and GABAB1d has a partial deletion of exon 23. The functions of 
GABAB1c and d have not been well studied (Isomoto, Kaibara et al. 1998). GABAB1e is 
mainly expressed in peripheral tissues. Because it has no exon 15, it is a C-terminal 
truncated form of GABAB1a. It prevents GABAB1a and GABAB2 heterodimerization 
(Schwarz, Barry et al. 2000). In rats, there is one more GABAB1 isoform, GABAB1j, 
expressed as highly as GABAB1a and b in CNS. It has only exons 1 through 4 and 3’ 
intron 4 of GABAB1a. Therefore, it is a very small C-terminal truncated GABAB1 
isoform. It binds to neuronal membranes, and its purified sushi domains impair the 
inhibitory effect of the GABAB receptor in whole cell patch clamp experiments (Figure 




Figure 1.3 GABAB1 splicing variants. 
A. Exon and intron structures of GABAB1 splicing variants. Human GABAB1 splicing 
variants are GABAB1a, b, c, d, and e. GABAB1j exists in rats. Black lines are open 
reading frames (ORFs), and grey lines indicate untranslated regions (UTRs). Thick and 
thin lines represent exons and introns, respectively. B. Functional domains of GABAB1 
splicing variants. GABAB1 functional domains are sushi domains, GABA binding sites, 
TMs, and C-terminal intracellular domain. Thick lines are ORFs of GABAB1 splicing 
variants, and bent thin lines are for splicing outs. Dashed lines represent UTRs. 
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1.4.3 GABAB1 functional domains 
GABAB1 has three major functional domains, e.g. GABA binding sites, TMs, 
and C-terminal intracellular domain (Figure 1.3B). These are common domains for two 
major splicing variants, GABAB1a and b. GABAB1 has a long extracellular region. It 
has three GABA binding sites, Ser359, Tyr479, and Asp584 of GABAB1a, and they are 
located at exon 7, 10, and 12, respectively. G proteins bind to an intracellular region 
between TM 3 and TM 4 for signal transduction. C-terminal intracellular domain has a 
GABAB1 and GABAB2 dimerization region as well as an activating transcription factor 
4 (ATF4) interaction region. Two sushi domains are t xon 3 and 4 (Couve, Moss et al. 
2000). 
Though GABAB1a contains all of the domains, N-terminal truncated GABAB1b 
does not have sushi domains (Couve, Moss et al. 2000). GABAB1c has only one sushi 
domain due to exon 4 that has been spliced out. The splicing out of 5’ exon 23 provided 
GABAB1d with a short C-terminal intracellular domain (Isomoto, Kaibara et al. 1998). 
GABAB1e does not have TM and C-terminal intracellular domains (Schwarz, Barry et al. 
2000). Rat GABAB1j has only sushi domains (Tiao, Bradaia et al. 2008) (Figure 1.3B). 
1.4.4 GABAB receptor and alcoholism 
GABAB receptor studies showed a strong link between th  GABAB receptor and 
alcoholism. The positive allosteric modulator, GS39783, suppresses alcohol drinking and 
reinforcement in rats (Maccioni, Fantini et al. 2008). A GABAB receptor agonist, 
gamma-Hydroxybutyrate (GHB), reduces voluntary ethanol drinking and withdrawal 
symptoms and is used as a treatment for alcoholism. GHB decreases inhibitory synaptic 
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transmission via GABAB receptors in CA1 of hippocampus (Schweitzer, Roberto et al. 
2004; Maccioni, Pes et al. 2008). Baclofen is another GABAB receptor agonist and is 
also used to treat alcoholism (Enserink 2011). In electrophysiology studies, ethanol 
potentiation of Cl- conductance required activation of both GABAA and GABAB 
receptors based on treatment with the GABAA antagonist, bicuculline, or GABAB 
antagonists, phaclofen or 2OH-saclofen (Allan, Burnett et al. 1991). This indicated that 
GABAB receptors are also involved in ethanol’s mechanism of action. 
From two previous microarray experiments, GABAB1 expression was increased 
in human prefrontal cortices from alcoholics (Flatscher-Bader, van der Brug et al. 2005; 
Liu, Lewohl et al. 2006). GABAB1 is also involved in behavioral actions of ethanol. In 
Drosophila, both GABAB1 RNA interference (RNAi) and the GABAB receptor 
antagonist, CGP 54626, reduced the behavior impairing effects of ethanol (Dzitoyeva, 
Dimitrijevic et al. 2003). 
However, other electrophysiological studies using GABAB receptor antagonists 
showed that an ethanol effect on GABAB receptors is controversial. In hippocampus 
pyramidal neurons (HPNs), GABAergic inhibitory postsynaptic potentials (IPSPs) were 
enhanced by low ethanol concentrations only after application of the GABAB antagonist, 
CGP-35348 (Wan, Berton et al. 1996). Another GABAB receptor antagonist, CGP 
55845A, did not change the ethanol enhancement of IPSPs and inhibitory postsynaptic 
currents (IPSCs) in central amygdala nucleus (CeA) neurons (Roberto, Madamba et al. 
2003). Therefore, GABAB receptor involvement in ethanol actions may vary with 




1.5.1 Splicing overview 
Splicing is a RNA modification after transcription, which removes introns and 
joins exons. For many eukaryotic RNAs, most splicings are done in a series of reactions 
of spliceosome, a complex of small nuclear ribonucleoproteins (snRNPs). Within introns, 
there are three conserved sites for splicing, e.g. a 5’ splice site, a 3’ splice site, and a 
branch site (Figure 1.4). The 5’ splice site, a splicing donor, includes a conserved 
sequence, GU, at the 5’ end of introns. The 3’ splice site is called a splicing acceptor and 
is terminated with mostly AG sequence. Upstream from this pyrimidine rich region is the 




Figure 1.4 Splicing sites. 
Spliced introns contain several important and conserved sites for splicing. A 5’ splice site 
has 5’ GU sequence, a branch site, A, located near a py imidine rich region (Py), and a 3’ 
splice site has 3’ AG sequence. 
(modified from http://www.hartnell.edu/tutorials/biology/splicing.html) 
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1.5.2 Splicing functions 
Splicing affects the function of splicing variants. A large number of splicing 
variants can either have novel functions or complete loss-of-function (Stamm, Ben-Ari et 
al. 2005). 
Splicing also determines the cellular localization of splicing variants. GABAB1a 
and GABAB1b localize specifically at pre- and post-synaptic locations, respectively 
(Vigot, Barbieri et al. 2006). Splicing alters membrane interaction and influences 
signaling. The splicing variants that lack membrane binding properties accumulate in the 
cytosol or are secreted into the extracellular space (Stamm, Ben-Ari et al. 2005). The 
newly located splicing variants can have different functions. C-terminal GABAB1 
splicing variants, GABAB1e and GABAB1j, lose membrane binding properties since 
they lack TMs. They inhibit other major GABAB receptor functions in both intracellular 
and extracellular spaces (Schwarz, Barry et al. 2000; Tiao, Bradaia et al. 2008). This 
phenomenon has been observed for splicing variants of other secreted genes that lose 
TMs by alternative splicing (Ezzat, Zheng et al. 2001; Bulanova, Budagian et al. 2007). 
Different splicing variants exist in specific tissues or cell types. A C-terminal 
truncated GABAB1 splicing variant, GABAB1e, is strongly expressed in peripheral 
tissues though other major GABAB splicing variants mainly exist in CNS (Schwarz, 
Barry et al. 2000). GABAB1a mostly expresses in granule cells, and an N-terminal 
truncated splicing variant, GABAB1b, is in Purkinje c lls (Billinton, Ige et al. 2001). 
Like GABAB1 splicing variants, spatially different localization patterns were also found 
from other N-terminal truncated splicing variants, including Cl-/HCO3
- exchanger 
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isoform anion exchange protein 2 (AE2), vitamin D receptor (VDR; a member of the 
nuclear hormone receptor superfamily that includes st roid, thyroid, retinoid, and orphan 
receptors), acetyl-CoA carboxylase-alpha, and P2 promoter-derived hepatocyte nuclear 
factor 4 alpha (HNF4 alpha) (Wang, Schultheis et al. 1996; Crofts, Hancock et al. 1998; 
Sunn, Cock et al. 2001; Travers, Vallance et al. 2003; Huang, Levitsky et al. 2009). 
The majority of splicing alterations result in loss-of-function. Mutation of a splice 
site can destroy spliceosome binding site. This prevents normal splicing mechanism and 
results in loss-of-function. This generates transcripts that contain undesired introns that 
often compromise gene function. Autosomal dominant spastic paraplegia patients have 
frequent splice site mutations in spastic paraplegia type 4 (SPG4) gene. The altered 
splicing causes loss-of-function of SPG4 in dominant spastic paraplegia (Patrono, Casali 
et al. 2002). 
1.5.3 Splicing regulators 
Splicing is not always conserved across species and is regulated by evolution. The 
vast majority of human splicing patterns in the expr ssed sequence tag (EST) database 
are not conserved in mouse (Yeo, Van Nostrand et al. 2005). The different splicings 
provide species specific phenotypes. Transient receptor potential cation channel 
subfamily V member 1 (TRPV1) of vampire bats shows a species specific splicing 
pattern in ganglia and generates infrared sensation (Gracheva, Cordero-Morales et al. 
2011). For GABAB1 gene splicing, human, mouse, and rat have their own unique 
splicing variants based on different splicing site equences at their introns (Billinton, Ige 
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et al. 2001; Wei, Jia et al. 2001; Tiao, Bradaia et al. 2008; Lee, Mayfield et al. 2010). 
Minor splicing variants produced by rare splicing events were less conserved in other 
genomes. The minor splicing variants were lost in one genome after divergence of the 
two genomes during evolution (Modrek and Lee 2003). 
Splicing can be regulated by development. Developmental stages provide unique 
cellular environments. The splicing of Sex-lethal (sxl) gene in female Drosohpila is 
regulated by developmental stages. The sxl splicing variants generated in the early 
embryogenesis stage masks a specific sxl gene splicing signal for the second intron in the 
late embryo resulting in a different splicing variant (SchuLtt, Hilfiker et al. 1998). 
Chemical signals also regulate splicings. Anticancer hemotherapeutic agents 
affect the splicings of Bcl-x gene and other 95 apoptotic genes (Shkreta, Froehlich et al. 
2008). Cocaine abuse regulates brain-derived neurotrophic factor (BDNF) splicing and 
changes its expression in brain (Liu, Lu et al. 2006). 
Chronic ethanol treatment is another splicing regulator. An N-Methyl-D-aspartate 
(NMDA) receptor subunit, NR2, is known as a potential target of alcohol action. Among 
NR2 splicing variants, chronic ethanol exposure specifically increased NR2B expression, 
and 18 hour withdrawal brought its expression back to normal (Hardy, Chen et al. 1999). 
Chronic ethanol exposure also increased 5’ splicing variant expression of another NMDA 
receptor subunit, NR1, though it had no effect on NR1 3’ variant expression (Hardy, 
Chen et al. 1999). L-type voltage-gated Ca2+ channel splicing variant expression was 
increased by chronic ethanol exposure (Walter, McMahon et al. 2000). One of the L-type 
voltage-gated Ca2+ channels, α1c, has two splicing variants, α1c-1 and α1c-2. Chronic 
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ethanol exposure specifically increased α1c-1 expression without affecting α1c-2 (Walter, 
McMahon et al. 2000). Large conductance Ca2+ activated K+ (BK) channel is a well-
established alcohol target. Different splicing variants of the BK channel have different 
alcohol sensitivity. Alcohol upregulates mir-9, a miRNA, and destabilizes BK splicing 
variants that have a mir-9 recognition element at the 3’ UTR (Pietrzykowski, Friesen et 
al. 2008). Therefore, chronic ethanol treatment changes specific alternative splicings 
resulting in increased or decreased splicing variant populations. 
1.5.4 GABAB1 splicing complexity 
Two previous cDNA microarray experiments showed the complexity of 
GABAB1 splicing. Their two probe sequences, NCBI accession numbers N80593 and 
W07715, were from one single probe, clone 300899. Its expression was increased in 
alcoholic brains (Figure 1.5A) (Flatscher-Bader, van der Brug et al. 2005; Liu, Lewohl et 
al. 2006). The probe was aligned to intron 4 of GABAB1a. This is a common intron 
region of the major human splicing variant isoforms (Figure 1.5B). Frequently, cDNA 
microarray probes were aligned to an intron region of specific genes and detected 
unknown splicing variants. The intron 4 probe could suggest the existence of other novel 
GABAB1 splicing variants. The increased expression detected by this probe after chronic 
alcoholism raises the possibility of enhanced expression of specific splicing variants of 
the GABAB1 gene. 
The previous microarrays had three GABAB1 microarray probes including clone 
300899, and they suggest complexity of GABAB1 gene splicing. Two out of three 
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GABAB1 probes were generated by unknown splicings. In addition to the clone 300899 
from intron 4 of GABAB1, clone 2312175 had an unknow  splicing out at exon 23 
(Figure 1.5C). Therefore, the probes also suggested th  existence of many unknown 
GABAB1 splicing variants and the overall complexity of GABAB1 splicing. The 
unknown novel alternative splicing variants could be important to understand brain 
changes in chronic alcoholism. 
Expression changes in brain tissue specific splicing variants also demonstrate the 
splicing complexity of GABAB1. One cDNA microarray experiment with human 
alcoholic brain used both prefrontal cortex and NAc (Flatscher-Bader, van der Brug et al. 
2005). They found that only 6 % of genes share commn expression patterns in both 
brain regions, and most genes showed different expression levels between the regions. 
They also found increased GABAB1 expression using clone 300899 in prefrontal cortex 
but not NAc (Figure 1.5A). Our Illumina oligo microarray data of ILMN_2395373 and 
ILMN_2395375 detected the expression level of splicing variants that have the 3’ end of 
the GABAB1 gene in four brain regions: prefrontal cortex, basal lateral amygdala (BLA), 
medial lateral amygdala, and CeA. The expression of ILMN_2395373 was decreased in 
alcoholic BLA but not in the other tissues (Figure 1.5A, C). ILMN_2395375 was aligned 
to the splicing out region of clone 2312175 (Figure 1.5C). However, expression of the 
two probes, ILMN_2395375 and clone 2312175, did not change significantly in any brain 
region of alcoholics though they target the same exon as ILMN_2395373 (Figure 1.5A). 
Therefore, in alcoholic brains BLA has less splicing variants containing specific 3’ end of 
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Figure 1.5 GABAB1 probes based on previous cDNA and Illumina oligo microarrays. 
A. Summary of previous cDNA and Illumina oligo microarray GABAB1 probes. Among 
three cDNA microarray probes, clone 2312175 and clone 300899 showed unknown 
splicing patterns. The expression of clone 300899 was increased in prefrontal cortex only, 
and the expression of ILMN_2395373 was specifically decreased in BLA. B. Probes in A 
were marked by colored asterisks based on the locations shown in B. C. The sequence 
alignment model of previous cDNA microarray probes (clone 298231 and clone 
2312175) and Illumina oligo microarray probes (ILMN_239373 and ILMN_2395375) at 
exon 23 of GABAB1a. Clone 2312175 has unknown 339 base pairs (bp) splicing out. 
ILMN_2395375 is aligned at the unknown splicing out region, and ILMN_239373 is 
aligned to 3’ UTR end. (-)s represent no expression change of probes in alcoholic brains, 
and (↓: BLA) is for expression decrease at BLA. 
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1.5.5 Splicing data limitation 
The NCBI database offers data sources to study GABAB1 splicing in brain. 
However, the database markedly underestimates splicing occurrences of the whole 
transcriptome (Fodor and Aldrich 2009). Splicing abundantly occurs in brain genes 
(Stamm, Ben-Ari et al. 2005), and more accurate splicing studies require another 
database construction using a high throughput sequencing technology, such as RNA-seq. 
 
1.6 RNA-SEQ 
1.6.1 RNA-seq overview 
RNA-seq is a next generation sequencing technique. This high throughput 
sequencing technique sequences cDNA to determine RNA content. It is currently 
replacing microarrays for study of gene expression (Lee, Seo et al. 2011). Unlike 
microarrays, it has no hybridization step and contains less systematic bias (Marioni, 
Mason et al. 2008; Lee, Seo et al. 2011). Though microarrays detect gene expression 
based on specific probes, RNA-seq can measure expression independent of probes, thus 
detecting all transcripts with less bias. In addition, its deep coverage and base level 
resolution also provide efficient ways to detect splicing junctions, SNPs, and gene fusions 
(Maher, Kumar-Sinha et al. 2009; Trapnell, Pachter e  al. 2009; Canovas, Rincon et al. 
2010; Shen, Catchen et al. 2011). 
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1.6.2 RNA-seq methods 
1.6.2.1 RNA-seq sequencers  
For RNA-seq, there are three major sequencers. They ar  Roche 454 genome 
sequencer, Illumina (Solexa) genome analyzer, and Sequencing by oligonucleotide 
ligation and detection (SOLiD) sequencer. 
Roche 454 genome sequencer was the first sequencer a d was developed by 454 
Life Sciences in 2004 (Shendure and Ji 2008). The library can be constructed with cDNA 
fragments flanked by two adaptors. For clonal amplification, the fragments are amplified 
by emersion PCR (ePCR), and each amplicon is captured by a single primer coated 28 
µm bead (Figure 1.6A). The sequencer has many picoliter volume wells each containing 
the bead and sequencing enzyme. The sequencing reaction uses luciferase and generates 
light to detect individual nucleotides. In 2008, the Roche 454 genome sequencer 
generated 400 - 600 million reads per run of about 400 - 500 bp read length (Table 1.1). 
This read length is the longest among the three sequencers. However, there are fewer 
Roche 454 genome sequencer users than Illumina genome analyzer or SOLiD sequencer 




Figure 1.6 Clonal amplifications of three major sequ ncers. 
A. ePCR for Roche 454 genome sequencer and SOLiD sequencers. B. Bridge 




Table 1.1 Comparison of RNA-seq among three sequencers. 
(modified from Mardis 2008) 
  
Roche 454 genome sequencer Illumina genome analyzer SOLiD sequencer
Amplification approach Emulsion PCR Bridge amplification Emulsion PCR
Paired end separation 3 kb 200 bp 3 kb
Mb per run 100 Mb 300 Gb 3000 Mb
Time per paired end run 7 hours 7-14 days 5 days
Read length (update) 250 bp (400 bp) 100 bp (50-100 bp) 35 bp (35-50 bp)
Cost per run $ 8,438 USD $ 11,750 USD $ 17,447 USD
Cost per Mb $ 84.39 USD $ 1.00 USD $ 5.81 USD
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Illumina genome analyzer was developed by Solexa in 2006, and it is currently 
the most popular sequencer for RNA-seq. To form clonal colonies, each adaptor ligated 
cDNA molecule is attached to a primer on a slide (Shendure and Ji 2008). It is amplified 
by the bridge amplification method (Figure 1.6B). During amplification, unlabeled 
nucleotides and enzyme were used. After denature the amplified molecules, first 
chemistry cycle determine first base using four labe ed reversible terminators. After a 
camera takes fluorescence images from the labeled nucleotides, the reaction is repeated to 
determine the sequence of bases (Mardis 2008). It generates about 200 million reads of 
75 - 100 bp (McPherson 2009). 
SOLiD sequencer was developed by Life Technologies in 2007. Like the Roche 
454 genome sequencer, ePCR is used for clonal amplification (Figure 1.6A). For its 
ePCR, 1 µm paramagnetic beads capture amplicons (Shendure and Ji 2008). Each bead 
contains the same cDNA molecule and is deposited onto a glass slide. The SOLiD 
sequencer employs sequencing by oligonucleotide ligation. Preferential ligation for its 
matching sequences generates a nucleotide signal at e ch position. Unlike the other two 
sequencers, it generates color signals. As the color signals encode dinucleotides, each 
base is encoded twice. As shown in the left hand table of Figure 1.7A, each color has 4 
possible combinations of the first and the second bases. For example, the combinations of 
red color are AT, CG, GC, and TA. If the first sequnce is A, color signals (red, green, 
blue, and yellow) encode the red circled dinucleotide. They indicate that the real 
nucleotide sequence is ATGGA (Figure 1.7B). The SOLiD sequencer can produce 400 
million reads of 50 bp length (McPherson 2009).  
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Figure 1.7 Color signals encoding at SOLiD sequencer. 
A. Four possible dinucleotides were encoded by each color. If a sequence starts with A, 
red, green, blue, and yellow color signals encode the red circled dinucleotides. B. The 
real sequence is ATGGA. (Modified from Mardis 2008) 
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1.6.2.2 RNA-seq library construction 
RNA-seq library construction methods vary for each sequencer. Most methods 
were generated using random primers for reverse transc iption (RT) (Cloonan, Forrest et 
al. 2008; Hansen, Brenner et al. 2010). Some customized methods were also designed 
based on research interests. For the RT step, libraries were primed using oligo(dT) 
primers or target specific primers (Li, Levanon et al. 2009; Yoon and Brem 2010). 
The RNA-seq libraries constructed using randomly primed RT can measure whole 
transcriptome expression. For the Illumina genome analyzer, mRNAs are extracted from 
total RNA using poly(T) magnetic beads (Morin, Bainbridge et al. 2008). After 
fragmentation of the mRNAs, cDNAs are synthesized by randomly primed RT. 
Sequencing is performed after adaptor ligation and amplification (Figure 1.8A). Though 
this method is the most popular method for RNA-seq library construction, it can lose 
non-coding RNA information from whole transcriptome expression data. For RNA-seq 
library construction using the SOLiD sequencer, ribosomal RNA (rRNA) depleted RNAs 
are prepared and fragmented. After adaptor ligation, cDNAs are generated by randomly 
primed RT. After size selection, the cDNAs are amplified and sequenced (Figure 1.8B) 
(Cui, Lin et al. 2010). This library construction can provide both mRNA and non-coding 
RNA expression data.   
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Figure 1.8 RNA-seq library constructions by randomly primed RT. 
A. RNA-seq library preparation for Illumina genome analyzer. B. RNA-seq construction 
for SOLiD sequencer. (Modified from Cui, Lin et al.2010)  
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RNA-seq libraries are also constructed to study 3’ and 5’ end sequences of whole 
transcriptome (Nagalakshmi, Wang et al. 2008; Yoon and Brem 2010). For library 
construction to generate 3’ end rich sequence data, polyA containing RNAs are selected 
after total RNA fragmentation. cDNAs are synthesized by oligo(dT) primers. After 
adaptor ligation and amplification, the library is sequenced (Figure 1.9A). To study 5’ 
end information of transcriptome, RNA-seq library is designed based on 5’ rapid 
amplification of cDNA ends (RACE) (Nagalakshmi, Wang et al. 2008). 
Target specific primers generate RNA-seq library for specific target transcript 
regions. For RNA editing study, padlock probes capture target cDNAs, and 
polymerization and ligation produce a circular cDNA library containing the target 
cDNAs. After amplification, the specific target region is sequenced (Figure 1.9B) (Li, 
Levanon et al. 2009). After comparing the sequencing data with genomic DNA 




Figure 1.9 RNA-seq library constructions using olig(dT) and target specific primers. 
A. RNA-seq library preparation by oligo(dT) primed RT. (Modified from Yoon and 
Brem 2010) B. RNA-seq library construction using target specific padlock probes for 
RNA editing. (Modified from Li, Levanon et al. 2009)  
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1.6.3 RNA-seq biases 
Though RNA-Seq has provided genome wide gene expression data, RNA-seq 
libraries can generate biases during library construction. The biases can distort expression 
data and prevent detections of SNPs and splicing juctions. RNA fragmentation, RT, and 
PCR amplification are known bias sources during RNA-seq library construction. For 
example, biased mapped read distributions are generated by fragmentations and RT 
primers. Randomly primed RT and PCR amplification result in sequence biases 
(Romaniuk, McLaughlin et al. 1982; Wang, Gerstein et al. 2009; Hansen, Brenner et al. 
2010; Metzker 2010; Willerth, Pedro et al. 2010). 
A biased mapped read distribution is generated from RNA-seq library 
construction using RNA fragmentation. This method uses randomly primed RT from 
fragmented RNAs (Figure 1.10) (Wang, Gerstein et al. 2009). After RNA fragmentation, 
about 200 bp RNA fragments are selected for library construction. However, 5’ and 3’ 
end containing fragments are mostly shorter than 200 bp and have less chance to be 
involved in the RNA-seq library construction. Therefor , fewer reads are mapped at the 
5’ and 3’ ends. RNA-seq library construction using cDNA fragmentation method also 
causes biased distribution (Figure 1.10). This method fragments the oligo(dT) primed 
cDNAs using sonication, and generates greater bias distribution compared to the RNA 
fragmentation method (Figure 1.10). It has extremely skewed mapped read distribution 
toward the 3’ end of transcripts and very few mapped r ads at the 5’ end. oligo(dT) 
primed RT usually cannot reach 5’ end of transcripts for long transcripts. cDNAs for 5’ 
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end transcripts are less cDNAs for 3’ end. This skewed cDNA distribution becomes even 




Figure 1.10 Mapped read distribution biases of RNA-seq libraries. 
The red line (RNA fragmentation) is for a RNA-seq library prepared using randomly 
primed RT after RNA fragmentation. The blue line (cDNA fragmentation) represents a 
RNA-seq library prepared using oligo(dT) primed RT. Its oligo(dT) primed cDNAs were 
fragmented for RNA-seq library construction. Tag count is the average sequencing 
coverage for 5,099 yeast gene ORFs. (from Wang, Gerstein et al. 2009) 
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Randomly primed RT also causes a sequence bias during RNA-seq library 
construction (Hansen, Brenner et al. 2010). All six RNA-seq library preparation methods 
for the Illumina genome analyzer introduced the same sequence bias (Figure 1.11A). The 
sequence bias was not related to RNA fragmentation. The random hexamers binding 
location is the starting 6 nucleotide positions of sequences data. From the starting point, 
about 10 nucleotide positions have severe sequence bias. 
PCR amplification has also been shown to generate sequence bias during RNA-
seq library construction (Willerth, Pedro et al. 2010; Aird, Ross et al. 2011). PCR 
amplified cDNA using target specific primers generat s reads containing significant 
homology with the primer. During library construction for the Illumina genome analyzer, 
PCR amplification depleted reads that have over 65 % GC ratio and diminished about 
90 % of reads that have less than 12 % GC ratio (Figure 1.11B) (Aird, Ross et al. 2011). 
To overcome the bias issues during RNA-seq library construction, new library 
preparation methods have been developed based on molecular biology techniques 
(Willerth, Pedro et al. 2010; Aird, Ross et al. 2011). Computational analyses also have 





Figure 1.11 Sequence biases. 
A. Sequence bias for RNA-seq library using randomly primed RT. Mapped reads were 
extended upstream and downstream of the first position of the actual read. The first 
position of the read is 1 at X-axis. Grey section (1 - 6 of X-axis) is the random primer 
binding location for RT, and six different libraries were compared. (modified from 
Hansen, Brenner et al. 2010) B. PCR amplification causes GC bias. (modified from Aird, 
Ross et al. 2011) 
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1.7 SPECIFIC AIMS 
The overall goal of this project is to study the splicing difference of human 
GABAB1 in non-alcoholic and alcoholic brains. The hypotheses are: 1) there are 
GABAB1 splicing variants yet to be identified; 2) chronic alcohol abuse alters GABAB1 
splicings; 3) less sequence biased RNA-seq libraries improve RNA-seq data quality for 
the splicing study. These experiments will define GABAB1 splicing in alcoholics and 
may lead to a better understanding of chronic alcohol action on the GABAB1 receptor. 
This plan includes three specific aims to be tested: 
Aim 1: Intron 4 containing novel GABAB1 isoforms impair GABAB receptor 
function 
Based on the analysis of previous microarray data, the existence of novel 
GABAB1 isoforms was predicted. After cloning of four new isoforms, GABAB1k, l, m, 
and n, their expression levels were evaluated. Their expression levels were much less 
than other known isoforms and similar in prefrontal cortex, frontal cortex, motor cortex, 
and total brain. Inhibitory actions of GABAB1l and m were identified using two-
electrode voltage clamp in Xenopus laevis oocytes expression system. 
Aim 2: Alcoholism correlates with GABAB1 splicing in human brain 
To better define GABAB1 splicing in human brains, gene specific RNA-seq study 
was performed. It found that the GABAB1 gene is at le st 2 to 3 times longer than the 
known GABAB1 gene and indicated that there are more short splicing variants than just 
GABAB1a, the longest known major transcript containing all known exons. Chronic 
alcohol altered exon/intron and splicing junction expression and decreased the population 
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of normal GABAB1 transcripts. This suggested the thrapeutic benefit of GABAB 
receptor agonists used in treating alcoholism. 
Aim 3: Use new RNA-seq library construction to solve RNaseIII and T4PNK 
sequence biases 
During the RNA-seq study, we found that unknown RNaseIII sequence biases that 
introduced duplicated mapped read pile-ups and gapsin known exons. To remove the 
biases, RNaseIII fragmentation was replaced with heat fragmentation using T4PNK and 
OptiKinase. The heat fragmentation removed the RNaseIII sequence biases and 
significantly reduced the pile-ups and gaps. OptiKinase minimized unexpected T4PNK 
sequence biases and removed all pile-ups and gaps. These also found unexpected 
sequence biases of RNaseIII and T4PNK. 
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CHAPTER 2. INTRON 4 CONTAINING NOVEL GABAB1 
ISOFORMS IMPAIR GABAB RECEPTOR FUNCTION 
 
2.1 INTRODUCTION 
The GABAB receptor is a metabotropic receptor that is highly expressed in brain 
and weakly expressed in heart, small intestine, uterus and other tissues (Calver, Medhurst 
et al. 2000). The functional receptor is a hetero-oligomer of GABAB1 and GABAB2 
subunits, where the intracellular domain of GABAB1 dimerizes with GABAB2. GABA 
binds to the extracellular domain of GABAB1 and transfers signals through G proteins. G 
protein α subunits are linked with AC, and G protein βγ subunits alter Ca2+ channels and 
G protein-activated inwardly rectifying K+ channel (GIRK) channels. The GABAB 
receptor decreases the activity of AC and decreases neurotransmitter release by inhibiting 
Ca2+ influx through presynaptic Ca2+ channels. At postsynaptic neurons, it activates K+ 
channels, and an outward K+ current induces hyperpolarization preventing Na+ channel 
opening and action potential firing (Couve, Moss et al. 2000). Thus, the GABAB receptor 
mediates an inhibitory neurotransmission. 
GABAB1 has two major splicing variants, GABAB1a and GABAB1b, in the 
human CNS. GABAB1a is the longest form and has 23 exons (Figure 2.1A). GABAB1b 
is an N-terminal truncated form of GABAB1a and has an alternative exon from intron 5 
resulting in a unique N-terminal without sushi domains (Figure 2.1A, B). GABAB1a and 
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b are the most widely studied isoforms to date and show some distinct expression patterns 
in brain as GABAB1a is more presynaptic in localization, and GABAB1b is more 
postsynaptic (Billinton, Ige et al. 2001; Bettler, Kaupmann et al. 2004; Gassmann, Haller 
et al. 2005). However, the differences in their loca ization and function are still not 
known precisely (Billinton, Ige et al. 2001). Additional splice variants of GABAB1 have 
been reported although some were found only in one species, and most do not have 
defined functions (Bettler, Kaupmann et al. 2004; Holter, Davies et al. 2005; Tiao, 
Bradaia et al. 2008). Human GABAB1c lacks exon 4 (Figure 2.1A), and its functions 
have not been studied in detail (Billinton, Ige et al. 2001). Human GABAB1e is mainly 
expressed in peripheral tissues. Because it lacks exon15, GABAB1e is a C-terminal 
truncated form of GABAB1a and does not have seven TMs, a G-protein coupling region, 
nor a C-terminal intracellular region (Figure 2.1A, B). However, it is functionally active 
and prevents GABAB1a and GABAB2 heterodimerization (Schwarz, Barry et al. 2000). 
In rat, the GABAB1j isoform was recently discovered and found to be expressed as 
highly as GABAB1a and b in brain. It contains exon 1 through 4 and the 5’ part of intron 
4 and is thus a small C-terminal truncated GABAB1 isoform (Figure 2.1A). The 
GABAB1j is a soluble isoform with sushi domains (Figure 2.1B), which selectively 
impair the function of presynaptic (but not postsynaptic) GABAB receptors (Tiao, 
Bradaia et al. 2008). Thus, alternative splicing provides a large diversity of structural and 
functional variation in GABAB1 receptors. 
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Figure 2.1 Schematic summary of GABAB1 isoforms. 
A. Introns and exons of known and novel GABAB1 isoforms were compared. The 
numbers listed at the top are exon numbers of GABAB1a. Blocks represent exons, and 
lines are introns of the GABAB1 gene. Black lines and blocks are ORFs, and grey lines 
and blocks are UTRs. Double line is cDNA microarray probe, clone 300899, which 
aligns to the intron 4 of GABAB1a. Human GABAB1a, b, c, e, and rat GABAB1j are 
previously identified isoforms. After cloning, the following novel isoforms were found in 
human: GABAB1k, GABAB1l, GABAB1m, and GABAB1n. Human GABAB1j was 
predicted. Mouse GABAB1j and GABAB1k were also cloned. GABAB1k contains the 
3’ part of intron 4 through exon 23. GABAB1l has additional splicing out of exon 15, and 
GABAB1m has similar splicing patterns as GABAB1l exc pt for additional splicing out 
at 5’ part of exon 6. GABAB1n has an SNP on exon 8. B. ORFs of GABAB1 isoforms 
are shown with important functional domains. Black bars are previously known isoforms, 
and grey bars represent novel isoforms. Dotted lines stand for unique sequence of each 
isoform. GABAB1k contains GABA binding sites, seven TMs, a G-protein coupling 
region, and a C-terminal intracellular region. GABA1l and GABAB1m do not have 
TMs, a G-protein coupling region, or C-terminal intracellular regions (same as 
GABAB1e). GABAB1m has a longer N-terminal than GABA1l. GABAB1n contains 
only a partial GABA binding site. 
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The diversity of GABAB1 receptors is indicated by these previous studies, and it 
is possible that additional unknown isoforms exist. Two previous cDNA microarray 
studies found strong GABAB1 signals in human brain mRNA (Flatscher-Bader, van der 
Brug et al. 2005; Liu, Lewohl et al. 2006). The two probe sequences used in these 
studies, NCBI accession numbers N80593 and W07715, were obtained from one single 
probe with clone ID 300899. The probe aligns to intro  4 of GABAB1a. This is a 
common intron region of the major human GABAB1 splice variants (Figure 2.1A) and 
has been noted as a potentially important location for alternative splicing in rat (Holter, 
Davies et al. 2005). Because the probe was made from a cDNA library, the probe region 
should be an alternative exon in the GABAB1 gene suggesting the existence of novel 
GABAB1 isoforms. The goals of this study were to identify the novel isoforms and 
determine their functions. 
 
2.2 RESULTS 
2.2.1 Microarray probe sequence analysis 
The expression of clone 300899 increased significantly i  human prefrontal 
cortices in two independent microarray studies (Flatscher-Bader, van der Brug et al. 
2005; Liu, Lewohl et al. 2006), and the clone aligned to the intron 4 region (Figure 2.1A). 
Sequencing of clone 300899 showed multiple stop codons from all six translated frames 
and likely represented UTRs. Thus, two possible isoform models, GABAB1j and 
GABAB1k, were proposed for human allowing us to study novel GABAB1 splicing 
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variant isoforms. Human GABAB1j and GABAB1k contain clone 300899 at their 3’ and 
5’ UTR, respectively. In human brain, GABAB1k was exp cted to have intron 4 and 
exon 5 through 23, and GABAB1j was also proposed to contain exon 1 through 4 and 
intron 4 like rat GABAB1j.  
2.2.2 GABAB1j: Cloning and mRNA levels in human and mouse brain 
GABAB1j was previously cloned in rat, but not in human or mouse. Rat 
GABAB1j ORF is 229 amino acids (aa) (Figure 2.2A) (Tiao, Bradaia et al. 2008). 
Though the predicted human GABAB1j has some different aa sequences and a shorter 
ORF of 190 aa, it shares similar motifs with rat GABAB1j such as C-terminal truncated 
splicing and lack of important functional domains of common GABAB1 isoforms. 
Although human GABAB1a has 23 exons, it has only the first 4 exons and partial 5’ 
intron 4 (Figure 2.1A). Two novel clones were found from the mouse cDNA microarray 
probe set after comparing sequences with the possible human GABAB1j (Ponomarev, 
Maiya et al. 2006). The lengths of the two clones are different because their UTR lengths 
are not the same, but they shared identical ORF. They have the same exon composition 
and ORF length as rat GABAB1j. Sequencing alignment also showed that mouse 
GABAB1j shares the similar ORF except a few aa differences (Figure 2.2A).  
The intron 4 sequence of the predicted human GABAB1j is different from mouse 
and rat GABAB1j. Therefore, sequence alignment showed that it has a very unique C-
terminal and a 39 aa shorter ORF than mouse and rat GABAB1j (Figure 2.2A). To do 
quantitative real-time PCRs, primer and probe sets for general GABAB1 isoform (GB1) 
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were designed between the last two exons of GABAB1a, exon 22 and 23, and they were 
specific for most known GABAB1 isoforms except GABA1j. GABAB1j specific 
primer and probe sets were also prepared. Using quantitative real-time PCR, the existence 
of the predicted human GABAB1j was verified. Relative mouse GABAB1j mRNA 
expression level was much higher than human GABAB1j when compared to GB1 
expression (Figure 2.2B). GB1 sets and the northern blot probe of the rat GABAB1j 
paper (Tiao, Bradaia et al. 2008) were supposed to etect the same major known 
isoforms. Though rat GABAB1j expression level in brain were as high as GB1, human 
and mouse GABAB1j expression were less than GB1 expression (Figure 2.2B). 
GABAB1j function in human and rodent might not be id ntical because of their 
expression and sequence differences. Rat GABAB1j expression is as strong as major 
GABAB1 isoforms (Tiao, Bradaia et al. 2008). Though mouse GABAB1j expression is 
only 5.5 fold lower than them (Figure 2.2B), human GABAB1j showed much lower 
expression (136 fold) (Figure 2.2C). If the fold differences were compared, the relative 
human GABAB1j expression level to GB1 was also dramatically less (25 times) than 
mouse GABAB1j expression though identical detection regions were used for both 
expression studies. Thus, GABAB1j expressions are not consistent across species. 
Interestingly, the C-terminal sequence of human GABAB1j did not share a common 
pattern with mouse and rat GABAB1j (Figure 2.2A). From previous research, purified 
sushi domains of rat GABAB1j impaired the inhibitory effect of the GABAB receptor, 
but the function of rat GABAB1j full ORF had not been studied in detail (Tiao, Bradaia 
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Figure 2.2 Sequences for human, mouse, and rat GABAB1j isoforms and relative 
expression levels. 
A. Sequence alignment of human, mouse, and rat GABAB1j showed a different C-
terminal pattern in human GABAB1j. B. Human and mouse GABAB1j mRNA 
expression levels were measured with quantitative real-time PCR. GB1 primer and probe 
sets were used to detect most known major GABAB1 isoforms except GABAB1j. 
Human and mouse GABAB1j primer and probe sets were specific for only GABAB1j. 
GB1 expressions were shown as fold differences from hu an and mouse GABAB1j. 
Although a previous rat GABAB1j study indicated that GB1 and GABAB1j expression 
levels were similar, human and mouse GABAB1j expressions were lower than GB1. 
Mouse GABAB1j expression was 5.5 fold lower than GB1 expression, and human 
GABAB1j showed 135.89 fold lower expression. If the fold differences were compared, 
human GABAB1j expression level was much less (25 times) than mouse GABAB1j 
expression. Therefore, GABAB1j expressions vary across species.  
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2.2.3 GABAB1k sequence analysis in human, mouse, and rat 
The predicted human GABAB1k is an N-terminal truncated splicing variant. It 
contains 3’ part of intron 4 and exons 5 through 23, and the ORF was 784 aa (Figure 
2.1A). It had important functional domains, such as GABA binding sites (Ser70, Tyr190, 
and Asp295), seven TMs (415 - 677 aa), a G-protein coupling region (linker region 
between TM 3 and 4), and a C-terminal intracellular region (678 - 784 aa: dimerize with 
GABAB2) (Figure 2.1B). It shared most domains with GABAB1b, a functional receptor 
subunit that had no the sushi domains (Steiger, Bandyopadhyay et al. 2004) (Figure 
2.1B). Thus, GABAB1k might also be a functional receptor subunit with greater 
physiological effect than human GABAB1j, given that GABAB1j only contains the sushi 
domains (without any important domains of GABAB1b) and exhibits much lower 
relative expression in human than in mouse and rat. Therefore, we decided to focus on 
the longer splice variant GABAB1k instead of the very short splice variant GABAB1j. 
Before cloning the predicted GABAB1k, its existence was verified in human, 
mouse, and rat. First, mRNAs containing microarray probe region, clone 300899, were 
detected across species. After purifying total RNA from human cultured cell lines, mouse 
midbrain, and rat hippocampus, DNase treatment remov d possible genomic DNA 
contamination. After making mRNA specific cDNA with oligo(dT) primer, PCRs were 
performed within the probe regions. Three different clones (#2, #3, and #4) were isolated 
from human (Figure 2.3). After probe homologous regions in mouse and rat were found 
with Blast N Search, #11 and #18 were cloned in mouse and rat, respectively (Figure 
2.3). The previous microarray probe sequence analysis proved that the microarray probe 
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was a part of intron 4 and either 3’ or 5’ UTR of novel isoforms. Because there was no 
known human GABAB1 isoform that had the intron 4 region as an exon, the two possible 
clones, GABAB1j and GABAB1k, were predicted to contai  the intron 4 regions as 3’ or 
5’ UTR, respectively. GABAB1j and GABAB1k were also only possible isoform models 
that contain the microarray probe in intron 4. Thus, #2, #3, #4, #11, and #18 can be 
partial GABAB1j or GABAB1k, and mRNAs containing the probe regions exist in 
human, mouse, and rat. 
To confirm the predicted GABAB1k existence and to remove the possibility of 
genomic DNA contamination, PCRs were performed betwe n the probe region and other 
exons. Partial GABAB1k forms containing exon-intron ju ctions were also cloned from 
human cultured cell lines, mouse midbrain, and rat hippocampus. There were six 
different N-terminal partial clones, #5-1, #5-2, #6-1, #6-2, #12, and 17&19 (Figure 2.3). 
They share the partial ORF sequences of other known isoforms in the N-terminal and also 
have common 5’ UTRs. There is no possibility of genomic DNA contamination because 
introns are spliced out. Thus, the N-terminal partial clones suggested that GABAB1k 
exists. They are not long enough to have other functio al domains, such as TMs, a G-
protein coupling region, and a C-terminal intracellular region. It was, thus, necessary to 
obtain the full ORF for functional study of GABAB1k. 
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Figure 2.3 Strategy for cloning GABAB1k. 
The top figure represents exon-intron composition of the proposed GABAB1k. 
Numbered rectangular boxes represent known exons, ad lines between boxes are 
introns. Two arrows on the bottom of the boxes represent ORF. Black bar is intron 4, and 
the two probe sequence data, NCBI accession numbers W07715 and N80593, are 
indicated as #1 and #2 above small rectangular boxes, respectively. They are 5’ and 3’ 
sequences of the microarray probe, clone 300899. A arrow above the black bar is a 
possible transcription initiation site. Horizontal lines indicate sequences detected after 
PCR. Based on microarray probe, clone 300899, the following clones were detected in 
human cultured cells, mouse midbrain, and rat hippocampus: #2, #3, #4, #11, and #18. 
From the previous microarray probe sequence analysis, the microarray probe aligned to 
intron 4 and was either 3’ or 5’ UTR of novel isoforms. Because there was no known 
human GABAB1 isoform that had intron 4 as an exon, the two possible isoform models, 
GABAB1j and GABAB1k, were proposed. The predicted GABAB1j and GAGAG1k 
contain intron 4 as 3’ or 5’ UTR, respectively. Because GABAB1j and GABAB1k are 
only two possible isoform models that contain clone 300899, #2, #3, #4, #11, and #18 can 
be partial GABAB1j or GABAB1k and show their existences. From the same RNA 
sources six different N-terminal partial clones, #5-1, #5-2, #6-1, #6-2, #12, and 17&19, 
indicated the existence of GABAB1k. They share common 5’ UTRs and partial N-
terminal ORFs of GABAB1k and suggest that GABAB1k exists in human, mouse, and 
rat. To clone the full ORF of GABAB1k, additional primers were designed at its possible 
3’ UTR region based on other known isoform sequence analyses. Full ORF containing 
clones were cloned from human brain and mouse midbrain. Bottom two boxes show 
clones which contain the full ORF (a&b, a&7, 3&7 in human and c&d in mouse). 
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2.2.4 Cloning GABAB1k, GABAB1l, GABAB1m, and GABAB1n 
To clone the full ORF, additional primers were designed at the possible 3’ UTR 
of the predicted GABAB1k based on known isoform sequence analysis. From human 
whole brain and mouse midbrain, several clones were d t cted by PCR. They were a&b, 
a&7, 3&7, and c&d (Figure 2.3). The expected human GABAB1k and mouse GABAB1k 
were cloned. They have the 3’ part of intron 4 through exon 23 (Figure 2.1A). They are 
an N-terminal truncated splicing variant isoforms, and their ORFs are 784 aa. They 
contain functional domains, such as GABA binding sites, seven TMs, a G-protein 
coupling region, and a C-terminal intracellular region (Figure 2.1B). 
In addition to GABAB1k, two other forms, GABAB1l and m, were also cloned in 
human. GABAB1l has additional splicing out of exon 15 and is both N-terminal and C-
terminal truncated (Figure 2.1A, B). The C-terminal truncated pattern is the same as 
GABAB1e (Schwarz, Barry et al. 2000), and its ORF is 401 aa. Though it contains 
GABA binding sites, it does not have the other functional domains (Figure 2.1B). 
GABAB1m has almost the same splicing pattern as GABAB1l except for an additional 
missing at 5’ part of exon 6 (Figure 2.1A). Thus, it  ORF is longer (423 aa) than human 
GABAB1l and starts at intron 4 whereas the ORFs of GABAB1k begin at exon 6 (Figure 
2.1B). 
During cloning, one more isoform, GABAB1n, was also found. It has a SNP at 
exon 8 and so has a very small ORF, 107 aa. It doesn t have any important functional 
domains except a partial GABA binding site (Ser70) (Figure 2.1A, B). 
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2.2.5 GABAB1k, GABAB1l, GABAB1m, and GABAB1n mRNA levels in 
human and mouse brains 
After cloning the novel GABAB1 forms, GABAB1k, GABAB1l, GABAB1m, 
and GABAB1n, their mRNA expression levels were compared with other known 
isoforms in brain. 
Previous human cDNA microarrays had three GABAB1 probes, clones 2312175, 
298231, and 300899 (Flatscher-Bader, van der Brug et al. 2005; Liu, Lewohl et al. 2006). 
Clones 2312175 and 298231 aligned to exon 23, and clone 300899 aligned to intron 4. 
Our mouse cDNA microarray probe set had six different GABAB1 probes (Ponomarev, 
Maiya et al. 2006). Three probes aligned to 3’ exons f the GABAB1 gene including 
exon 23, and the other three probes contained intron 4. Therefore, the human and mouse 
probe sets are two types that include exon 23 or intron 4 of GABAB1 gene. Based on the 
probe sequence information, GB1 primer and probe sets of the previous GABAB1j 
expression measurement experiments were used for quantitative real-time PCR. GB2 and 
GB3 primer and probe sets were designed (Figure 2.4A). GB1 sets targeting exon 22 and 
23 junction represented human and mouse cDNA microarray probes that aligned to 3’ 
exons of GABAB1 gene. They detect all known GABAB1 isoforms except GABAB1j. 
Since they identify the two major isoforms, GABAB1a and b, their expressions were 
expected to be strong. Because GB1 probe sets were designed at the exon junction, there 
is no possibility of false signals due to genomic contamination. Among commercial 
primer and probe sets, GB1 sets also best represented the microarray probes that contain 
exon 23. GB2 sets were specific for other microarray probes containing intron 4. The 
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probes were human cDNA microarray clone 300899 and its mouse homologs. GB3 sets 
were designed within intron 4 and exon 6. The two primer sets, GB2 and GB3, were used 
to measure mRNA levels of multiple overlapping splice variants (e.g. primer set GB2 
could detect expression of variants GABAB1j, k, l, m, and n while primer set GB3 could 
detect GABAB1k, l, m, and n except GABAB1j). Therefore, GB2 expression could 
include GB3. 
Quantitative real-time PCR experiments showed different expression patterns 
between human and mouse brain. In both species, GB2 and GB3 expression was less than 
GB1 (Figure 2.4B, C). After comparing GB2 and GB3 expr ssion with GB1, the relative 
GB2 and GB3 expression in human was less than in mouse (Figure 2.4B, C). The relative 
GB3 expression level difference between human and mouse was 4.2 fold which was less 
than the relative GABAB1j expression difference (25fold) as shown in Figure 2.2B. 
Prefrontal cortex, frontal cortex, and motor cortex were also used to characterize 
GB3 expression in human; GB3 expression levels were not significantly different across 




Figure 2.4 Expression of GABAB1 isoforms. 
A. For quantitative real-time PCR, primer and probe sets were designed from human and 
mouse. GB1 sets were designed by the last two exons, exon 22 and 23, and were used for 
detecting most known GABAB1 isoforms except GABAB1j. They also represented the 
microarray probes that aligned to 5’ exons of GABAB1 gene. GB2 sets were for 
detection of GABAB1j, k, l, m, and n. They aligned to intron 4 and designed for human 
cDNA microarray probe, clone 300899, and its mouse homologous probes. GB3 sets 
targeted intron 4 through exon 6 and were specific for GABAB1k, l, m, and n. B. In 
human brain, GB1 showed much more dominant expression than GB2 and GB3. C. GB1 
expression was also stronger than GB2 and GB3 in mouse brain. However, GB2 and GB3 
expression levels in mouse brain were much higher tan human brain if they were 
compared with GB1 expressions. D. In human, GB3 expressions were similar in 
prefrontal cortex, frontal cortex, and motor cortex.  
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2.2.6 GABAB1k, GABAB1l, and GABAB1m function 
The GABAB receptor is a heterodimeric (GABAB1 + GAB2) GPCR. GABA 
binding to GABAB1 transfers a signal through G proteins whose functions are linked to 
several effectors, including GIRK. Thus, GIRK currents were measured using two-
electrode voltage clamp to evaluate the functions of the new GABAB1 isoforms. 
GABAB receptor responses were first measured in oocytes expressing GABAB1a 
and GABAB2 along with GIRK1 and GIRK2 with a range of GABA concentrations. 
1mM GABA was the maximum response concentration. The EC50 was 1.9 uM, and Hill 
slope was 0.59 (Figure 2.5A). 
For functional characterization, GABAB1k, l, and m were chosen because they 
have more functional domains than GABAB1n. Various amounts of each isoform cDNA 
were injected into oocytes together with GABAB2, GIRK1, and GIRK2. GIRK currents 
were measured following the previous GABAB1a and GABAB2 response measurement 




Figure 2.5 GABAB1a/2 concentration response curve. 
A. cDNA and complementary RNA (cRNA) double injections were performed. For 
cDNAs, both GABAB1a and GABAB2 were injected into the nucleus of Xenopus 
oocytes. GIRK1 and GIRK2 cRNAs were also injected into the cytosol of the same 
oocytes. Current response of GABAB receptor and GIRK expressing oocytes were 
measured by two-electrode voltage clamp. 1mM GABA was the maximum response 
concentration; EC50 was 1.9 uM; Hill slope was 0.59. B. For GABAB1a/2 concentration 
response curve measurement, GABA dissolved in 49 mM high-K+ solution (49mM HK) 
was applied for 1 min following a 2 min 49mM HK application. After 2 additional min of 
49mM HK application, a 20 min wash with ND96 was followed. 
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Although GABAB1k, l, and m combined with GABAB2 did not induce GIRK 
currents, we asked if they might inhibit GABAB receptor function. Each isoform cDNA 
was injected along with GABAB1a, GABAB2, GIRK1, and GIRK2 into oocytes. For 
vector controls, the same amount of vector (instead of the new isoform) was injected 
along with GABAB1a, GABAB2, GIRK1, and GIRK2 into the control oocytes. The new 
isoform- and vector-injected oocytes were paired into groups based on injection amount. 
Injection amounts varied from 0 to 15 times the amount of GABAB1a injection (Figure 
2.6). After 5 days of incubation, GABA-evoked GIRK currents were measured. GABA, 3 
mM - an approximate EC100 for GABAB1a and GABAB2 receptors, was used. For each 
batch of oocytes, individual GIRK currents from the isoform-expressing group were 
normalized as a percentage of the average current of the vector control group. For 
nonparametric test, log10 values were calculated for the individual percentage values. 
One-way ANOVA and Dunnett’s tests showed significant effects of GABAB1l and m (p 
= 0.006 and p = 0.004, respectively); however, GABAB1k did not show significant 
effects (Figure 2.6A, B, C). For GABAB1l and m data, one-tailed unpaired Student’s t-
tests were performed between no isoform injection data (0 x) and the other individual 
data (0.1 x ~ 15 x). GABAB1l significantly decreased GIRK currents at 5 x and 6 x of the 
GABAB1a concentration (**p = 0.0014 and *p = 0.023, respectively; Figure 2.6B). 
GABAB1m also evoked significant decreases at 11 x and 12 x of the GABAB1a 
concentration (***p = 0.0003 and **p = 0.0064, respctively; Figure 2.6C). Among 9 to 
12 different oocyte batches, the inhibitory patterns were consistently observed. Except for 
the GABAB1l and m injection ranges that decreased GIRK currents, other injection 
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amounts did not show the inhibitory effects. This pattern was also observed at additional 
injection amounts (8 x of GABAB1k, 4.5 x and 5.5 x of GABAB1l, and 8 x of 
GABAB1m). In the GABAB1l inhibition range (5 x ~ 6 x of the GABAB1a 
concentration), 5.5 x also decreased GIRK current. The other injection amounts did not 





Figure 2.6 Functional effects of three novel human isoforms, GABAB1k, l, and m. 
Inhibitory effects were measured in Xenopus oocytes 5 days after injecting GABAB1a, 
GABAB2 cDNA and GIRK1, GIRK2 cRNA along with GABAB1k, l, or m cDNA. For 
vector controls, vectors were injected in the same a ounts as used for the isoforms. 
Isoform and vector injection amounts varied from 0 to 15 times of GABAB1a injection 
amount. Used GABA concentration was 3 mM, an approximate maximum response 
concentration. For each batch, individual GIRK currents from isoform injected oocytes 
were normalized to percentage by the average vector cont ol current. For nonparametric 
tests, the individual percent values were changed to log10. After one-way ANOVA and 
Dunnett’s tests, one-tailed unpaired Student’s t-tests were performed between no isoform 
injected groups and the isoform injected groups. A. G BAB1k had no inhibitory effect. 
B. GABAB1l data showed significant differences by ANOVA and Dunnett’s tests (p = 
0.0058), and caused significantly decreased GIRK currents at 5 x and 6 x GABAB1l (**p 
= 0.0014 and *p = 0.0229, respectively). C. ANOVA and Dunnett’s tests showed the 
significant differences of GABAB1m data (p = 0.0040). GABAB1m showed significant 
decreases at 11 x and 12 x GABAB1m (***p = 0.0003 and **p = 0.0064, respectively). 
The numbers of recorded oocytes are shown above the bars by each group. Data are 
expressed as the mean ± standard error of the mean (SEM).  
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2.3 DISCUSSION 
In this study, novel GABAB1 splicing variants contai ing the intron 4 region 
were cloned from human and mouse confirming and extending the previous suggestion 
that this intron is a frequent alternative splicing spot in the rat (Wei, Jia et al. 2001; 
Holter, Davies et al. 2005; Tiao, Bradaia et al. 2008). Previous studies cloned GABAB1g, 
i, and j from rat, all of which have a portion of intron 4 (Wei, Jia et al. 2001; Holter, 
Davies et al. 2005; Tiao, Bradaia et al. 2008). However, intron 4 containing GABAB1 
splicing variants were not previously reported from human or mouse. Our quantitative 
real-time PCR data implied that intron 4 is also an alternative exon in human and mouse. 
Therefore, mouse GABAB1j clones were found from the cDNA microarray probe set. 
Though human GABAB1j was not cloned in this study, its existence was confirmed by 
quantitative real time PCR. From human and mouse, four more intron 4 containing clones 
were identified. GABAB1k, l, m, and n were cloned from human, and another GABAB1k 
was also cloned from mouse. Our study further emphasizes that intron 4 is a frequent 
splicing spot of the GABAB1 gene in multiple species. 
Though expression levels of these novel isoforms in total brain were lower than 
other abundant isoforms (GABAB1a and b), they may be preferentially expressed in 
specific cell types just as GABAB1a and GABAB1b show specificity for pre- and 
postsynaptic localization (Vigot, Barbieri et al. 2006) and are localized in the different 
cells using their own unique promoters (Bettler, Kaupmann et al. 2004; Gassmann, Haller 
et al. 2005). In cerebellum, GABAB1a is predominantly expressed in granule cells, and 
GABAB1b is abundant in Purkinje cells (Billinton, Ige et al. 2001). Like GABAB1a and 
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GABAB1b, there are many other precedents for N-terminal truncated splicing variants 
that have their own promoters and show spatially different expression patterns (Wang, 
Schultheis et al. 1996; Crofts, Hancock et al. 1998; Sunn, Cock et al. 2001; Travers, 
Vallance et al. 2003; Huang, Levitsky et al. 2009). The novel isoforms are also N-
terminal truncated splicing variants and probably use specific promoters for their 
expression. After identifying GABAB1 gene putative transcription factor binding sites 
from the PROMO website, possible promoter regions were found on exon 4 and the 5’ 
part of intron 4 (data not shown) (Messeguer, Escudero et al. 2002; Farre, Roset et al. 
2003). Thus, the novel isoforms may be restricted to specific cell types and inhibit 
GABAB receptor function. 
GABAB1l and m might be secreted like GABAB1e because they also lack TMs 
and have the same C-terminal truncated patterns as GABAB1e (Schwarz, Barry et al. 
2000). This phenomenon has been observed for splicing variants of Interleukin-15 
receptor α, Fibroblast growth factor receptor 4, human GABAB1e, and rat GABAB1j 
which lose TMs by alternative splicing and are secreted (Schwarz, Barry et al. 2000; 
Ezzat, Zheng et al. 2001; Bulanova, Budagian et al. 2007; Tiao, Bradaia et al. 2008). Our 
functional studies used continuous perfusion of the oocytes, and it is possible that 
GABAB1l and m were secreted and washed away resulting in low intracellular and 
extracellular concentrations and obscuring some functio al effects. However, many 
secreted splicing variants including the C-terminal truncated GABAB1 isoforms inhibit 
the functions of their other membrane-bound isoforms (Mosley, Beckmann et al. 1989; 
Schwarz, Barry et al. 2000; Ezzat, Zheng et al. 2001; Bulanova, Budagian et al. 2007; 
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Tiao, Bradaia et al. 2008). It is possible that secreted GABAB1l, m, and n could also 
inhibit GABAB receptor function. 
The inhibitory effects of GABAB1l and m were found only within a narrow 
concentration window of injected cDNA. The reasons are not clear, but it is not likely 
due to nonspecific artifact or toxicity with the hig est amounts injected. Therefore, above 
the optimal concentration window, their effects were diminished. The vector controls also 
had the same injection amounts, but their GABA respon es were constant and stable. 
Also, the inhibitory effects were seen consistently among all 9 - 12 different oocyte 
batches. Some genes require optimal expression levels to display their functional 
properties (Lamond and Travers 1985; Voliva, Aronheim t al. 1992; Park, Lee et al. 
2005), and GABAB1m and n may also need optimal exprssion ranges to inhibit 
function. 
GABAB1e binds GABAB2 though a dimerization motif (166 - 439 aa of 
GABAB1e) and appears to dominantly bind GABAB2 as well as competing with 
GABAB1a (Schwarz, Barry et al. 2000). Its dimerizaton motif is not sushi domains but 
the rest of the N-terminal extracellular domain. GABAB1k, l, m, n, but not GABAB1j 
contain the dimerization motif and would be expected o bind GABAB2 dominantly 
instead of GABAB1a and even reduce receptor functio. 
In summary, alternative splicings at intron 4 generat  novel isoforms, GABAB1j, 
k, l, m, and n (Figure 2.1A). The relative mRNA expression patterns of GABAB1k, l, m, 
and n are more conserved than GABAB1j across species when compared to general 
GABAB1 isoform expression. However, the expression of novel N-terminal splicing 
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variants, GABAB1k, l, m, and n, is low in whole brain (Figure 2.4D). They may have 
restricted expression at specific cell types because they have putative promoter sites. 
Though GABAB1k, l, m, and n are expected to dominantly dimerize with GABAB2 like 
GABAB1e, only GABAB1l and m were observed to disrupt the function of GABAB1a 
and 2. GABAB1e has only C-terminal truncation (Schwarz, Barry et al. 2000), but the 
GABAB1l and m have both C-terminal and N-terminal truncated patterns (Figure 2.1B). 
Therefore, this additional N-terminal truncated pattern may increase their inhibitory 
functions.  
This work expands evidence for the diversity of GABAB1 splice variants in brain. 
It is important to note that variants were found in multiple species, and it has been noted 
that splice variants which are likely to contribute to evolution and have functional value 
are conserved across species (Lareau, Green et al. 2004). In considering possible 
functional roles of these splice variants, we should note that GABAB receptors provide 
diverse neuronal signaling through G proteins and may have additional functions as they 
form complexes with other proteins (Chang, Tu et al. 2007). 
 
2.4 MATERIALS AND METHODS 
2.4.1 Sequence analysis 
To predict two possible isoforms, GABAB1j and GABAB1k, SOURCE 
(http://smd.stanford.edu/cgi-bin/source/sourceSearch) was used to search the sequence of 
the microarray probe, clone 300899. The sequence was converted to a FASTA format by 
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EditSeq programs of DNASTAR (DNASTAR, Inc., Madison, WI, USA). Blast N Search 
(www.ncbi.nlm.nih.gov/blast) showed where the probe aligned in GABAB1 gene. Its 
multiple stop codons were founded from six different translated frames using MapDraw 
programs of DNASTAR. 
To compare GABAB1 isoform sequences, their sequences and exon-intron 
structure information were found from NCBI data base (http://www.ncbi.nlm.nih.gov). 
Their sequences were aligned with MegAlign programs of DNASTAR, and their 
conserved domains were searched by ExPASy Proteomics Server (http://expasy.org) and 
CD-Search (http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi). To align GABAB1j 
sequences, ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2/index.html) were used. 
2.4.2 Identification of new GABAB1 isoform, GABAB1k  
To determine the existence of novel GABAB1 isoforms, GABAB1j and 
GABAB1k, across species, the microarray probe, clone 300899, was cloned from human, 
and its homologous regions were also cloned from mouse and rat based on Blast N 
Search. For further examination, partial GABAB1k clones were identified. The partial 
GABAB1k clones contain the microarray probe and GABAB1k unique region, 3’ intron 
4 of GABAB1a. For these experiments, total RNA was isolated from human cultured 
cells, including human embryonic kidney 293 (HEK-293) (ATCC, Manassas, VA, USA), 
SH-SY5Y (ATCC, Manassas, VA, USA), and SK-N-SH (ACTT, Manassas, VA, USA). 
Total RNA was also isolated from mouse midbrain andrat hippocampus. After treating 
DNase (Qiagen, Valencia, CA, USA), cDNAs were made using oligo(dT) primer 
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(Invitrogen, Carlsbad, CA, USA). To clone the microarray probe, primers were designed 
within the probe region using Primer3 (http://frodo.wi.mit.edu/primer3/) and 
PrimerSelect program of DNASTAR. For partial GABAB1k cloning, the probe region 
and other 3’ exons were targeted to design primers. PCRs were performed using the 
primers and the prepared human, mouse, and rat cDNAs. 
PCR primers (5’ to 3’): 























2.4.3 Cloning novel isoforms, GABAB1k, GABAB1l, GABAB1m, and 
GABAB1n  
To clone full ORFs of the novel isoforms, cDNAs were generated with oligo(dT) 
primer from human brain total RNA (Ambion, Austin, TX, USA) and mouse midbrain 
total RNA. Primers were designed based on intron 4 f GABAB1a and common 3’ UTR 
of known isoforms, and PCRs were performed using the human and mouse brain cDNAs. 
PCR primers (5’ to 3’): 











2.4.4 Quantitative real-time PCR 
TaqMan® Gene Expression Assays and Custom TaqMan® Gene Expression 
Assays (Applied Biosystems, Foster City, CA, USA) were used to detect GABAB1 
isoform expressions. cDNA microarray probes are two different kinds containing exon 23 
or intron 4. The probes containing exon 23 detect all known isoform expressions except 
GABAB1j. The exon 22 - 23 junction was targeted using predesigned TaqMan® Gene 
Expression Assays. Custom TaqMan® Gene Expression Assays were used for intron 4 
containing probes, and thus were able to detect GABAB1j, GABAB1k, GABAB1m, 
GABAB1l, and GABAB1n. Using the same method, the uniq e alternative splicing 
region of GABAB1k, GABAB1m, GABAB1l, and GABAB1n wer  targeted, and 
GABAB1j specific expression was also detected. For endogenous control gene, beta-
glucuronidase (GUSB) was used. 
After making cDNAs with random primers (Invitrogen, Carlsbad, CA, USA), 
quantitative real-time PCR was performed. Isoform expr ssions were compared between 
human and mouse whole brain RNAs (Ambion, Austin, TX USA). To measure isoform 
expression differences in select human brain regions, RNAs from whole brain, prefrontal 
cortex, frontal cortex (Ambion, Austin, TX, USA), and motor cortex (Liu, Lewohl et al. 
2004) were used. 
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2.4.5 cDNA and cRNA preparation 
To do injections into Xenopus oocytes for electrophysiological recordings, 
cDNAs and cRNAs were prepared. For cDNA injection, human GABAB1a clone in 
pcDNA3.1(-) vector (Invitrogen, Carlsbad, CA, USA) and human GABAB2 clone in 
pcDNA3 vector (Invitrogen, Carlsbad, CA, USA) were kindly provided by Dr. Uezono 
(Nagasaki University, Nagasaki, Japan) with the permission of GlaxoSmithKline 
(Brentford, Middlesex, UK). The cDNAs encoding novel human GABAB1 isoforms, 
GABAB1k, GABAB1l, and GABAB1m, were also subcloned into pcDNA3.1(-) vector. 
The cRNAs for GIRK1 and GIRK2 were synthesized as de cribed previously for cRNA 
injections (Lewohl, Wilson et al. 1999). 
2.4.6 Electrophysiological recording 
For electrophysiological recordings, oocytes from Xenopus laevis frog were used. 
The frog was used according to the National Institutes of Health guide for the care and 
use of laboratory animals. 
To form functional receptors, nuclear injection of GABAB1a and GABAB2 
cDNAs were performed into Xenopus oocytes with 0.75 ng and 0.63 ng, respectively. 
GIRK1 (0.2 ng) and GIRK2 (0.2 ng) cRNAs were also injected into the cytosol of the 
same oocytes in order to measure GABAB receptor-induce  currents. Total injection 
volumes of cDNAs and cRNAs were 60 nl. Electrophysiological recordings were made 
with the oocytes after 5 to 7 day incubation at 19 °C. Using two-electrode voltage clamp, 
the oocytes were clamped at -60 mV while being perfused (2 ml/min) with ND96 buffer 
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(in mM: 96 NaCl, 2 KCl, 1 CaCl2, 1 MgCl2, 5 HEPES, pH7.5). A 49mM HK (in mM: 48 
NaCl, 49 KCl, 1 CaCl2, 1 MgCl2, 5 HEPES, pH7.5) was applied to the oocytes for 2 min 
(Uezono, Kanaide et al. 2006). GABA (Sigma, St. Louis, MO, USA), ranging in 
concentration from 10 nM to 1 mM, was dissolved in 49mM HK and applied for 1 min. 
ND96 was applied for 20 min following the 2 min application of 49mM HK.  
The responses of GABAB1a and GABAB2 to the range of GABA concentrations 
were used to generate GABA concentration response curves with GraphPad Prism, 
Version 5.01 (GraphPad Software, San Diego, CA, USA). EC50 and Hill coefficient 
values were calculated from the GABA concentration response curves. A maximally 
effective GABA concentration was also determined from it and was used to test 
inhibitory effects of the isoforms. 
To test if the isoforms can substitute for GABAB1a as a functional receptor 
subunit, 0.63 ng GABAB2, 0.2 ng GIRK1, and 0.2 ng GIRK2 were injected into oocytes 
with various amounts (0.001 ng to 20 ng) of isoform cDNAs. Total injection volumes 
were 60 nl. As in the GABA concentration response experiment, GABA-evoked GIRK 
currents were measured to determine receptor function. 
To determine the inhibitory functions of isoforms, GABAB1a was co-injected 
with each isoform. Except the isoforms, the injection amounts of GABAB1a, GABAB2, 
GIRK1, and GIRK2 were the same as the GABA concentration response experiment. For 
vector controls, the same amount of vector, pcDNA3.1(-), was injected into control 
oocytes instead of the isoforms. Total injection volumes were 60 nl. The isoform and 
vector injection amounts varied from 0 to 15 times the GABAB1a injection amount (0.75 
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ng). After a 5 day incubation at 19 °C, GABA-evoked GIRK currents were measured. 
The GABA concentration was 3 mM which was the maximal concentration for GABA 
responses in GABAB1a and GABAB2 expressing oocytes. Nine batches of oocyte were 
used for both GABAB1k and m experiments, and 12 batches were for GABAB1l. For 
each batch of oocytes, individual GIRK currents in isoform injected oocytes were 
expressed as a percentage of average current in vector control oocytes. For nonparametric 
tests, log10 data were calculated from the values. 
2.4.7 Statistical analysis 
For statistical analysis and graphing, GraphPad Prism and Excel (Microsoft, 
Redmond, WA, USA) were used. For electrophysiology data, one-way ANOVA tests and 
unpaired Student’s t-tests were used to define statistic l significances. Dunnett’s tests 
were also used for post hoc tests. 
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CHAPTER 3. ALCOHOLISM CORRELATS WITH GABAB1 
SPLICING IN HUMAN BRAIN 
 
3.1 INTRODUCTION 
GABAB receptors have been implicated in regulation of alcohol drinking. The 
positive allosteric modulator, GS39783, suppresses alcohol drinking and reinforcement in 
rat models (Maccioni, Fantini et al. 2008). A GABAB receptor agonist, GHB, can reduce 
voluntary ethanol drinking and withdrawal symptoms in humans and is a treatment for 
alcoholism (Cammalleri, Brancucci et al. 2002; Schweitzer, Roberto et al. 2004). Another 
GABAB receptor agonist, baclofen, may also be effectiv  in treating the disease 
(Enserink 2011). 
Previous microarray studies have shown strong GABAB1 expression in prefrontal 
cortices from human alcoholics (Flatscher-Bader, van der Brug et al. 2005; Liu, Lewohl 
et al. 2006). These experiments suggested complexity of GABAB1 gene splicing, which 
we confirmed by cloning of new splice variants from human brain (Isomoto, Kaibara et 
al. 1998; Schwarz, Barry et al. 2000; Tiao, Bradaia et al. 2008; Lee, Mayfield et al. 
2010). The microarray experiments used a cDNA probe set, and two out of three 
GABAB1 probes were generated by unknown splicings. A GABAB1 probe, clone 
300899, was aligned to intron 4 of GABAB1. The intro  4 is a common intron region 
from Reference Sequence (RefSeq) Genes model and major GABAB1 splicing variants 
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(Lee, Mayfield et al. 2010). Another probe, clone 231 175 targeted an unknown splicing 
out at exon 23 of GABAB1, and a new variant, GABAB1m, has unexpected splicing out 
at exon 6 of GABAB1 in brain (Lee, Mayfield et al. 2010). Five different splicing 
variants were cloned as containing clone 300899 (Tiao, Bradaia et al. 2008; Lee, 
Mayfield et al. 2010). These also showed many unknown GABAB1 splicings and the 
overall complexity of GABAB1 splicing. 
Among the three GABAB1 microarray probes, only the intron 4 containing probe, 
clone 300899, showed increased expression in alcoholi  brain(Flatscher-Bader, van der 
Brug et al. 2005; Liu, Lewohl et al. 2006). This suggested a specific GABAB1 splicing 
change resulting from chronic alcohol exposure. Signal intensities of the three probes 
were different, and the difference was not explicable with current known splicing 
variants. Due to this complexity of GABAB1 splicing, it is likely that previously 
unknown GABAB1 splicing variants are differentially expressed in alcoholic brains. 
Other studies have also shown that chronic ethanol treatments change specific splicing 
patterns of channel or receptor genes in brain. Chronic ethanol exposure and withdrawal 
increased 5’ splicing variant expression of the NMDA receptor subunit, NR1, without 
NR1 3’ splicing variant expression changes (Hardy, Chen et al. 1999). The L-type 
voltage-gated Ca2+ channel, α1c, has two splicing variants, α1c-1 and α1c-2. Chronic 
ethanol treatment enhanced specific splicings to increase only the α1c-1 population 
(Walter, McMahon et al. 2000). 
To identify novel splicing junctions of GABAB1, the NCBI sequence database is 
one possible option. However, the actual splicing variant number of the whole genome is 
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far higher than the database (Fodor and Aldrich 2009). Therefore, many unknown 
splicings of the GABAB1 gene likely exist, and we used RNA-seq to detect new variants 
of GABAB1 and to quantitate splicing differences in prefrontal cortex of brain tissue 
from alcoholic and non-alcoholic subjects. 
 
3.2 RESULTS 
3.2.1 Gene specific library construction to maximize GABAB1 splicing 
junction detection 
A gene specific library was designed for RNA-seq to maximize splicing junction 
identification in the GABAB1 gene. Current approaches to RNA-seq libraries construct 
often utilize random primers or oligo(dT) primers for reverse transcription. However, this 
approach does not generate the required number of mapped reads from single RNA-seq 
run to find rare splicing junctions in the GABAB1 gene. Therefore, we used a different 
approach by generating a gene specific library for our splice junction study in addition to 
the whole transcriptome library. The gene specific l brary was constructed using gene 
specific primers instead of random primers for the reverse transcription; thus, it provided 
a large population of gene specific reads and maximized detection of gene specific splice 
junctions. 
rRNA constitutes 90-95% of total RNA. If we use total RNA for gene specific 
library construction, it must generates more nonspecific sequence data from rRNAs than 
GABAB1 gene specific data. Therefore, we used rRNA depleted total RNA (Figure 
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3.1).Two gene specific primers were designed at the common 3’ UTR of the GABAB1 
transcripts. After reverse transcription using one gene specific primer, the template 
switching method generated double strand cDNAs (dscDNAs). For amplification, we 
used the other gene specific primer designed closer to the ORF at the 3’ UTR. Gel 
extraction removed unbound primers, and the dscDNAs were fragmented. After adaptor 
ligation, SOLiD sequencing was performed (Figure 3.1). The whole transcriptome library 
was also prepared for SOLiD sequencing in order to compare the gene specific library 




Figure 3.1 Gene specific library construction. 
To prepare the gene specific library, rRNA was depleted from total RNA. Single stranded 
cDNA (sscDNA) was generated by reverse transcription using a gene specific primer. By 
template switching dscDNA was synthesized, and another gene specific primer was used 
for amplification. After gel extraction, size select d dscDNAs were sonicated, and 
adaptors were ligated. The gene specific library was sequenced by SOLiD system. 
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3.2.2 Comparison between result derived from gene specific and whole 
transcriptome libraries 
The gene specific and the whole genome libraries were compared in several 
different ways: 1) number of GABAB1 specific mapped r ads, 2) splicing junctions, 3) 
mapping patterns, and 4) possible transcription initiation sites. As expected, the gene 
specific library had more GABAB1 specific mapped reads than the whole transcriptome 
library (Figure 3.2). The gene specific library had 134-fold more mapped reads at 
GABAB1 than the whole transcriptome library. More splicing junctions were also 
identified in the gene specific library than the whole transcriptome library as visualized 
by the Integrative Genomics Viewer (IGV) (Figure 3.2). 
The gene specific library contained more mapped reads on the 3’ end of 
GABAB1 while mapped read numbers were decreased at the 5’ end of GABAB1 (Figure 
3.2A). Due to the uneven read distribution of the gene specific library, 5’ exons (from 
exon 1 to exon 5) had no mapped reads while the whole transcriptome library did (Figure 
3.2). The biased distribution likely resulted from gene specific reverse transcription and 
amplification based on the GABAB1 3’ UTR. Similar biased distributions were also 
found from another 3’ UTR targeting whole transcriptome libraries using oligo(dT) 





Figure 3.2 Compared result from between gene specific library and whole transcriptome 
library. 
All TopHat mapping files, .wig, .bed, and .sam, were loaded on the IGV and showed at 
the GABAB1 gene in blue, red, and grey, respectively. The .wig files (blue) contain the 
number of mapped reads at each nucleotide position. Splicing junctions (red) were 
uniquely represented using the .bed files. The .sam (grey) files contained individual 
mapped reads. For the .bed and .sam files, the thick lines represented mapped reads, and 
the thin lines represented splicing junctions. Mapped read numbers were compared in log 
space using the .wig files. With the three files, the gene specific library and whole 
transcriptome library results were shown at A and B, respectively. Because GABAB1 is 
negatively oriented at chromosome 6, the 5’ and 3’ ends of GABAB1 are located on the 
right and left during IGV visualization, respectively. For the gene specific library, only 
the upper portion of the .sam file data is shown due to space limitations. The gene 
specific library results had more GABAB1 specific mapped reads and splicing junctions 
than the whole transcriptome library. The black baron top of figure A represents the 
location of both RT and amplification primers. Exon numbers are labeled below the gene 
model of A and B. 
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3.2.3 RNA-seq data from alcoholic and control human subjects 
To compare GABAB1 splicing in prefrontal cortex alcoholics and matched 
controls, the data were processed to optimize the discovery of splice junctions and 
minimize false negative. The comparison of the gene specific and the whole 
transcriptome libraries showed that the gene specific library was better suited for splicing 
junction identification because the gene specific library could found more GABAB1 
specific splicing junctions than the whole transcriptome library. Moreover, TopHat 
mapping using additional junction information can identify additional splice junctions 
(http://tophat.cbcb.umd.edu/manual.html). 
To maximize the search for splice junctions, an additional junction search step 
was added prior to the final mapping (Figure 3.3). For the junction search step, we used 
both the gene specific and whole transcriptome librar es. Specically, the gene specific 
libraries provided a large population of GABAB1 gene specific splicing junctions 
including rare splicing junctions (Figure 3.2A). After TopHat mapping of individual 
libraries, all splice junction data were collected (Figure 3.3), and unique junction 
information was used for the final mapping of the whole transcriptome library data from 
brain tissues of 14 alcoholic and 15 control human subjects. Splice junction information 
was collected again from the individual mappings. Based on the splicing junction 
information, minimum GABAB1 gene length was defined and further data analyses were 




Figure 3.3 Data analysis to maximize splice junction detection. 
To maximize the identification of splice junctions u ing TopHat, a junction search step 
was added to the data analysis pipeline. We used gene specific libraries (GSLs) and 
whole transcriptome libraries (WTLs) prepared from commercial and postmortem human 
prefrontal cortices. After filtering low quality reads and undesired sequence containing 
reads, the data were converted to .fq files. After TopHat mapping, splice junction 
information was collected for the remapping step. We used the whole transcriptome 
library data from 14 alcoholic and 15 control human brain samples for the remapping 




For each step, the remaining read number and its ratio compared to raw reads 
were calculated (Table 3.1). Control and alcoholic samples had similar ratios from each 
step though there were some individual variations. Based on the quality filter, about 20 % 
of raw reads were filtered out, and the second filter for non-coding RNAs and adaptors 
left approximately 55 % of raw reads. Format change caused about an additional 2 ~ 3 % 
loss. After TopHat mapping, the unique mapped reads showed about 41 % mappability 




Table 3.1 Mapping statistics of 15 control and 14 alcoholic human subjecs.  
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3.2.4 GABAB1 splicing junctions and gene lengths 
After the final mapping, unique splicing junction data were visualized using the 
University of California, Santa Cruz (UCSC) genome browser (Figure 3.4A). 20 splicing 
junctions were found among the 22 known splicing junctions from the RefSeq Genes 
model. An additional 43 novel splicing junctions were also found; therefore, there are at 
least 65 splice junctions associated with GABAB1 (visualized in Figure 3.4A). The 43 
splicing junctions are rare splicing junctions. Rare splicing junctions are also identified 
from other intensive junction discovery based on computational approach (Pickrell, Pai et 
al. 2010). They found 23 rare splicing junctions out f total 33 splicing junctions from 
HERPUD1 gene. Their rare junction finding ratio was almost the same as out data. Also, 
TopHat false discovery rate is lower than 1 % for rare splicing junction (Dimon, Sorber et 
al. 2010). 
Based on this splicing junction information, the mini um GABAB1 gene length 
is 72,333 bp (chr6: 29,653,437 - 29,725,769) on the human reference genome (hg18) 
(Figure 3.4A). This GABAB1 gene length is about 41 Kbp longer than the known 
GABAB1 length of 30,958 bp (chr6: 29,677,984 - 29,708,941). The minimum GABAB1 
gene length from UCSC databases (i.e., human mRNAs from GeneBank and human 
ESTs that have been spliced) is 100,266 bp (chr6: 29,631,387 - 29,731,652). These 
findings provide strong evidence that the GABAB1 gene is larger than previously 
reported. 
We categorized the 65 GABAB1 splicing junctions into four groups: known, 
known-alternative, partial-novel, and novel splicing junctions (Figure 3.4B). The known 
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splicing junctions represent those found in the RefSeq Genes model. The known-
alternative splicing junctions represent different splicing site combinations of the known 
splicing junctions. The partial-novel splicing junctions represent junctions with one 
known splicing site and another unknown site. The novel splicing junctions represent 
junctions with both unknown splicing sites. For GAB1, there were 22 known, 5 
known-alternative, 8 partial-novel, and 30 novel splicing junctions. Thus, the number of 
known-alternative, partial-novel, and novel splicing junctions are almost twice the 
number of known splicing junctions. 
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Figure 3.4 GABAB1 splicing junctions and gene boundaries. 
After combining splicing junctions from the gene specific and the whole transcriptome 
library, we found that there are at least 65 splicing junctions associated with the 
GABAB1 gene. A. The 65 splice junctions were visualized with the UCSC genome 
browser using a .juncs file and hg18. From the splice junction information, we 
determined that the GABAB1 gene is at least 72,333 bp (chr6: 29,653,437 - 29,725,769) 
long which is about 41 Kbp larger than the expected size of 30,958 bp (chr6: 29,677,984 
- 29,708,941) based on the RefSeq Genes model. From tw  databases of the UCSC 
genome browser (Human mRNAs from GeneBank and Human ESTs that Have Been 
Spliced), we estimated a minimum GABAB1 gene length of 100,266 bp (chr6: 
29,631,387 - 29,731,652). From top to bottom the tracts include a user supplied track 
(.juncs file loaded track), RefSeq Genes, Human mRNAs from GeneBank and Human 
ESTs that Have been spliced. GABAB1 gene is at the center of RefSeq Genes tract, and 
its 5’ end exons are located to the right side of 3’ end exons. Red arrows point to clones 
that showed extended GABAB1 gene length from the two UCSC genome browser 
databases. B. The 65 splicing junctions were one of four types (known, known-
alternative, partial-novel, and novel splicing junctions). Known” represents the known 
splicing junctions from the RefSeq Genes model. Know -alternative” represents splicing 
junctions that have different splicing site combinations of the known splicing junctions. 
Partial-novel” represents splicing junctions that hve only one known splicing site and an 
unknown splicing site. Novel” represents splicing junctions that do not have any known 
splicing sites. The numbers in parentheses are counts of each type. The known splicing 
junctions are about one third of the other GABAB1 splicing junctions. 
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3.2.5 GABAB1 gene expression differences in alcoholic versus control 
subjects 
We compared GABAB1 gene expression levels between 14 alcoholics and 15 
controls (Figure 3.5). Reads per kilobase of exon model per million mapped reads 
(RPKM) is most commonly used for current RNA-seq expr ssion studies and is 
calculated from all known exons (Mortazavi, Williams et al. 2008). However, we found 
that unknown splicing junctions were found at intros and intergenic regions and many 
reads were also mapped there. Reads per kilobase of g ne model per million mapped 
reads (RPGM) was introduced to consider the intron and intergenic regions. RPGM 
allowed calculation of expression levels from each gene as well as any interesting region 
within gene model in genome wide study. 
RPGMs were calculated from the three different GABAB1 gene boundaries: 1) 
known GABAB1 gene boundary from the RefSeq Genes model, 2) minimum GABAB1 
gene boundary from RNA-seq, and 3) the other GABAB1 gene boundary from UCSC 
genome browser databases (Figure 3.5). However, the expression levels of these three 




Figure 3.5 GABAB1 gene expression comparison in alcoholics and controls. 
GABAB1 expression was compared in 14 alcoholics and 15 controls. A. At the known 
GABAB1 gene boundary of the RefSeq Genes model, expression levels were compared 
between alcoholics and controls. After log2 transformation of RPGM values, unpaired 
student’s t-tests were carried out to define statistically significant differences. Y-axis 
represents log2RPGM. From top to bottom, horizontal lines of each boxplots represent 
the largest non-outlier, upper quartile, median, lower quartile, and the smallest non-
outlier values. B. GABAB1 gene expression levels were compared based on the 
minimum GABAB1 gene boundary from RNA-seq data. C. Gene expression levels were 
assessed based on the minimum GABAB1 gene boundary obtained from the UCSC 
genome browser database. 
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To confirm GABAB1 gene expression level changes in alcoholics, RPGM values 
were calculated for all genes from RefSeq Genes model and analyzed using another 
statistical analysis, DEGseq package (Wang, Feng et al. 2010). Among differentially 
expressed gene in alcoholics, GABAB1 gene was not found. As shown in Figure 3.5A, 
the expression level at the known GABAB1 gene length, 30,958 bp, was not changed 
significantly. 
DEGseq was developed for RPKM values to analyze transcript expression data. 
RPKM and RPGM generate different values for their expr ssions. To verify RPGM 
values are also good data input for DEGseq, we compared their transcripts expression 
data analyses using DEGseq (Figure 3.6). Both RPGM and RPKM showed similar MA 
plot data. They also found similar number of significantly changed transcripts in 
alcoholics. Their ratios to total transcripts were 0.74 % and 0.99 % at RPGM and RPKM 







Figure 3.6 Genome wide transcripts expression change comparison in alcoholics using 
RPGM and RPKM values. 
A. Genome wide transcripts expression changes were compared in alcoholics using 
RPGM. From RPGM values of all transcripts based on the RefSeq Genes model, we 
compared transcripts expression levels between alcoholi s and controls. B. Based on 
RPKM, genome wide transcripts expression changes were also compared in alcoholics. 
Like RPGM calculation, RPKM values were calculated for all transcripts based on the 
RefSeq Genes model, and their expression changes in alcoholics were examined. Both 
RPGM and RPKM data showed similar patterns from MA plot analyses using DEGseq 
package. The significantly changed transcripts were 0.74 % and 0.99 % at A and B, 
respectively (p-values < 0.001). X-axes represent the averages of log2RPGM or 
log2RPKM values for alcoholic and control groups. Y-axes are for differences between 
the values. Red dots represent genes, exons, introns, or splicing junctions that changed in 




3.2.6 GABAB1 exon and intron expression changes in alcoholics 
We next asked if expression levels of individual exons and introns of the 
GABAB1 gene might be different in non-alcoholic and alcoholic brain. GABAB1 has 23 
exons and 22 introns based on the RefSeq Genes model (Figure 3.4A). Among RPGM 
values of the exons and introns from all alcoholic and control samples, intron RPGM 
values were much smaller than exon expression levels although exon RPGM values vary 
among individual exons (Figure 3.7). RPGM values from exon 1 to 6 were much less 
than other exon expression levels. This indicates that GABAB1a splicing variant that 
contains all 23 exons cannot represent the overall GABAB1 gene expression though it is 
regarded as a major GABAB1 transcript and used for m st GABAB1 functional studies 
(Schwarz, Barry et al. 2000; Lee, Mayfield et al. 2010). Various exon combinations can 
yield numerous short GABAB1 transcripts, and their combined expression levels 




Figure 3.7 GABAB1 exon and intron expressions. 
RPGM values were calculated for each GABAB1 exon and intron from15 alcoholic and 
14 control samples. 5’ end GABAB1 exons showed extremely lower expression and 
indicated the abundant existence of small splicing variants instead of splicing variants 




For each GABAB1 exon and intron, we assessed expression level changes in 
alcoholics. From RPGMs for all exons and introns baed on the RefSeq Genes model, 
differentially expressed exons and introns were identifi d in alcoholics using the DEGseq 
package (p-value < 0.05). Among them, GABAB1 data were selected (Table 3.2). 
Among 23 GABAB1 exons, the expression of 9 exons increased, and 2 exon expressions 
decreased in alcoholics. Based on the expression level and direction, the exons were 
grouped (exons 7 - 8, exon 10, exons 11 - 12, exons 14 - 16, and exon 17). Within 
groups, expression levels (Figure 3.7) and directions (Table 3.2, Figure 3.8) were similar. 




Figure 3.8 GABAB1 exon, intron, and splicing junction changes in alcoholics. 
Exon and intron expression and splicing junction exist nce changes were compared 
between alcoholics and controls. Based on the RefSeq Genes model, RPGM values were 
calculated for all exons and introns. For all splicing junctions found from TopHat 
mapping, we calculated reads per kilobase of splicing junction model per million 
uniquely mapped reads (RPJMs). Among significant RPGM and RPJM changes, 
GABAB1 specific data were selected and summarized. The expressions of 11 exons were 
changed in alcoholics. In alcoholics, exon 10 and 17 expressions decreased, and 
expressions increased at 9 exons, e.g. exon 7, 8, 11, 12, 14, 15, 16, 19, and 22. Exon 7 - 
8, exon 10, exon 11 - 12, exon 14 - 16, and exon 17 were grouped based on expression 
directions and levels at Figure 3.7. Most the splicing junctions well explained why exon 
expressions were changed in alcoholics. Two more splicing junction changes could not 
alter neighboring exon expressions and showed the complexity of GABAB1splicing. Red 
and blue stars indicate significant exon expression increases and decreases in alcoholics, 
respectively. Double stars indicate p-values below 0.001, and single stars represent p-
values less than 0.05. Red and blue bars represent splicing junctions that significantly 
increased and decreased in alcoholics, respectively. Thick bars represent p-value below 
0.001, and thin bars represent represented p-value lower than 0.05. 
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Exon / intron Fold change p-value q-value(Benjamini et al. 1995) 
exon 7 1.47 9.39E-08 5.38E-06 
exon 8 1.38 2.30E-07 1.18E-05 
exon 10 0.79 2.33E-08 1.55E-06 
exon 11 1.27 1.68E-03 2.15E-02 
exon 12 1.14 9.58E-03 8.28E-02 
exon 14 1.31 2.99E-12 4.55E-10 
exon 15 1.32 2.30E-10 2.43E-08 
exon 16 1.47 9.02E-12 1.24E-09 
exon 17 0.63 3.72E-03 4.02E-02 
exon 19 1.22 3.76E-03 4.06E-02 
exon 22 1.16 1.96E-02 1.41E-01 
Table 3.2 GABAB1 exon and intron expression changes in alcoholics. 
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3.2.7 GABAB1 splicing junction changes in alcoholics 
To study GABAB1 splice junction changes in alcoholics, we calculated RPJM for 
each junction. The RPJM calculation also considered th  introns and intergenic regions 
because many unknown splicing junctions and mapped rea s were often found at introns 
and intergenic regions. 
Among RPJMs of all splice junctions from TopHat mappings, we identified 
junctions that significantly change in alcoholics (p-value < 0.05). Among these, 11 
differentially expressed GABAB1 junctions were found (Figure 3.8). They were ten 




Table 3.3 GABAB1 splicing junction existence changes in alcoholics.  
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The changes of splicing junctions could explain most exon and intron changes in 
alcoholics. Splicing junctions increased at exon 6 - 7 and exon 7 - 8 probably altered their 
neighboring exons 7 and 8 expression and explained why their expression increased. 
Splicing junctions decreased at exon 9 - 10 and exon 10 - 11 showing that exon 10 
spliced in transcripts were less abundant in alcoholics. The exon 11 - 12 splicing junction 
increase potentially explained why exon 11 and 12 expression increased in alcoholics. 
Splicing junctions increased at exon 13 - 14 as suggesting expression increase of 
transcripts that contained exon 14. Lastly, splicing junctions increased at exon 15 - 16 
and deceased at exon 16 - 17 indicating that the expression of transcripts containing exon 
15 and 16 increased without exon 17 (Figure 3.8). 
Changes in splicing junctions did not always change eighboring exon expression 
levels (Figure 3.8). A known junction at exon 20 - 21 and a novel splicing junction at 
exon 23 changed without affecting surrounding exon expression levels. Exon 20 and 21 
were the third and fourth left end exons of GABAB1 at RefSeq Genes tract (Figure 
3.4A). Between the two exons many unknown novel splicing junctions were loaded at 
User Supplied Track from our RNA-seq junction search step. They possibly diminished 
exon 20 and 21 expression though their splicing junctio  increased in alcoholics. A novel 
splicing junction spliced out 108 bp at the 3’ UTR and decreased existence in alcoholics. 
This novel splicing junction was not as abundant as other known junctions (Pickrell, Pai 
et al. 2010; Sorber, Dimon et al. 2011), and its length was much shorter than 1489 bp 
exon 23. Therefore, this splicing junction could not change exon 23 expression level. 
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However, miRBase search (http://www.mirbase.org/) showed that the splicing junction is 
a possible target of two miRNAs, e.g. has-miR-3916 and has-miR-2060. 
 
3.3 DISCUSSION 
In this study, our first gene specific RNA-seq study demonstrated the power of its 
deep sequencing to detect unexpected rare splicing junctions and splicing complexity 
from a single gene, GABAB1. The gene specific library data were provided to query 
whole transcriptome library data for junctions and exon/intron usage changes in a human 
psychiatric disease. Specifically, we showed that chronic alcohol abuse alters the 
production of variants of the GABAB1 gene without altering the overall abundance of 
transcripts. Our results from the GABAB1 gene raise the possibility that chronic alcohol 
abuse may affect the splicing of many genes in brain and other tissues. This is supported 
by our preliminary genome wide analysis showing many changes in exons/introns and 
splicing junctions in the brain samples used for the analysis of GABAR1 (data not 
shown). 
Exons were grouped based on similar expression patterns and large RPGM 
changes of their neighboring exons. These groups showed increased or decreased 
expression in alcoholics, and their RPGM changes were supported by RPJM changes. 
However, the expression changes seen with individual exon groups were apparently not 
large enough to change overall GABAB1 expression. Reasons for this include the 
possibility of transcript lengths much shorter than the whole GABAB1 gene and the 
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finding that different exons did not follow the same expression direction. For all 23 
GABAB1 exons, 9 exons increased in alcoholics. 2 exons decreased, and 12 exons had 
no change. This variable expression pattern probably prevented an overall GABAB1 
expression change in alcoholics. 
Quantitative real-time PCR and microarray data validated the variable GABAB1 
splicing changes. Our RNA-seq study showed that a known splicing junction at exon 22 - 
23 increased RPJM value in alcoholics and a known-alternative splicing junction between 
exon 14 and 16 did not show RPJM change (Figure 3.8). Quantitative real-time PCR data 
also generated the same patterns as the RNA-seq splicing junctions and showed the 
variable splicing changes (data not shown). Previous microarray studies using cDNA and 
oligonucleotide probes also validated most of our RNA-seq data. Although the increase 
in one cDNA microarray probe signal at intron 4 was not found in our RNA-seq data, 
four probes targeting exon 23 and another probe for intron 5 showed no GABAB1 
expression changes in agreement with our RNA-seq data (Flatscher-Bader, van der Brug 
et al. 2005; Liu, Lewohl et al. 2006; Ponomarev, Wang et al. 2011). 
It is of interest to note the functional importance of exons 10 and 17 which 
showed decreased expressions in alcoholics. Exon 10 participates in the binding of 
GABA on the receptors (Couve, Moss et al. 2000; Lee, Mayfield et al. 2010). A loss of 
GABA binding sites would likely diminish the response of GABA, and signal 
transduction of the GABAB receptor would be less efficient. Exon 17 contains the entire 
TM 3 as well as intracellular and extracellular regions between neighboring TMs. G 
proteins bind to the intracellular region between TM 3 and 4 (Lee, Mayfield et al. 2010). 
 101 
Without exon 17, GABAB receptors are not able to transfer signals through G proteins. 
At exon 23, alcoholics showed a RPJM decrease of a novel splicing junction that is a 
potential target for miRNAs at 3’ UTR. Therefore, splicing out of the miRNA target site 
decreases resulting in more of this target site in alcoholics allowing the miRNAs to 
destabilize GABAB1 transcripts that contain exon 23. The exon 23 containing transcripts 
include the most major GABAB1 splicing variants as well as some short splicing 
variants. Because overall GABAB1 gene expression does not change in alcoholics, an 
increase in non-functional variants would decrease the fraction of functional GABAB1 
receptors in alcoholic brain. Taken together, these r ults raise the possibility that altered 
splicing may reduce GABAB receptor function in the alcoholic brain and GABAB 
agonists may produce their beneficial effects in alcoholics because they enhance receptor 
signaling (Schweitzer, Roberto et al. 2004; Enserink 2011). 
Most RNA-seq libraries have been constructed using random primers and 
oligo(dT) primers for reverse transcription. The random primer method generates 
sequencing data from all existing RNAs based on expression levels, and the oligo(dT) 
method provides mostly 3’ UTR sequencing information f r all individual transcripts.. To 
maximize splicing junction detection for the GABAB1 gene, we prepared a gene specific 
library using gene specific primers for reverse transcription. This reverse transcription 
step captured GABAB1 specific transcripts and provided high resolution data for 
GABAB1 gene specific splicing studies. Although it is possible to capture cDNA from 
specific genes by modifying current DNA capture techniques (Hodges, Xuan et al. 2007; 
Ng, Turner et al. 2009; Fisher, Barry et al. 2011), it requires large amounts of cDNAs for 
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RNA-seq library construction. Human postmortem samples often provide very limited 
RNA and may not allow use of the capture method for RNA-seq library construction. 
To study gene expression and splicing junction exist nce changes, we employed 
two new strategies, RPGM and RPJM. From RNA-seq mapping data, we found 
numerous mapped reads at known intron regions of the RefSeq Genes model, and deep 
splicing junction searches using a gene specific library also identified many novel 
splicing junctions at known intronic and intergenic regions. RPKM, which is commonly 
used to study gene expression levels, is calculated based only on exon models and 
excludes the intron and intergenic regions (Mortazavi, Williams et al. 2008). For high 
resolution gene specific splicing study, we included s quence information from intronic 
and intergenic regions. Therefore, we modified the standard RPKM to consider these 
regions and defined new terminology, RPGM. Although RPKM is used for full-length 
transcript expression level calculations, RPGM can be used from gene level to small 
regions of the gene, such as exons and introns. If gene lengths are larger than the RefSeq 
Genes model as observed for GABAB1, RPGM can be calculated based on the new gene 
lengths. For RPJM calculation, we considered all of the exon, intron, and intergenic 
regions as modifying the RPGM calculation method. Previous research only identified 
splicing junctions without comparing splicing junctions quantitatively between groups 
(Pickrell, Pai et al. 2010; Sorber, Dimon et al. 2011). However, RPJM allows such 
quantitative comparisons among experimental groups. 
Among 65 splicing junctions found in human brain GABAB1 transcripts, about 
45 were rare and most were unknown junctions. Similar to this result, other studies have 
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also identified rare splicing from different genes and organisms (Pickrell, Pai et al. 2010; 
Sorber, Dimon et al. 2011). Splicing can provide new splicing variants with unique 
functions, e.g. down-regulating other major splicing variants (Mosley, Beckmann et al. 
1989; Schwarz, Barry et al. 2000; Ezzat, Zheng et al. 2001; Bulanova, Budagian et al. 
2007; Tiao, Bradaia et al. 2008; Lee, Mayfield et al. 2010), controlling transcript 
intracellular localization (Bell, Miyashiro et al. 2008; Jang, Park et al. 2010), or providing 
novel functions (Bell, Miyashiro et al. 2010; Gracheva, Cordero-Morales et al. 2011). 
There are potential implications of changes in GABAB1 splicing and function in 
prefrontal cortex of alcoholics. First, optimal function of this brain region is required for 
decision making and regulation of reward pathways, and reduced prefrontal cortex 
function is linked with dependence on alcohol and other drugs (Piomelli 2001; Flatscher-
Bader, van der Brug et al. 2005; O'Brien and Gardner 2005). Second, drugs acting on 
GABAB receptors have been used for treatment of alcoholism. In particular, baclofen, a 
GABAB agonist, may be effective at high doses (Enseri k 2011) but was not beneficial 
at lower doses (Garbutt, Kampov-Polevoy et al. 2010). Thus, it is possible that 
remodeling of the GABAB receptor by chronic alcohol abuse may reduce the 
effectiveness of baclofen requiring higher than expected doses for successful treatment. 
In summary, the complexity of GABAB1 receptor splicing and the perturbation of 
splicing by chronic alcohol abuse demonstrate the power of RNA-seq to provide new 
insight into gene expression and suggest that many other important brain genes may have 




3.4 MATERIALS AND METHODS 
3.4.1 rRNA depletion from total RNA 
15 control and 14 alcoholic postmortem prefrontal corti es were obtained from 
the Tissue Resource Centre (TRC) at the University of Sydney in Australia 
(http://www.braindonors.org/). TRC was funded by the National Institute on Alcohol 
Abuse and Alcoholism (NIAAA) and provide brain tissues for alcoholic research. 
Prefrontal cortex has important roles in reward circuit y to develop alcoholism and is the 
primary site of the pharmacological action of alcohol drug abuse (Alexander and Brown 
2011; Yizhar, Fenno et al. 2011). Samples were matched by gender, age, brain pH, and 
post-mortem interval (PMI) as closely as possible. D tailed sample information was 
described at our previous microarray research that used the same samples (Ponomarev, 
Wang et al. 2011). After RNA extraction, DNase (Ambion, Austin, TX, USA) was 
treating to their RNAs and commercial human prefrontal cortex total RNAs (Ambion, 
Austin, TX, USA). rRNAs were depleted using RiboMinus kit (Invitrogen, Carlsbad, CA, 
USA). 
3.4.2 RNA-seq library construction and sequencing 
To study GABAB1 specific splicing pattern changes, GABAB1 splicing junction 
identification was maximized using gene specific libraries prepared from the rRNA 
depleted commercial and postmortem prefrontal cortex total RNAs. During library 
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constructions, we used the commercial RNAs as internal standards. Unlike other common 
libraries that used random primers or oligo(dT) primers for reverse transcription, the gene 
specific library used gene specific primers. Because most known GABAB1 splicing 
variants share a common 3' UTR, the gene specific primers were designed at 3’ UTR of 
human GABAB1. The primers were designed using Primer3 
(http://frodo.wi.mit.edu/primer3/) and tested for their ability to bind the GABAB1 gene 
specifically with PrimerSelect (DNASTAR, Inc., Madison, WI, USA). One gene specific 
primer, GABBR1-C-ter-GSP-2, 5’ - AGAGACACCACAGTGTGAAAGG - 3’, was 
optimized for reverse transcription at 42 °C using SMARTer PCR cDNA Synthesis Kit 
(Clontech, Mountain View, CA, USA). Using a template switching method, dscDNAs 
were generated. For the amplification step, SMARTer2A-22mer, 5’ - 
AAGCAGTGGTATCAACGCAGAG - 3’ was designed based on the provided sequence 
of a primer, SMARTer II A Oligonucleotide, 5’ - 
AAGCAGTGGTATCAACGCAGAGTACXXXXX - 3’, which was bound at the 5’ end 
of transcripts during template switching step (X is a closed base in the proprietary 
sequence). After amplification with SMARTer2A-22mer and another gene specific 
primer, GABBR1-C-ter-GSP-1, 5’ - AGGTCCATCTGTCTATCCAAC - 3’, dscDNA 
generation was confirmed with gel electrophoresis. Using quantitative real-time PCR, an 
amplification cycle that had the least non-specific PCR products was selected among 
cycles generating maximum GABAB1 specific PCR products. The amplification cycles 
were from 25 to 35 cycles, and they vary whenever gene specific libraries were prepared. 
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Gel extraction removed unbound primers including small amplification products. 
Following the SOLiD™ 3 System Library Preparation Guide (Applied Biosystems, 
Carlsbad, CA, USA), the remaining dscDNAs were fragmented into about 200 bp, and 
gene specific libraries were prepared. 
The 3’ end exon of the GABAB1 gene is a long 3' UTR. he exon length is about 
1315 bp and about one third of the longest known tra script, GABAB1a. Because the 
gene specific library has a 3' bias, alternative gene specific primers were also designed at 
the 5’ end of the 3’ UTR to find more splicing junctions from ORF. For the alternative 
gene specific library, the primers for reverse transcription and amplification were 
substituted to GB1-Cter-1st-4, 5' - TCCCAGAGGTATGAG - 3', and GB1-Cter-2nd-1, 5' 
- CTACTGGCCTGTCCTCCCTCA - 3', instead of GABBR1-C-ter GSP-2 and 
GABBR1-C-ter-GSP-1, respectively. 
For whole transcriptome libraries, we used 15 control and 14 alcoholic 
postmortem prefrontal cortex total RNAs and commercial human prefrontal cortex total 
RNA. The whole transcriptome libraries were prepared using SOLiD™ Total RNA-Seq 
Kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s 
protocol. 
The gene specific and whole transcriptome libraries were sequenced at the 
Genomic Sequencing and Analysis Facility (GSAF) at the University of Texas at Austin 
using SOLiD system. For whole transcriptome libraries, some sequencing runs were 
repeated if they generated less than 10 million raw reads. For a few whole transcriptome 
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libraries, sequencing runs were maximized and generated approximately 100 million 
reads. The all reads that we used for our study were 50 mer single end reads. 
3.4.3 Comparison of gene specific and whole transcriptome libraries 
Total raw reads were filtered by sequencing quality. For every read, the number 
of quality values that were below 8 was counted. If the numbers were larger than 13 for a 
50 mer read, the reads were filtered out. For 35 mer reads, the reads were removed if the 
numbers were over 9. Non-coding RNAs (mostly rRNAs and transfer RNAs (tRNAs)) 
and adaptors were filtered out using Mapreads mapper (Applied Biosystems, Carlsbad, 
CA, USA). Two mismatches out of 20 mer reads were allowed for the mapper. TopHat, a 
splicing junction mapper, was used to detect splicing junctions (Trapnell, Pachter et al. 
2009). Most TopHat applications use .fq files as input files, and its test data set for 
installation was also the files as sequence inputs and we also used .fq files for our studies. 
To generate .fq files, our filtered sequencing data were converted to Illumina raw data 
format, .fastq files, as changing color base to base space. We modified to .fq files using 
fq_all2std.pl program (http://maq.sourceforge.net/fq_all2std.pl) (Trapnell, Pachter et al. 
2009). During format conversion, we removed reads that contain quality values, -1. For 
each sample, mapping was performed against hg18 using default option of TopHat. To 
visualize the mapping data, .sam files were modifie using igvtools 
(http://www.broadinstitute.org/software/igv/download). The modified files were 
visualized using IGV (http://www.broadinstitute.org/software/igv/) including the other 
TopHat outputs, .wig and .bed files. 
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3.4.4 Detection of splicing junctions 
To maximize splicing junction mining from individual sample mappings, the data 
process used to compare gene specific and whole transcriptome libraries was modified, 
and splicing junction data were subjected to TopHat m pping. To prepare splicing 
junction data, we added splicing junction search step before the final mapping. The step 
is individual TopHat mapping for the gene specific libraries and the whole transcriptome 
libraries from all commercial and postmortem brain samples. After filtering based on 
quality values and non-desired sequences (non-coding RNA and adaptor), their read 
formats were converted to .fq files. After the splicing junction search step, we collected 
splicing junctions from .bed files of the individual mapping results. To use only unique 
splicing junctions for next mapping, the .bed files were combined and converted to 
a .juncs file. Using the .juncs file, whole transcriptome library data of 14 alcoholics and 
15 controls were remapped. 
After recollecting splicing junction data from the s cond mapping, we generated a 
new .juncs file that contained unique splicing junction information. For visualization of 
the file, the splicing junction data was loaded at User Supplied Track of the UCSC 
genome browser. To compare our RNA-seq splicing junctio  data with other information 
at UCSC genome browser, RefSeq Genes, Human mRNAs from GeneBank, and Human 
ESTs That Have Been Spliced were also visualized. New minimum GABAB1 gene 
lengths were estimated based on the RNA-seq splicing junction data and mapped reads as 
well as the UCSC genome browser data. 
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3.4.5 Expression analyses using RPGM 
Using supercomputers at the Texas Advanced Computing Center (TACC) of the 
University of Texas at Austin, RPGMs were calculated for gene, exon, and introns based 










For the three different GABAB1 gene lengths, mapped r ads were counted from 14 
alcoholic and 15 control whole transcriptome libraries. RPGMs were calculated by 
dividing the mapped reads by the total million unique mapped reads to whole human 
genome and by kilobase gene length. After log2 transformation of the RPGM values, their 
differences in alcoholics were compared with two-tailed unpaired Student’s t-tests using 
R. 
We also calculated RPGMs for all genes, exons, and introns based on RefSeq 
Genes model. The RPGM value differences between alcoho i s and controls were tested 
using MARS of DEGseq R package. For multiple testing correction, the package 
calculated p-values adjusted to q-values by two alternative strategies (Wang, Feng et al. 
2010). GABAB1 specific data were selected from the analyses. 
To identify GABAB1 exon and intron expression level differences, RPGM values 
of the exons and introns were also calculated from 14 alcoholic and 15 control samples. 
Their data were compared based on mean ± SEM. 
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3.4.6 Splicing junctions in alcoholic samples 
To study GABAB1 splicing junction changes in alcoholics, we calculated RPJMs 
for all splicing junctions found from TopHat mapping using the supercomputers at 











Mapped reads were counted for each splicing junctio fr m whole transcriptome 
libraries of 14 alcoholics and 15 controls. The mapped reads were normalized per million 
unique mapped reads (total mapped read #) of the whole human reference genome. The 
reads were also divided by kilobase of splicing junction area length where mapped reads 
can reach the splicing junction. The splicing junction area length is (read length -1) × 2. 
Therefore, the splicing junction area length for ou50 mer read was 98. 
After calculating RPJM for individual samples, RPJM value differences between 
alcoholic and control groups were also analyzed using DEGseq package. The analysis did 
multiple test correction as adjusting p-values using two alternative q-values. Among 
splicing junctions that significantly change in alcoholics, GABAB1 splicing junctions 
were selected if they were found from multiple samples. 
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CHAPTER 4. USE NEW RNA-SEQ LIBRARY CONSTRUCTION TO 
SOLVE RNASEIII AND T4PNK SEQUENCE BIASES 
 
4.1 INTRODUCTION 
Next generation sequencing is revolutionizing biological data acquisition. It can 
be used instead of many existing specialized measurment approaches. For example, one 
of the next generation sequencing techniques, RNA-seq, may ultimately replace 
microarrays. Microarrays detect gene expression levels based on known probes. By 
contrast, RNA-seq does not have this limitation andcan measure expression levels at any 
region. In addition, it also provides information about SNP and the location of splicing 
junctions (Trapnell, Pachter et al. 2009; Canovas, Rincon et al. 2010; Shen, Catchen et al. 
2011). 
However, one disadvantage of RNA-seq is that its sequence data can be biased 
during library construction. For example, mapped read counts can over or underestimate 
true RNA abundances based on a variety of library construction steps, such as RT, 
adaptor ligation, or amplification (Romaniuk, McLaughlin et al. 1982; Hansen, Brenner 
et al. 2010; Metzker 2010; Willerth, Pedro et al. 2010). In a comparison of multiple 
library preparation methods for RNA-seq, all methods introduced their own bias and 
showed different expression patterns from the same sample (Linsen, de Wit et al. 2009). 
Here, we developed three new RNA-seq library preparation methods and compared them 
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with the current RNA-seq library construction method for the Applied Biosystems 
SOLiD system. We identified the step in library preparation that caused the most 
pronounced bias and outlined alternative preparation echniques that can virtually 
eliminate this concern. 
 
4.2 RESULTS 
4.2.1 RNA-seq library construction 
RNA-seq library construction methods vary among sequencing instruments. ABI 
SOLiD, Illumina HiSeq, and Roche 454 are three major RNA-seq sequencers. They have 
their own library preparation methods, and other companies also developed library 
construction methods for the sequencers. Furthermore, customized methods were 
designed based on researchers’ interests, for example, RNA-editing or poly(A) tail 
studies (Li, Levanon et al. 2009; Morabito, Ulbricht et al. 2010; Yoon and Brem 2010). 
In previous studies, random primers or oligo(dT) primers were used for RT of 
library preparation (Cloonan, Forrest et al. 2008; Hansen, Brenner et al. 2010; Yoon and 
Brem 2010). However, we used gene specific primers to develop a gene specific library 
for GABAB1 (Figure 4.1). The gene specific primers were designed for the 3’ UTR since 
most human GABAB1 transcripts share a common 3’ UTR (Lee, Mayfield et al. 2010). 
They were used for both RT and amplification (Figure 4.1). For our study, the gene 




Figure 4.1 Preparation of gene specific library. 
mRNA is visualized as a grey box flanked by black lines. The grey box represents the 
ORF, and the black lines represent UTRs. We obtained total RNA and depleted rRNA 
from it. RT was carried out using a GABAB1 gene specific primer. The resulting 
sscDNAs were converted to dscDNAs via template switching. After amplification with 
another gene specific primer, dscDNAs were sonicated. Adaptor ligated dscDNAs were 
sequenced with the SOLiD system.  
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4.2.2 Sequence mapping and visualization 
SOLiD system generates color space raw data that are expressed by numbers. 
Because two sequential bases are encoded by one number, the color space data was 
converted to base space sequence data for sequence analysis. Before converting the 
format, raw sequence reads were filtered by sequence quality values. Non-coding RNAs 
and adaptor sequences were also removed. The non-coding RNAs were primarily rRNAs 
and tRNAs. The filtered sequences were converted from color base .csfasta files to base 
space .fastq files that are used as Illumina sequence data format. After further file 
modification, the sequence data were mapped and visualized (Figure 4.2). 
Figure 4.2A shows the mapped reads that result from the gene specific library. 
Figure 4.2B illustrates the mapped reads resulting from the whole transcriptome library 
for the same chromosome location. The mapping patterns between these two libraries 
were dramatically different. Even though the chromosome region was a known exon and 
should be covered with continuous reads, the mapped rea s of the whole transcriptome 
library showed gaps and pile-ups. (We use the term pile-ups to refer to a substantial 
number of reads having exactly the same sequence as s en in Figure 4.2B.) This uneven 
coverage of exons with mapped reads demonstrates that the whole transcriptome library 




Figure 4.2 Mapping patterns of the gene specific library and the whole transcriptome 
library. 
A. Mapped reads for the gene specific library were visualized at IGV. B. For the same 
genomic region as in A, mapped reads for the whole transcriptome library were 
visualized. Compared to the gene specific library, the whole transcriptome library 
showed read pile-ups as well as gaps. At the gaps, no read was mapped at a known exon 
even though the gene specific library reads were mapped to these sites. 
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4.2.3 Comparison of the two sequencing data sets 
The pile-ups shown in Figure 4.2B might be the result of sequence bias at the 5' 
end of the read. To examine this possible sequence bias, we collected all mapped reads 
and calculated sequence logos (using WebLogo) and entropy at each nucleotide position 
(Figure 4.3). The height of letters in the sequence logo is based on entropy. Thus, our 
entropy profiles mimic the sequence logo profiles. We found that the 5’ ends of reads 
from the whole transcriptome library have a specific sequence pattern. The sequence logo 
results showed a predominant pattern of AA at the 5’ nd of the whole transcriptome 
library reads (Figure 4.3A). In contrast, reads from the gene specific library did not 
display this sequence pattern (Figure 4.3B). The strong bias in the whole transcriptome 
library was reflected in reduced entropy at the 5’ nd of reads (Figure 4.3C). In contrast, 
entropy for the gene specific library showed only a minor fluctuation without the 5’ end 
drop (Figure 4.3D). For controls of each library, we generated random exome sequences 
in silico based on mapped read locations. These controls showed almost no bias 
whatsoever (Figure 4.3, bottom rows in A, B, C, andD). The 5’ end sequence bias of the 
whole transcriptome library was also confirmed from GC ratio and nucleotide frequency 




Figure 4.3 Sequence logo and entropy analysis of mapped reads. 
We analyzed mapped reads for deviations from randomess using sequence logo and 
entropy. (Note that the height of letters in the sequence logo is given by the reduction in 
entropy from random expectation. Thus, large letters in the sequence logo correspond to 
depressions in the entropy numbers.) Subgraphs, A and C, show sequence logo and 
entropy data for the whole transcriptome library, respectively. Subgraphs, B and D, show 
the same quantities for the gene specific library. In each subgraph, the top graph shows 
actual results, and the bottom graph shows a computational control obtained by randomly 
generated sequences from human exome based on mapped read locations of each library. 
In all cases, we analyzed a window of 50 bp starting with the 5’ ends of the sequence 
fragments. The gene specific library showed almost n  deviations from randomness. By 




4.2.4 Comparison of the two library preparation methods 
The gene specific library and the whole transcriptome library were constructed 
very differently (Figure 4.4). To identify the source of the bias, we carefully reviewed all 
steps at which library construction differed. Most importantly, the bias could have arisen 
from fragmentation or its following steps. For the g ne specific library, dscDNA 
fragmentation was performed with sonication, and adaptors were ligated to the 
fragmented dscDNA using DNA ligase (Figure 4.4A). Sonication and DNA ligase 
possibly introduced the extremely minor noise (Figure 4.3B, D). However, these two 
steps were not known to cause sequence bias, and reds in our experiment were not 
sufficiently biased to introduce read pile-ups and mapping gaps (Figure 4.2A). By 
contrast, the whole transcriptome library construction method used RNaseIII 
fragmentation at the very beginning of the protocol (Figure 4.4B). Perhaps RNaseIII 
fragmentation causes a bias that has not been previously evaluated. However, the three 
steps following RNaseIII fragmentation (adaptor ligat on, RT, and amplification) (Figure 
4.4B) were already known to have sequence biases (Romaniuk, McLaughlin et al. 1982; 
Hansen, Brenner et al. 2010; Willerth, Pedro et al. 2010). Therefore, we first inspected 




Figure 4.4 Simplified construction methods of the gene specific library and the whole 
transcriptome library.  
A. The construction method of the gene specific library was simplified from Figure 4.1. 
B. The whole transcriptome library construction method was simplified. 
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We used RNA ligase for adaptor ligation. RNA ligase pr fers to bind to certain 
phosphate donors, but preference patterns have been studied only for short oligomers 
(Hansen, Brenner et al. 2010). In our case, phosphate donors were the fragmented single 
stranded RNAs (ssRNAs) of 200 bp in length. Figure 4.3A did not show the same 
sequence pattern as the short oligomer case (Hansen, Br ner et al. 2010). Therefore, its 
sequence bias either appeared in a different way at the fragmented ssRNAs or was too 
small to be detected from whole transcriptome library data. We concluded that the 
sequence bias we saw was likely not caused by RNA ligase. 
The bias for RT has been previously studied for the Illumina RNA-seq system 
(Hansen, Brenner et al. 2010). The randomly primed RT of Illumina RNA-seq causes 
substantial sequence biases at the 5' and 3' ends. However, our RT method was different 
from the Illumina method, and their respective biases are likely different. While the 
random primers of Illumina RNA-seq can hybridize on a y locations of mRNAs, the 
primers in our method are the overhangs of adaptors and can bind only to ends of 
fragmented ssRNAs. The overhangs are 4 bp random sequence and are used for RT. 
Because of this targeted priming, the sequence bias of the whole transcriptome library 
was totally different from the Illumina random primer case (Figure 4.3A) (Hansen, 
Brenner et al. 2010). Therefore, we concluded that it was unlikely that RT was a major 
source of bias in our library preparation. 
Finally, amplification is known to have GC bias (Willerth, Pedro et al. 2010). 
This bias could affect some transcript regions that might appear more or less highly 
expressed, but this could not generate 5' end sequence bias. 
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Therefore, we excluded the three steps (adaptor ligation, RT, and amplification) 
as major sources of 5’ end sequence bias of the whole transcriptome library. We next 
focused our efforts on RNaseIII. RNaseIII can digest ssRNA of preribosomal RNA and 
bacteriophage T4 (Dunn 1976; Elela, Igel et al. 1996). However, we removed all 
ribosomal RNAs and used only human RNA samples. Thoug  we used only about 200 bp 
fragmented RNAs, their ssRNA digestion products were not the length. During 
eukaryotic dsRNA metabolism, RNaseIII is generally considered to be a random cutter 
when it digests RNAs into 200 bp. It recognizes double stranded RNA structures and 
cleaves them (Elela, Igel et al. 1996). Cleavage usually produces both short and long 
fragments from RNA. In yeast, the short fragments are about 28 - 32 bp in length and 
have unique sequence (AGNN) in the middle as containi g hairpin structures 
(Lamontagne, Larose et al. 2001). In our system, the long fragments were around 200bp 
and used for RNA-seq. The short fragments were too sh rt for RNA-seq. 
Because RNaseIII specifically recognizes RNA secondary structure and leaves the 
unique sequence in the short fragments, it is not likely to be a perfect random cutter. 
Therefore, the long fragments could have an RNaseIII pecific sequence pattern as well. 
On the basis of this reason, we replaced RNaseIII fragmentation by an alternative method 
using heat. 
4.2.5 Alternative library construction 
We fragmented RNA at 95 °C when it was denatured. In denatured RNA, the 
hydrogen bonds are broken, and only covalent bonds remain. Denatured RNA has no 
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secondary structure. Therefore, each base can be attacked equally by heat, and we don’t 
expect that heat fragmentation can introduce 5’ end bias. 
However, heat fragmented RNA could not be used directly for adaptor ligation. 
The 5' and 3' ends of the heat fragmented RNA needed to be modified. We used T4PNK 
for the modification (Figure 4.5B). Its kinase activity adds phosphate groups at 5’ 
fragment ends. Its phosphatase activity removes phosphate from 3’ fragment ends and 
leaves hydroxyl groups. 
However, T4PNK is known to have sequence bias in its kinase activity according 
to the OptiKinase product information of Amersham Biosciences 
(http://www.gelifesciences.com/aptrix/upp00919.nsf/Content/2B2B93BBD26B478FC12
57628001D0D0C/$file/63005432.pdf). Therefore, we also tested an alternative 
preparation method where we applied OptiKinase before T4PNK treatment (Figure 
4.5C). OptiKinase has been shown not to have the sequence bias of T4PNK, but it does 
not have phosphatase activity at the 3' end. Here, we assumed that T4PNK has negligible 
bias in its phosphatase activity and used it following OptiKinase treatment for its 
phosphatase activity. (Our results showed that this assumption is valid, as shown below.) 
Note that for kinase activity, T4PNK treatment required the optimization for enzyme 
tittering and treatment time. Therefore, OptiKinase was clearly a better choice for future 
RNA-seq studies. 
To assess the sequence bias of these two newly proposed heat fragmentation 
methods, we prepared two new whole transcriptome libraries, together with a second 
iteration of the whole transcriptome library prepared according to the standard protocol 
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based on RNaseIII (Figure 4.5A). To reduce batch-to-batch sequencing variation, we 




Figure 4.5 Alternative fragmentation methods. 
A. RNaseIII was used for the current fragmentation method. B. Heat fragmentation 
method was used as an alternative fragmentation method. After heat fragmentation, 
T4PNK was applied to modify RNA fragment ends for adaptor ligation. T4PNK adds 
phosphate and hydroxyl groups at their 5’ and 3’ ends, respectively. C. Modified heat 
fragmentation method was designed using OptiKinase. OptiKinase reduces T4PNK bias 
introduced during the RNA fragment modification. Because OptiKinase has only kinase 
activity, T4PNK was used for phosphatase activity af er OptiKinase treatment. 
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4.2.6 Mapping results of novel libraries 
We processed paired-end reads instead of previous single-end reads and 
visualized both 5' and 3' read mapping results (Figure 4.6). Ctl refers to the library 
prepared with RNaseIII. Heat refers to the library generated with heat fragmentation and 
T4PNK. Heat + OptiK refers to the library that was generated with an additional 
OptiKinase step right after the heat fragmentation. 
As described before for Figure 4.2B, read pile-up is a indicator of the fragment 
end sequence bias. Ctl showed clear pile-ups for 5' read mapping results as expected 
(Figure 4.6A). By contrast, Heat had much fewer pile-ups, and Heat + OptiK had 
virtually no pile-ups. Also, Heat + OptiK had the most even and smoothly connected 
distribution of the mapped reads. 
Figure 4.6B shows mapping results for 3' reads. Ctl showed pile-up patterns just 
like in the 5' case. The pile-up patterns were weaker using Heat and largely disappeared 




Figure 4.6 Mapping patterns of the three whole transcriptome libraries. 
A. 5’ read mapping results of the three whole transcriptome libraries were visualized at 
IGV. Ctl refers to the library constructed using RNaseIII. Heat refers to the library 
constructed using the heat fragmentation method. Heat + OptiK refers to the library 
constructed using the modified heat fragmentation method. The pile-ups of duplicated 
reads are indicators for fragment end sequence bias. The red circles represent the pile-
ups. Ctl showed pile-ups. Heat had fewer numbers of pile-ups, and no pile-ups were 




4.2.7 Identifying the detailed sequence bias patterns of the three libraries, 
Ctl, Heat, and Heat + OptiK 
Next, we carried out sequence logo and entropy analyses for the three libraries 
(Figure 4.7). Figure 4.7A and C represent results for 5' reads, and Figure 4.7B and D 
represent results for 3' reads. 
As described before for Figure 4.3A, Ctl had a strong bias of AA at the 5’ end of 
reads and showed minor bias at the other positions (Figure 4.7A). Heat had less bias right 
at the 5’ end but had some bias throughout the entire 50 bp window. T4PNK is biased 
though its bias is somewhat less than RNaseIII bias at the 5’ end. Finally, Heat + OptiK 
had almost no bias throughout the entire 50 bp window. Even though its negligible bias 
shares the same sequences with Heat, OptiKinase decr as s the T4PNK sequence bias. 
For 5’ reads, Heat + OptiK was the least biased method overall. 
For 3' reads, biases of Ctl were generally more sevre than for the 5’ reads (Figure 
4.3B), but the overall bias pattern followed that of he 5’ reads. Ctl showed the strongest 
bias at the beginning of reads with a preferred sequence of GGTNTA. Heat was biased 
towards sequences starting with A or T and had small bi s ubiquitously throughout the 
sequence. The bias pattern was very different from the one found in Ctl. Thus, we believe 
that this bias was caused by the phosphatase activity of T4PNK. Most enzymes acting on 
nucleic acids are generally affected by nucleotide sequences near their reaction sites 
(Romaniuk, McLaughlin et al. 1982). Surprisingly, Heat + OptiK showed a much smaller 
sequence bias for 3' reads than Heat. Thus, it seems that pretreatment with OptiKinase 
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weakens the bias of T4PNK phosphatase activity because T4PNK mostly has 
phosphatase activity rather than kinase activity. 
As expected, the entropy results generally mirrored the sequence logo results 
(Figure 4.7C, D). The entropy plots show clearly that the entropy values for Heat + OptiK 
fall consistently above the entropy values for Ctl and Heat for both 5' and 3' end reads. 




Figure 4.7 Sequence logo and entropy analysis of mapped reads. 
A. We compared sequence logo results for 10,000 randomly selected mapped 5’ reads of 
Ctl, Heat, and Heat + OptiK. B. Sequence logo results of 3’ reads were also compared as 
in A. Ctl showed strong biases near the beginning of reads both for 5’ and 3’ reads. Heat 
had less biases at 5’ and 3’ reads but showed persist nt low level biases at all nucleotide 
positions. The biases did not have the same sequence bias patterns as Ctl. Therefore, 
RNaseIII generates sequence biases at both 5’ and 3’ ends. The 3’ end sequence bias, A 
or T, indicated the sequence bias of T4PNK phosphatase activity. Though Heat + OptiK 
had a similar sequence bias pattern as Heat, it was much smaller throughout the entire 
nucleotide positions. Thus, OptiKinase weakens T4PNK sequence biases, and Heat + 
OptiK is the best method. C and D show entropy results for 5’ and 3’ end reads, 
respectively. Lower entropy values correspond to greater sequence bias. 
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As a result of our study, we have obtained the sequence biases of RNaseIII and 
T4PNK. T4PNK kinase activity has a minor bias at the 5’ end of fragmented ssRNA. 
T4PNK phosphatase activity is biased mostly towards sequences with an A or T 
nucleotide at the fragment end of 3’ reads. Its sequence biases make less severe pile-ups 
than the broad RNaseIII sequence biases (Figure 4.6B). 
RNaseIII has biases at both the 5' and 3' ends (summarized in Figure 4.8A). Its 
sequence pattern was mostly 5' - AA···   ···TANACC - 3' (We reverse complemented 
the 3’ sequence here). Based on the known RNaseIII reaction mechanism, the two 5’ and 
3’ biased sequences were separated by the short fragmented RNAs (Figure 4.8B). Thus, 





Figure 4.8 RNaseIII specific cutting sites. 
A. Sequence biases of RNaseIII were summarized. RNaseIII specific cutting sites were 
mostly 5' - AA···   ···TANACC - 3'. (The 3' end reads are shown as reverse 
complement.) The red circle represents the 5' end cutting sites, and the blue circle 
represents the 3' end cutting site. B. The figure shows how these cutting sites map onto 
the helical regions cut by RNaseIII. The sites are disconnected by short fragment RNAs. 




We have found that the standard ABI RNA-seq protocol, SOLiD™ Total RNA-
Seq Kit, has substantial sequence biases and pile-us in mapped reads. The biases could 
be tracked to RNaseIII activity which preferentially cuts at specific locations. Other steps 
in library preparation, specifically RNA ligation, RT, and amplification seemed to be free 
of bias in the RNA-seq preparation method. By changing fragmentation from RNaseIII to 
heat, the sequence bias was largely eliminated, and the vast majority of the sequence pile-
ups disappeared. Therefore, heat fragmentation was superior to commercial RNaseIII 
methods when preparing RNA-seq. 
The pile-ups and gaps produced by the sequence biass c use erroneous results in 
the identification of SNPs and splicing junctions (which might be missed) and in the 
measurement of expression levels. Even though overall gene expression levels and 
finding were probably not significantly affected bythe pile-ups and gaps, a more precise 
expression analysis, e.g. a comparison of expression patterns among short exons, could 
be significantly affected by these biases. Also, genome wide splicing junction detection 
numbers were not significantly different among the ree different library preparations 
(data not shown). During RNA-seq study, most genes w re not highly expressed, and 
only few reads were mapped the genes. Therefore, read pile-up and gap cannot be issue at 
the less expressed gene and genome wide junction finding probably could not show 
significant difference. Also, whole transcriptome library could not show any failure to 
find splicing junctions from GABAB1 and GAPDH gene (data not shown). GABAB1 
gene is strongly expressed in brains, and GAPDH gene is an endogenous control for 
 133 
molecular biology experiments to measure RNA and protein. Therefore, splicing junction 
finding generally was not affected by the pile-up and gap issues except extremely high 
expressed genes. The issues probably can mostly fail in SNP finding or precise gene 
expression calculation. 
Our RNA-seq data showed the power of next generation sequencing to find 
unexpected sequence biases from enzymes and revealed previously unknown enzyme 
reaction sites. A huge population of RNA-seq reads llowed us to identify previously 
unknown sequence biases and targeting sites of two enzymes, RNaseIII and T4PNK. 
RNaseIII was previously considered to be a random cutter for dsRNAs. However, 
our study has shown that it indeed has preferred cutting sites. RNaseIII recognizes RNA 
secondary structure and digests the middle of double stranded RNA (Elela, Igel et al. 
1996; Lamontagne, Larose et al. 2001). Yeast RNaseIIIs recognizes the AGNN loop of 
the double stranded RNA (Lamontagne, Larose et al. 2001). Thus, it is not surprising that 
its cutting site should be non-random even if it had never before been identified. Our high 
resolution study of RNA-seq found that RNaseIII caused pile-up mapping at RNA-seq 
and had specific digesting sites to provide fragment ends with conserved sequences. Even 
though one recent study had identified conserved sequences at 5’ and 3’ end reads from 
several RNA-seq library construction methods (Roberts, Trapnell et al. 2011), it did not 
identify RNaseIII as the source of the sequence bias. It also did not provide a solution to 
remove the bias during library preparation. Importantly, we have been able to propose 
RNA-seq library construction methods that solve thebias issue and result in precise 
expression analysis. 
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Similarly, whether T4PNK phosphatase activity had a sequence bias was not 
previously known even though the bias in its kinase ctivity was known for short 
oligomers. We found a bias in its phosphatase activity and a unique minor bias in its 
kinase activity at ssRNA fragments. However, the amount of bias was strongly reduced 
when we treated RNA fragments with OptiKinase first. Apparently, when T4PNK is used 
for both kinase and phosphatase activities, its phos atase activity is more strongly 
biased than when it is used only for phosphatase activity. 
Among the various methods of library preparation we studied, Heat + OptiK was 
overall the least biased. However, while vastly improved over the manufacturer’s 
protocol, it is not a completely unbiased method. Entropy calculations and sequence 
logos showed small amounts of bias near the beginning of both 5’ and 3’ reads. Clearly, 
some of the remaining biases at fragment ends seem to be caused by T4PNK. The origins 
of any other minor deviations from complete randomness are not clear. They may be due 
to any combination of the other steps in library preparation, i.e. RNA ligation, RT, PCR 
amplification, and so on. Unfortunately, it is impossible to exclude all of the possibly 
biased steps from RNA-seq library preparation due to current technical limitations. 
Therefore, the individual steps should be optimized or substituted for less biased steps. 
If all RNaseIII families share the same cutting site , our identification of the 
RNaseIII specific cutting sites may provide useful applications in the prediction of 
miRNA genes. Drosha and Dicer belong to the RNaseIII family and produce miRNAs 
(Nam, Shin et al. 2005). Drosha recognizes hairpin structures in primary transcripts and 
produces pre-miRNAs after digestion in the nucleus. Dicer detects the hairpin structures 
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of the pre-miRNAs and carries out one more cleavage. Current prediction of miRNA 
genes is mostly based on RNA secondary structure. Th  mature miRNA sequences are 
mostly predicted by more than one hairpin precursor locus (Griffiths-Jones, Saini et al. 
2008). However, prediction accuracy tends to be low(Nam, Shin et al. 2005). If the 
RNaseIII specific cutting sites that we have identified are conserved for other members of 
the RNaseIII family including Drosha and Dicer, the RNaseIII specific cutting sites can 
be incorporated into methods of miRNA gene prediction and improve the prediction 
accuracy. 
 
4.4 MATERIALS AND METHODS 
4.4.1 Whole transcriptome library construction 
Total RNA from human prefrontal cortex was obtained from Ambion (Austin, 
TX, USA). RNA quality was evaluated using the Agilent 2100 Bioanalyzer RNA Nano 
Chip (Agilent Technologies, Santa Clara, CA, USA). fter treating samples with DNase 
(Ambion, Austin, TX, USA), rRNA was depleted from total RNA using the RiboMinus 
kit (Invitrogen, Carlsbad, CA, USA). rRNA depletion was verified by the Agilent 2100 
Bioanalyzer RNA Nano Chip. Whole transcriptome libraries were prepared using the 
SOLiD™ Total RNA-Seq Kit (Applied Biosystems, Carlsbad, CA, USA) according to 
the manufacturer’s protocol. 
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4.4.2 Gene specific library construction 
To prepare a gene specific library, gene specific primers for RT and amplification 
were designed at the 3’ UTR of human GABAB1. The prime s were designed using 
Primer3 (http://frodo.wi.mit.edu/primer3/) and testd for binding specificity with 
PrimerSelect (DNASTAR, Inc., Madison, WI, USA). After treating the human prefrontal 
cortex total RNA with DNase, GABBR1-C-ter-GSP-2, 5’ - 
AGAGACACCACAGTGTGAAAGG - 3’, was used for RT with the SMARTer PCR 
cDNA Synthesis Kit (Clontech, Mountain View, CA, USA). Using a template switching 
method, dscDNA was generated (Cloonan, Forrest et al. 2008). For the amplification 
step, SMARTer2A-22mer, 5’ - AAGCAGTGGTATCAACGCAGAG - 3’, was designed 
based on the sequence of a provided primer, SMARTer 2 A Oligonucleotide, that was 
bound at the 5’ ends of transcripts during the template switching step. After amplification 
with SMARTer2A-22mer and GABBR1-C-ter-GSP-1, 5’ - 
AGGTCCATCTGTCTATCCCAAC - 3’, the dscDNA generation was confirmed with 
gel electrophoresis. 
From the gel electrophoresis data, we optimized the number of amplification 
cycle based on band intensity. As soon as the band intensity reached maximum, an 
optimal amplification cycle was selected. The chosen cycle had the lowest level of non-
specific PCR products among the amplification cycles containing maximum levels of 
GABAB1 gene specific PCR products. The optimal amplification cycle was verified with 
quantitative real-time PCR experiments using TaqMan® Gene Expression Assays 
(Applied Biosystems, Carlsbad, CA, USA). Based on a previous GABAB1 study (Lee, 
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Mayfield et al. 2010), the primer and probe set targeting the exon 22 - 23 junction of 
GABAB1 was used to measure gene specific amplificaton level. 18S and GUSB were 
used for endogenous controls. For each amplification cycle, gene specific amplification 
levels were calculated from both endogenous controls. Among amplification cycles, a 
cycle was selected as soon as both gene specific amplification levels reached plateau. The 
selected cycle was the same as the optimal amplification cycle chosen from the gel 
electrophoresis data. 
Gel extraction removed small amplification products and the primers for RT, 
template switching, and amplification. According to the SOLiD™ 3 System Library 
Preparation Guide (Applied Biosystems, Carlsbad, CAUSA), the remaining dscDNA 
was sonicated to about 200bp length, and the gene specific library was prepared for 
SOLiD sequencing. 
4.4.3 Sequence mapping and visualization 
The libraries were sequenced using the SOLiD system, and TopHat was used for 
sequence mapping (Trapnell, Pachter et al. 2009). During mapping, reads that had low 
quality values were difficult to map and increased total mapping time. To eliminate these 
issues, we set up quality filter parameters to remove the reads. For every read, we 
counted the number of quality values that were below 8 (higher than 15% probability of 
incorrect base call). If the numbers were larger than 13 at 50 mer sequence reads, the 
reads were filtered out. For 35 mer sequence reads, reads were removed if the numbers 
were over 9. Non-coding RNAs (mostly rRNA and tRNA) and adaptors were filtered out 
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using the Mapreads mapper (Applied Biosystems, Carlsb d, CA, USA). Two mismatches 
out of 20 mer reads were allowed for the non-coding RNAs and adaptors mappings. After 
filtering, the remaining reads were converted to the .fastq file format. For TopHat 
mapping, the .fastq files were also converted to .fq files using fq_all2std.pl 
(http://maq.sourceforge.net/fq_all2std.pl). To visualize the mapping data, .sam files were 
processed by igvtools (http://www.broadinstitute.org/software/igv/download) and 
visualized with the IGV (http://www.broadinstitute.org/igv/). 
4.4.4 Sequence analysis 
All mapped reads were selected from the .fq files. From all the mapped reads we 
calculated entropy ( ) at each nucleotide position. Here, PA, PT, PG, 
and PC represent the relative abundances of each of the 4bases (A, T, G, and C). Among 
them, a random sample of 10,000 reads was used as input for sequence logo (a graphical 
representation of a conserved sequence pattern; http://WebLogo.berkeley.edu) (Crooks, 
Hon et al. 2004). For the gene specific library, we removed reads that contained the 
primer sequences used for amplification, and the remaining mapped reads were used for 
entropy calculation and sequence logo. We used the same number of reads as the 
remaining reads for the whole transcriptome library. As controls, for each library we 








4.4.5 Heat fragmentation library construction 
We evaluated two alternative heat fragmentation methods. Under the first method, 
300 ng rRNA depleted total RNA was added into nuclease free water (Ambion, Austin, 
TX, USA) up to 4.5 ul. Using a PCR machine, the RNA containing 0.2 ml tube was 
incubated at 95 °C for 80 minutes. Fragmented RNAs were verified using the Agilent 
2100 Bioanalyzer RNA Nano Chip. The size of RNA fragments was around 200bp. For 
the second method, we performed heat fragmentation in a buffer containing divalent ions 
following a previous study (Cloonan, Forrest et al. 2008) and other on-line protocols 
(http://grcf.jhmi.edu/hts/protocols/mRNA-Seq_SamplePr p_1004898_D.pdf; 
http://www.neb.com/nebecomm/ManualFiles/manualE6114.pdf). Its incubation time was 
shorter (10 minutes) than in the nuclease free water. Agilent 2100 Bioanalyzer RNA 
Nano Chip data verified that the second fragmentation method produced RNA fragments 
of comparable size to the ones produced by the first ragmentation method. The 
incubation time for both methods was optimized based on PCR machines, incubation 
temperature, solutions, RNA sources, and tube shape. 
After heat fragmentation in a buffer containing divalent ions, RNA ends had to be 
modified to allow adaptor ligation. We used T4PNK (USB, Cleveland, OH, USA) to add 
phosphate groups to 5’ ends and hydroxyl groups to 3’ ends. Adaptor ligation and 
subsequent steps of library construction were identcal o the manufacturer’s protocol of 
the SOLiD™ Total RNA-Seq Kit (Applied Biosystems, Carlsbad, CA, USA). 
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4.4.6 Updated heat fragmentation library construction 
To minimize known sequence bias of T4PNK, we introduced an additional 
treatment step to the heat fragmentation library construction. After heat fragmentation, 
we used OptiKinase (USB, Cleveland, OH, USA) to addphosphate groups to the 5’ ends 
of fragmented RNAs. Subsequently, we proceeded with T4PNK as before to leave 
hydroxyl groups to the 3’ ends of fragmented RNAs.  
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CHAPTER 5. DISCUSSION 
5.1 SUMMARY 
GABAB receptors are composed of two subunits, GABAB1 and GABAB2. 
Splicing provides GABAB1 with structural and functional diversity. cDNA microarrays 
showed strong signals from human prefrontal cortex using GABAB1 intron 4 region 
probes, suggesting the existence of novel splice variants. Based on the probe sequence 
analysis, we proposed two possible splice variants, GABAB1j and GABAB1k. The 
existence of human GABAB1j was verified by quantitative real-time PCR, and mouse 
GABAB1j was found from a microarray probe set based on the human GABAB1j 
sequence. GABAB1j ORFs and expression patterns werenot conserved across species, 
and they did not contain any important functional domains except sushi domains. We 
next focused our attention on GABAB1k. 
After obtaining PCR evidence for the presence of GABAB1k in human, mouse, 
and rat, it was cloned from human and mouse by PCR along with three additional 
isoforms, GABAB1l, GABAB1m, and GABAB1n. Their expression levels measured by 
quantitative real-time PCR were relatively low in brain although they may be expressed 
more robustly in specific cell types. GABAB1l and GABAB1m inhibited GABAB 
receptor induced GIRK currents in Xenopus oocytes measured using the two-electrode 
voltage clamp system. 
This study supports previous suggestions that intron 4 of the GABAB1 gene is a 
frequent splicing spot shared across species. Like GABAB1e, GABAB1l and GABAB1m 
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do not have TMs but have a dimerization motif. So, they also could be secreted and bind 
GABAB2 dominantly instead of GABAB1a. Only GABAB1l and GABAB1m are N- and 
C-terminal truncated splicing variants, and they impaired receptor function. This suggests 
that the intron 4 containing N-terminal truncation s necessary for the inhibitory action of 
the new splice variants. 
Given the complexity of these GABAB1 splicing variants, we sequenced gene 
specific libraries to maximize identification of GAB B1 specific splicing junctions. We 
obtained splicing junction data from sequencing data of gene specific and whole 
transcriptome libraries from human prefrontal cortex. We found that the GABAB1 gene 
is at least 2 to 3 times longer than the known GABAB1 gene. 
Mapped reads and splicing junctions were frequently found from intronic and 
intergenic regions of the RefSeq Genes model. To consider these regions, we introduced 
new strategies, RPGM and RPJM, to calculate gene expression and splicing junction 
levels, respectively. GABAB1 exon and intron RPGM data showed extremely low 
expression at the 5’ end exons and exon grouping pattern. This indicated that there are 
other short splicing variants besides GABAB1a, the longest known major transcript 
containing all exons. 
Previous microarray studies have shown increased expression of GABAB1 in 
alcoholic brains although this was dependent upon the probes used to measure 
expression. Chronic alcohol also changed expression of specific GABAB1 splicing 
variants. In our current studies, chronic alcohol altered expression of exons/introns and 
splicing junctions in human brain more than whole transcriptome expression including 
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GABAB1 gene expression. Most of the splicing junction changes could be explained 
based on changes in exons and introns. 
Decreased exon expression at a GABA biding site, a TM, and a miRNA binding 
site probably decrease the population of normal GABAB1 transcripts and thereby 
decrease normal signal transduction. This suggests that the therapeutic benefit of 
GABAB receptor agonists used in treating alcoholism may be due to a normalization of 
the impaired GABAB function produced by splicing in alcoholic brains. 
In these studies, we found GABAB1 splicing complexity and change in alcoholic 
brains. Its splicing complexity allowed us to clone ovel intron 4 containing GABAB1 
splicing variants that impair GABAB receptor function and to find many rare GABAB1 
splicing junctions using gene specific RNA-seq approaches. Because chronic alcohol 
treatment targets GABAB1 splicing rather than gene xpression, RNA-seq study found 
splicing junction and exon expression changes in alcoholic brains without gene 
expression changes. Additionally, our RNA-seq study showed the power of next 
generation sequencing using a huge population of reads. It found rare splicing junctions 
from GABAB1 gene and unexpected RNA-seq sequence biases including previously 
unknown enzyme reaction sites. 
During this RNA-seq study, we noticed that the whole transcriptome library 
displayed numerous read duplications (pile-ups) and gaps in known exons. The pile-ups 
and gaps of the whole transcriptome library caused a loss of SNP and splicing junction 
information and reduced the quality of gene expression results. Further, we found clear 
sequence biases for both 5’ and 3’ end reads in the whole transcriptome library. 
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To remove the biases, RNaseIII fragmentation was replac d with heat 
fragmentation. For adaptor ligation, T4PNK was used following heat fragmentation. 
However, its kinase and phosphatase activities introduced additional sequence biases. To 
minimize them, we used OptiKinase before T4PNK. Our results suggest that the heat 
fragmentation removed the RNaseIII sequence bias and sig ificantly reduced the pile-ups 
and gaps. OptiKinase minimized the T4PNK sequence biases and removed all remaining 
pile-ups and gaps thus maximizing the quality of RNA-seq data. 
In addition to the sequence bias solutions, our study f rther revealed the specific 
target sequences of RNaseIII and T4PNK. This is the first application of RNA-seq to 
discover unknown enzyme target sequences. The identif cation of RNaseIII target 
sequences could improve miRNA gene prediction accuracy if other members of the 
RNaseIII family, including Drosha and Dicer, also have specific target sequences. 
 
5.2 FUTURE DIRECTIONS 
5.2.1 Further studies of intron 4 containing splicing variant 
5.2.1.1 Further characterization of GABAB1k, l, m, and n 
To initially characterize novel GABAB1 splicing vari nts, we performed some 
electrophysiological experiments with four of the splice variants. Though additional 
GABAB1 splicing variant functions were predicted based on domain homology, their 
functions have not been studied. Therefore, further c a acterization studies are warranted. 
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GABAB1l and m do not contain TM and C-terminal intracellular domains but contain the 
dimerization motif (Figure 5.1A). Because they have th  same C-terminal pattern as 
GABAB1e (Schwarz, Barry et al. 2000), they are probably secreted and thus inhibit the 
function of other major splicing variants (Mosley, Beckmann et al. 1989; Schwarz, Barry 
et al. 2000; Ezzat, Zheng et al. 2001; Bulanova, Budagian et al. 2007; Tiao, Bradaia et al. 
2008) (Figure 5.1B). Further studies must be conducted to determine their cellular 
localization and function. For example, additional electrophysiology experiments should 
be performed using purified GABAB1l and m. To have inhibitory function in cytosol, 
their dimerization motif would probably dimerize with GABAB2 in a dominant manner 
as reported for GABAB1e (Schwarz, Barry et al. 2000). Co-immunoprecipitation (Co-IP) 
experiments could be performed to confirm the binding. 
Like GABAB1l and m, GABAB1k and n also need further characterization to 
find their functions. GABAB1k has exon 15 as a common splicing pattern in CNS 
(Schwarz, Barry et al. 2000) and possibly mediates a CNS specific function (Figure 
5.1A). Though GABAB1n has only a short extracellular region of GABAB1a, it contains 
one GABAB binding site and a part of the dimerization motif (Figure 5.1A). Therefore, it 




Figure 5.1 GABAB1 splicing variant domains and function. 
A. Functional domains of GABAB1 splicing variants. Thick black lines represent known 
splicing variants, and thick grey bars represent intron 4 containing splicing variants. TM 
and dimerization motif are emphasized by light blue lin s. B. Predicted mechanisms of 
GABAB1l and m (GB1l/m). Their secreted portion probably inhibits the function of 
major GABAB1 splicing variants (GB1). In the intracellular region, GB1l/m will 
dominantly bind to the GABAB2 subunit (GB2) excluding GB1. 
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GABAB1k, l, m, and n are good candidates for alcohol targets, and their alcohol 
effects needs to be studied. Alcohol actions on the known major GABAB1 isoforms 
(GABAB1a and b) are controversial (Dzitoyeva, Dimitrijevic et al. 2003; Roberto, 
Madamba et al. 2003), and we could not find an acute alcohol effect on GABAB1a 
mediated currents in oocytes (Figure A.1). However, GABAB receptor agonists are used 
in the treatment for alcoholism and alter acute behavioral and electrophysiological effects 
of alcohol (Allan, Burnett et al. 1991; Schweitzer, Roberto et al. 2004; Maccioni, Fantini 
et al. 2008; Maccioni, Pes et al. 2008; Enserink 2011). The previous microarray data 
showed expression increase at intron 4. Therefore, alcohol effects of the intron 4 
containing isoforms, GABAB1k, l, m, and n, should be examined using the two electrode 
voltage clamp system in Xenopus oocytes to find alcohol targets. 
5.2.1.2 Unknown intron 4 containing splicing variant studies based on 
GABAB1 splicing complexity 
RNA-seq and quantitative real-time PCR studies did not duplicate some of the 
previous cDNA microarray data. Though intron 4 targeting probes of the previous 
microarrays showed expression increases in alcoholic prefrontal cortices, RNA-seq 
experiment could not detect the expression increase at intron 4 (Figure 3.8). For 
quantitative real-time PCR experiments, GB2 was design d based on the microarray 
probe. However, it did not show increased expression at intron 4 (Figure A.2). Technical 
differences in the methods combined with the GABAB1 splicing complexity could result 
in differences in expression levels. RNA-seq and quantitative real-time PCR detect only 
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short portions (about 50 bp) from highly amplified short cDNA amplicons. However, the 
cDNA microarrays had about 1 Kbp detection resolutin. Their experiments were 
designed based on hybridization between cDNA probes and cDNAs prepared using 
amplified total RNAs. Therefore, RNA-seq and quantit tive real-time PCR experiments 
are not always the best methods to verify microarray d ta. To better repeat the previous 
microarray data, we should prepare identical cDNAs used for the previous microarrays 
and carry out Southern blot analyses. 
In view of the GABAB1 splicing complexity, there are likely additional intron 4 
containing splicing variants that change expression after chronic alcohol exposure. To 
verify their existences and expressions, northern blot experiments comparing non-
alcoholic and alcoholic brains are required. To clone the variants, we can screen 
prefrontal cortex cDNA libraries using colony hybridization experiments based on the 
intron 4 probe of the cDNA microarray. The roles of these splice variants and the effect 
of chronic alcohol on their expressions and functions are of future interest given the 
promising role of GABAB agonists in treating alcoholism. 
N-terminal truncated splicing variants have their own promoters and unique 
cellular distributions (Wang, Schultheis et al. 1996; Crofts, Hancock et al. 1998; Sunn, 
Cock et al. 2001; Travers, Vallance et al. 2003; Huang, Levitsky et al. 2009). The N-
terminal truncated intron 4 containing GABAB1 splicing variants probably follow the 
same patterns. During the promoter search using the PROMO website (Farre, Roset et al. 
2003), we found potential transcription factor binding sites based on sequence homology. 
To validate the potential promoters, we need to find the transcription initiation sites using 
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3’ RACE. Reporter assays will confirm transcription factor binding and promoters 
upstream from their transcription initiation sites. Chromatin immunoprecipitation (ChIP) 
and electrophoretic mobility shift assay (EMSA) will provide exact binding sites for 
specific transcription factors predicted by the PROMO search. Though their ORFs do not 
contain unique peptide sequences to design antibodies, they have unique transcript 
sequences. For cellular distribution studies, the transcript sequences will allow in situ 
hybridization or quantitative real-time PCR experiments. 
5.2.2 Further GABAB1 splicing and whole transcriptome studies 
5.2.2.1 Validation of splicing junction changes found from RNA-seq 
Our RNA-seq study found 65 GABAB1 splicing junctions. Some splicing 
junction changes in the RNA-seq data were also observed in alcoholics using quantitative 
real-time PCR (Figure A.2, A.3). GB1 targeted a know  splicing junction at exon 22 - 23 
and showed increased expression in alcoholic brains (Figure A.2). Using quantitative 
real-time PCR, GBc targeted known-alternative splicing junction between exon 14 and 16 
and showed similar results to the RNA-seq study (Figure A.3). We used human prefrontal 
cortex samples like the previous microarray studies (Liu, Lewohl et al. 2006). However, 
the quantitative real-time PCR experiments were performed for only two splicing 
junctions out of the 65 splicing junctions found from RNA-seq study. Therefore, more 
splicing junction data should be confirmed using quantitative real-time PCR. 
The splicing junction changes can be measured in two different ways. We can 
measure splicing out or in from transcripts. RPJM calculation of RNA-seq junction study 
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counted mapped reads that have splicing out. TopHat mapper has multiple junction 
finding steps that validate found splicing out each time to reduce false discovery rates. 
Though its default setting for maximum intron length is 500,000 Kbp, to diminish false 
discovery rate split segments of individual reads can be aligned much further and do not 
miss splicing out that is longer than 500,000 Kbp. Therefore, splicing junction finding 
and RPJM calculation for splicing out are highly accurate (Dimon, Sorber et al. 2010). 
However, for rare splicing junctions RPJM values are extremely low. RNA-seq may have 
difficulty in detecting rare splicing junctions for multiple samples and may not provide 
enough power for statistical tests. If we calculate nother value counting mapped reads 
that are spliced in, it will provide high values and higher power for rare splicing 
junctions. Therefore, it could a solution for rare splicing junction study. Mapped reads 
containing splicing in have short mapping extension into splicing junction regions. Read 
mapping always allows mismatches. The short mapping extension can have higher 
chance for false mapping if it has mismatches. Therefore, quantitative real-time PCR 
validation is strongly required for splicing in validation. In Figure A.2 and A.3, primer 
and probe sets, GB2, 3, 4, a, b, d, and e, specifically detected splicing ins, and their 
primers or probes were designed based on splicing ju ction sequences to detect them. For 
further study of rare splicing junctions, we can design primer and probe sets like them to 
perform quantitative real-time PCR experiments. 
 151 
5.2.2.2 Characterization of GABAB1 splicing junctions 
After RNA-seq data analysis, we predicted GABAB1 splicing functions in 
alcoholic brains based on functional domains. To confirm the predicted functions, we 
need to characterize particular splicing variants. U ing splicing variants without exon 10 
(exon 10 contains one GABA binding site), a GABA binding affinity test will help 
identify the function of this exon. Also, functional measurements (e.g., electrophysiology 
or cAMP production) can prove functional failure of the splicing variants due to less 
GABA binding sites. Splicing variants lacking exon 17, and thus lacking TM3, will not 
be localized on the membrane as functional receptors. Perhaps these variants would 
mimic the function of other secreted GABAB1 splicing variants and act to inhibit other 
major GABAB1 isoform functions. For exon 17 studies, we can follow the GABAB 
receptor inhibitory tests used for GABAB1k, l, and m outlined in chapter 2. Even if the 
abnormal TMs allow localization to the membrane, the receptors could not transfer 
GABA signals because a functional G protein binding site located at the intracellular 
region between TM 3 and 4 would not exist. Altered structural conformation based on the 
missing TM 3 would be expected to alter their locations and functions. Co-IP 
experiments of the splicing variants and G proteins would test their interaction. 
At exon 23, one miRNA target site is less spliced out and exposes more at 3’ UTR 
in alcoholic brains (Figure 3.8). Our RNA-seq data showed that the splicing site is a 
novel splicing junction, and the splicing site was a possible target site of 2 miRNAs. To 
confirm if the two miRNAs downregulate GABAB1 transcript expressions, miRNA 
luciferase reporter assay is required. For this assay, vectors need to be constructed using 
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GABAB1 3’ UTR with/without the splicing site. After co-transfection with one target 
miRNA and each vector construct, the assay will verify if the miRNA specifically targets 
the junction. Chronic alcohol also can alter miRNA expression levels (Avissar, McClean 
et al. 2009; Lewohl, Nunez et al. 2011). Therefore, expression studies of the two 
miRNAs should be tested in alcoholic brains. If they did not express in alcoholic brains, 
the miRNA effects will not likely play a critical role in alcoholics. 
5.2.2.3 Genome wide RNA-seq data analyses 
Chronic alcohol may target splicing machinery globaly in alcoholic brains. 
Altered splicing junction ratio in whole transcriptome is about 8 times higher than global 
gene expression change ratios in our RNA-seq study (Figure A.4). Splicing factors can 
affect splicing junctions (Grosso, Gomes et al. 2008), and neuronal splicing factors alter 
splicings in a neuron specific manner (Allen, Darnell et al. 2010). Splicing factor 
expressions were modulated by cellular and environmental signals (Pihlajamaki, Lerin et 
al. 2011). Therefore, it is feasible that chronic al ohol could influence splicing factor 
expressions in brain. Among all genes from the RefSeq Genes model, a preliminary 
analysis suggests that the most significantly changed genes found in the MA plot analysis 
(p-value < 0.001) were small nucleolar RNAs (snoRNAs) that can also regulate splicing 
like splicing factors (Table A.1) (Kishore and Stamm 2006). The functional study of 
snoRNAs and chronic alcohol will help determine if chronic alcohol preferentially targets 
the splicing mechanism compared to overall gene expression changes. 
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Like the longer GABAB1 gene length that we identified from its splicing 
junctions, other genes also can have longer gene lengths than their known gene lengths of 
the RefSeq Genes model based on their splicing junctions. The current gene model is not 
always accurate (Bernal, Crammer et al. 2007), and gene predictions have lower accuracy 
in finding the beginning and end of genes. Longer 3’ UTRs were frequently found in 
mammalian RNA-seq data (Mortazavi, Williams et al. 2008; Mangone, Manoharan et al. 
2010). Therefore, gene prediction models need to be updated to improve their accuracy 
(Guigo, Agarwal et al. 2000; Schweikert, Zien et al. 2009). Accurate gene lengths mean 
that we can calculate gene expression levels with hig er accuracy. Splicing junction data 
of our RNA-seq study helped update only GABAB gene length. To update all known 
gene lengths in genome wide, we also need to collect and analyze more splicing junction 
data for each gene from RNA-seq data. 
Though we found 291,553 splicing junctions from thewhole transcriptome, only 
65 GABAB1 junctions were used for our gene specific study. We thus need to analyze 
genome wide splicing junction data. After updating all gene lengths based on the RefSeq 
Genes model, we can assign splicing junctions to individual genes. Using gene and 
splicing junction expression levels, we can study their relationship like the correlation 
study between chromatin immunoprecipitation sequencing (ChIP-seq) and RNA-seq data 
(Pepke, Wold et al. 2009). Our splicing junction data showed that significantly changed 
junctions are mostly from the mitochondria chromosome (Table A.2). Among the top 100 
splicing junctions based on p-values, 85 junctions are from the mitochondria 
chromosome. Though the RefSeq Genes model is the most commonly used gene model 
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for RNA-seq, it does not have gene information for the mitochondria chromosome, and 
we have not calculated gene expression data for the mitochondria chromosome due to 
lack of a gene model. However, the mitochondria genes and splicings should be further 
characterized given the chronic alcohol effect thatwe observed. 
5.2.2.4 Case analysis to study splicing variation of individual samples 
RPJM values can be altered based on individual sample variations. Including 
alcoholism, their age, gender, brain pH, PMI, and smoking probably affect RPJM values. 
For our RNA-seq study, their RPJM fold changes in alcoholics vary among splicing 
junctions (Figure A.5). Among 65 GABAB1 splicing junctions, some selected GABAB1 
splicing junctions at Table A.3 had various mapped reads across samples. Some novel or 
partial_novel splicing junctions only existed in specific samples (Table A.3). These 
variations could not be simply grouped and explained only by alcoholism. Therefore, 
other variables (genetic polymorphisms, age, gender, brain pH, PMI, and smoking) for 
each sample should be also considered to understand the expression variations. 
5.2.3 Further RNA-seq bias studies 
5.2.3.1 Further library constructions to diminish RNA-seq biases 
In our RNA-seq study using alcoholic brains, we prepar d whole transcriptome 
libraries by RNaseIII fragmentations. To remove RNaseIII bias, a Heat + OptiK method 
should be used for RNA fragmentation of RNA-seq library reconstructions instead of 
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RNaseIII. The new libraries will allow more accurate gene expression level calculations 
and identify more splicing junctions and SNPs. 
To remove additional T4PNK sequence bias of the Heat + OptiK method (Figure 
4.7B, D), phosphatase could be used instead of T4PNK (Figure 5.2). Because no 
phosphatase sequence bias has been reported, it probably has less chance to have 





Figure 5.2 Possible whole transcriptome library construction to remove T4PNK sequence 
bias. 
A. Heat + OptiK method uses T4PNK after OptiKinase treatment. B. Updated Heat + 




5.2.3.2 Minor RNA-seq bias finding 
Our study is the first sequence bias study using the SOLiD sequencer. Most RNA-
seq biases were found from the Illumina genome analyzer. The biases are from PCR 
amplification, GC bias, and randomly primed RT (Hanse , Brenner et al. 2010; Aird, 
Ross et al. 2011). Our preliminary study showed that whole transcriptome libraries do not 
have GC bias (Figure A.6A). WebLogo sequence analyses u ing our whole transcriptome 
libraries did not show the same sequence biases found from the RNA-seq libraries that 
used randomly primed cDNA for the Illumina genome analyzer (Figure 1.11A, 4.3, 4.7) 
(Hansen, Brenner et al. 2010). The GC bias studies for the Illumina genome analyzer 
compared relative read abundances at each GC ratio (Figure 1.11B) (Aird, Ross et al. 
2011), but we used absolute read populations (Figure A.6). For our sequence bias study, 
we measured entropy instead of the nucleic acid frequency that used for the RNA-seq 
libraries for the Illumina genome analyzer (Figure 1.11A, 4.3, 4.7). The different 
measurements for the biases might not provide identical results. Nucleic acid frequency 
test in Figure 1.11A was more sensitive than our ent opy calculations. Small sequence 
biases can result in large signals during nucleic acid frequency calculation. Therefore, we 
should also measure the biases for our sequencing data following their methods. It will 
find more minor sequence bias patterns and improve our RNA-seq data quality. 
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5.3 LIMITATION OF STUDY 
As discussed previously, most human postmortem samples provided very limited 
RNA amounts and did not always allow further experim ntal designs including data 
validation. Though we proposed library reconstruction to diminish sequence biases of 
current RNA-seq data and quantitative real-time PCR to validate expression changes as 
further studies, they could not be performed using identical samples due to the material 
limitation. 
Though intron 4 containing GABAB1 splicing variant transcripts have unique 
nucleotide sequences, the peptide sequences are not likely to be sufficiently different to 
allow design splice-specific antibodies. Therefore, epitope tags (His, Flag, hemagglutinin 
(HA), or anti c-Myc (Myc) Tags) should be used to find their binding partners using Co-
IP experiments, but one must consider unexpected effects of epitope tags for data 
interpretation. Also, in situ hybridization could be designed based on their uniq e 
transcript sequences for their cellular localization studies. However, the in situ 
hybridization experiment can show only mRNA location. 
RNA-seq study collects reads generated from fragmented RNAs and needs further 
analysis steps for transcriptome reconstruction to find full length splicing variants. 
Though there are some software packages, such as Scripture and Cufflinks, for the 
transcriptome reconstruction (Garber, Grabherr et al. 2011), they could not always 
construct known splicing variant transcripts. Transcriptome reconstruction is inaccurate 
for genes that have high splicing complexity like GABAB1. Though RPGM calculation 
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is currently recommended for gene expression study, it is impossible to study individual 
transcript expressions. 
Due to the difficulty of transcriptome reconstruction, the 65 GABAB1 splicing 
junctions found from our RNA-seq study cannot be characterized completely. Though we 
have junction information, we cannot clearly predict the combinations that will constitute 
all the individual transcripts. We can characterize sp cific junction containing GABAB1 
transcripts based on known splicing transcript sequence, but there will be still questions 
for their functions. 
As previously mentioned, it is currently impossible to design non-biased RNA-
seq library due to technical limitation. All individual library preparation steps possibly 
contain unknown biases. Though computational approaches and new library 
constructions tried to overcome the bias issue, there is no perfect solution. Therefore, we 




In this study, intron 4 containing novel splicing variant cloning and our first gene 
specific RNA-seq experiments showed the splicing complexity of GABAB1 gene. They 
detected unexpected novel splicings from GABAB1 gene. The novel GABAB1 splicing 
variant cloning confirmed that intron 4 is a frequent alternative splicing spot (Wei, Jia et 
al. 2001; Holter, Davies et al. 2005; Tiao, Bradaia et al. 2008). The gene specific RNA-
 160 
seq detected about 40 unknown splicing junctions from GABAB1 genes and 
demonstrates the power of deep sequencing. The splicing junctions provided strong 
evidence to extend GABAB1 gene length and indicated that GABAB1 gene area is 
overlapped with neighboring genes. Therefore, GABAB1 gene has extreme complexity in 
splicing. 
Chronic alcohol abuse alters GABAB splicing rather than overall gene expression 
in prefrontal cortex. Though our RNA-seq data showed no GABAB1 gene expression 
change in alcoholics, GABAB1 splicings were affected by chronic alcohol. Ten splicing 
junctions out of 22 known GABAB1 junctions were changed, and 11 exons among total 
22 known exons were also altered their expressions in alcoholics. Genome wide RNA-
seq data analysis also found that chronic alcohol canges splicing and exon/intron 
expressions more than gene expressions (Figure A.4) and suggested that splicing as a 
mechanism of brain and transcriptome changes from chronic alcohol. Microarray 
experiments showed expression increases with only one intron 4 targeting probe among 6 
different GABAB1 probes (Flatscher-Bader, van der Brug et al. 2005; Liu, Lewohl et al. 
2006; Ponomarev, Wang et al. 2011). Our quantitative real-time PCR experiments 
showed an expression increase only at exon 22 - 23 junction among 11 target regions at 
GABAB1 gene (Figure A.2, A.3). These data suggest production of splice variants that 
will have impaired function with no increase in total GABAB receptors. This could have 
important implications for use of GABAB drugs in treatment of alcoholism. However, 
the critical and difficult goal for the future is defining the functional changes produced by 
the diverse GABAB splicing changes found in alcoholics. This should provide a 
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paradigm for addressing the broader question of the role of splicing in other genes and 







Figure A.1 Alcohol effect on GABAB1a mediated currents in oocytes. 
GABAB1a cRNAs were injected into Xenopus oocytes including GABAB2 cRNAs and 
GIRK1/2 cDNAs. GABAB1a mediated currents were measured using the two electrode 
voltage clamp system. A, B, and C. Acute ethanol (EtOH) effects on GABAB1a 
mediated currents were tested using 50, 100, and 200 mM EtOH, respectively. D. Effect 
of 1.1 mM hexanol on GABAB1a mediated currents. E. Experimental design for ethanol 
and hexanol experiments. 49mM HK, EtOH or Hexanol, and GABA were represented by 
black, blue, and red, respectively. Each line showed tr atment time. 20 minutes (mins) 
were for washing using ND96 buffer.  
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Figure A.2 Quantitative real-time PCR data for previous microarray probes and intron 4 
containing splicing variants. 
Based on the cDNA microarray data, quantitative real-time PCR was performed. The 
primer and probe sets, GB1 and GB2, were designed based on previous microarray 
probes. GB1 targets a splicing junction between exon 22 and 23. GB2 was a microarray 
probe from intron 4. GB3 and GB4 target splicing variants that have intron 4 in their 
transcripts. GB3 represents GABAB1k, l, m, and n, and GB4 targets GABAB1j. Though 
a GB2 expression increase was expected in alcoholic bra ns based on the microarray data, 






Figure A.3 GABAB1 splicing junction studies using quantitative real-time PCR. 
A. After searching known GABAB1 splicing junction iformation from human, mouse, 
and rat, quantitative real-time PCR primer and probe sets were designed for the splicing 
junctions. GBa-1 and GBc represent know-alternative splicing junctions, and GBf 
represents a spliced out site at exon 23. GBa targets splicing variants containing exon 4. 
GBb, GBd, and GBe detect splicing variants containing introns that have been spliced in. 
B. None of the primer and probe sets showed significant difference between alcoholics 
and controls, but no expression change of GBc was similar to our RNA-seq data. GBd 





Figure A.4 Genome wide gene, exon, intron, and splicing junction changes in alcoholics. 
A. Genome wide gene expression changes were compared in alcoholics. From RPGM 
values of all genes based on the RefSeq Genes model, we compared gene expression 
levels between alcoholics and controls. B. Exon and intron expressions were compared 
between alcoholics and controls. Based on the RefSeq Genes model, RPGM values were 
also calculated for all exons and introns, and significant RPGM changes were assessed. 
C. For all splicing junctions found from RNA-seq study, we assessed RPJM changes in 
alcoholics. Significantly different RPGM and RPJM values in alcoholics were identified 
using the DEGseq package. Significant gene expression changes by alcoholism were 
about 1.8 % of total number, but exons/introns and splicing junctions were about 14 % 
and 15 %, respectively (p-values < 0.001). X-axes represent the averages of log2RPGM 
or log2RPJM values for alcoholic and control groups. Y-axes are for differences between 
the values. Red dots represent genes, exons, introns, or splicing junctions that changed in 
alcoholics (p-values < 0.001), and the red dotted lines are p-value 0.001 lines. 
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Figure A.5 Fold changes in alcoholics for GABAB1 splicing junctions. 
We calculated log2(fold change) for each splicing junction that significantly changed 






Figure A.6 GC distributions of whole transcriptome library and random sequences. 
A. GC distribution was calculated based on read population at each GC ratio. B. GC 
distribution calculation using random sequences. X-axis is for GC ratio, and Y-axis 
represents read number. The left, the middle, and the right red lines represent minimum, 





Num gene ID type fold change p-value q-value(Benjamini et al. 1995) q-value(Storey et al. 2003)
1  SNORA42 non-coding RNA 1.90 0.00E+00 0.00E+00 0.00E+00
2  SNORD27 non-coding RNA 0.65 0.00E+00 0.00E+00 0.00E+00
3  RNU6ATAC non-coding RNA 0.63 0.00E+00 0.00E+00 0.00E+00
4  SNORA81 non-coding RNA 0.72 0.00E+00 0.00E+00 0.00E+00
5  SNORD47 non-coding RNA 0.52 0.00E+00 0.00E+00 0.00E+00
6  SNORD115-10_dup3 non-coding RNA 0.69 0.00E+00 0.00E+00 0.00E+00
7  SNORD115-5_dup1 non-coding RNA 1.13 2.49E-177 6.73E-174 6.73E-174
8  SNORD115-39 non-coding RNA 0.78 4.11E-176 9.72E-173 9.72E-173
9  SNORD76 non-coding RNA 0.68 1.80E-171 3.78E-168 3.78E-168
10  SNORD115-34 non-coding RNA 0.81 6.29E-164 1.19E-160 1.19E-160
11  SNORD100 non-coding RNA 1.24 3.73E-151 6.41E-148 6.41E-148
12  CDR1 coding RNA 1.75 1.36E-148 2.14E-145 2.14E-145
13  SNORD116-8 non-coding RNA 0.68 5.20E-111 7.57E-108 7.57E-108
14  SNORD114-12 non-coding RNA 0.76 1.61E-106 2.17E-103 2.17E-103
15  SNORD115-30 non-coding RNA 0.80 3.38E-102 4.26E-99 4.26E-99
16  SNORD115-33 non-coding RNA 0.78 1.65E-99 1.95E-96 1.95E-96
17  SNORD116-18 non-coding RNA 0.62 1.65E-98 1.84E-95 1.84E-95
18  SNORD115-42 non-coding RNA 0.81 4.67E-98 4.65E-95 4.42E-95
19  SNORD115-15_dup2 non-coding RNA 0.81 4.67E-98 4.65E-95 4.42E-95
20  SNORD115-10_dup5 non-coding RNA 0.81 4.67E-98 4.65E-95 4.42E-95
21  SNORD44 non-coding RNA 0.53 2.11E-92 1.90E-89 1.90E-89
22  SNORA84 non-coding RNA 2.18 7.52E-88 6.47E-85 6.47E-85
23  SNORA67 non-coding RNA 1.59 4.33E-86 3.56E-83 3.56E-83
24  SNORA52 non-coding RNA 1.74 9.46E-84 7.46E-81 7.46E-81
25  MALAT1 non-coding RNA 1.36 6.94E-83 5.25E-80 5.25E-80
26  SNORD113-6 non-coding RNA 0.50 3.03E-78 2.20E-75 2.20E-75
27  SNORD115-23 non-coding RNA 0.88 1.04E-76 7.28E-74 7.28E-74
28  SCARNA20 non-coding RNA 2.44 1.93E-76 1.30E-73 1.30E-73
29  SNORD33 non-coding RNA 1.24 4.03E-73 2.63E-70 2.63E-70
30  SNORD117 non-coding RNA 0.66 1.61E-68 1.02E-65 1.02E-65
31  SNORA10 non-coding RNA 1.63 5.53E-65 3.37E-62 3.37E-62
32  LOC85389 non-coding RNA 1.24 2.42E-62 1.43E-59 1.43E-59
33  SNORA80 non-coding RNA 1.65 1.47E-61 8.44E-59 8.44E-59
34  SNORD115-38 non-coding RNA 0.87 1.04E-54 5.79E-52 5.79E-52
35  SNORD115-14 non-coding RNA 0.76 1.03E-53 5.55E-51 5.55E-51
36  SNORA54 non-coding RNA 0.82 6.62E-53 3.48E-50 3.48E-50
37  SNORD84 non-coding RNA 0.76 1.53E-51 7.80E-49 7.80E-49
38  SNORD95 non-coding RNA 1.31 1.39E-49 6.94E-47 6.94E-47
39  SNORD112 non-coding RNA 0.55 2.75E-49 1.33E-46 1.33E-46
40  SNORA28 non-coding RNA 0.57 3.71E-49 1.75E-46 1.75E-46
41  SNORD115-32 non-coding RNA 0.87 7.05E-49 3.25E-46 3.25E-46
42  SNORD61 non-coding RNA 0.84 1.44E-48 6.47E-46 6.47E-46
43  KIAA0907 coding RNA 1.88 1.57E-43 6.92E-41 6.92E-41
44  SNORD116-22 non-coding RNA 0.76 6.48E-43 2.79E-40 2.79E-40
45  SNORD58A non-coding RNA 0.73 7.75E-37 3.26E-34 3.26E-34
46  SNORA70 non-coding RNA 1.57 6.52E-36 2.68E-33 2.68E-33
47  SNORD97 non-coding RNA 0.81 7.39E-35 2.97E-32 2.97E-32
48  SNORA63 non-coding RNA 0.77 7.81E-34 3.08E-31 3.08E-31
49  SNORD114-1 non-coding RNA 0.81 8.68E-33 3.35E-30 3.35E-30
50  SNORD116-29 non-coding RNA 0.75 7.84E-32 2.97E-29 2.97E-29
51  SNORD26 non-coding RNA 0.90 7.88E-31 2.92E-28 2.92E-28
52  SNORD115-41 non-coding RNA 0.88 2.54E-30 9.24E-28 9.24E-28




Num gene ID type fold change p-value q-value(Benjamini et al. 1995) q-value(Storey et al. 2003)
54  SNORD58B non-coding RNA 0.79 3.08E-28 1.08E-25 1.08E-25
55  SNORD115-40 non-coding RNA 0.86 3.13E-28 1.08E-25 1.08E-25
56  SNORD12C non-coding RNA 0.63 2.52E-27 8.51E-25 8.51E-25
57  SNORD31 non-coding RNA 0.75 1.03E-26 3.43E-24 3.43E-24
58  SNORD59B non-coding RNA 0.71 2.43E-25 7.91E-23 7.91E-23
59  SNORD83A non-coding RNA 3.85 1.62E-24 5.20E-22 5.20E-22
60  SNORD115-4 non-coding RNA 0.67 3.89E-24 1.23E-21 1.23E-21
61  GFAP coding RNA 2.00 1.19E-23 3.70E-21 3.70E-21
62  SNORA20 non-coding RNA 0.82 1.64E-23 5.01E-21 5.01E-21
63  SNORA53 non-coding RNA 0.57 1.86E-23 5.59E-21 5.59E-21
64  SNORD46 non-coding RNA 0.82 3.00E-23 8.87E-21 8.87E-21
65  SCARNA1 non-coding RNA 0.59 4.20E-23 1.22E-20 1.22E-20
66  SNORA75 non-coding RNA 0.73 8.75E-23 2.51E-20 2.51E-20
67  SNORD50B non-coding RNA 0.74 4.55E-22 1.28E-19 1.28E-19
68  SNORA14B non-coding RNA 0.86 4.93E-22 1.37E-19 1.37E-19
69  SNORA2A non-coding RNA 1.58 1.91E-21 5.22E-19 5.22E-19
70  SNORA8 non-coding RNA 0.79 1.02E-20 2.76E-18 2.76E-18
71  SNORA41 non-coding RNA 0.74 2.29E-20 6.10E-18 6.10E-18
72  SNORD42B non-coding RNA 0.71 4.00E-20 1.05E-17 1.05E-17
73  SNORD8 non-coding RNA 0.85 8.47E-20 2.19E-17 2.19E-17
74  SNORD115-15_dup1 non-coding RNA 0.92 2.33E-19 5.96E-17 5.96E-17
75  PAR4 non-coding RNA 0.88 3.09E-19 7.78E-17 7.78E-17
76  SNORD90 non-coding RNA 0.70 3.30E-19 8.21E-17 8.21E-17
77  SNORD116-16 non-coding RNA 0.84 7.64E-19 1.88E-16 1.88E-16
78  SNORD10 non-coding RNA 0.60 1.82E-18 4.40E-16 4.40E-16
79  SNORD9 non-coding RNA 0.90 1.48E-16 3.54E-14 3.54E-14
80  SNORD115-2 non-coding RNA 0.73 4.82E-16 1.14E-13 1.14E-13
81  SNORD113-9 non-coding RNA 0.82 4.00E-15 9.35E-13 9.35E-13
82  SNORA46 non-coding RNA 0.67 8.11E-14 1.87E-11 1.87E-11
83  SNORD116-1 non-coding RNA 0.92 9.92E-14 2.26E-11 2.26E-11
84  SNORD113-7 non-coding RNA 0.75 1.02E-13 2.30E-11 2.30E-11
85  SNORA7B non-coding RNA 1.50 1.16E-13 2.58E-11 2.58E-11
86  IFITM1 coding RNA 3.19 2.21E-13 4.85E-11 4.85E-11
87  SNORD5 non-coding RNA 0.77 4.20E-13 9.13E-11 9.13E-11
88  SNORD104 non-coding RNA 1.08 6.62E-13 1.42E-10 1.42E-10
89  SNORD105 non-coding RNA 0.69 7.55E-13 1.61E-10 1.61E-10
90  SCARNA5 non-coding RNA 1.09 1.76E-12 3.69E-10 3.69E-10
91  SNORA71D non-coding RNA 2.08 3.84E-12 7.98E-10 7.98E-10
92  SNORD41 non-coding RNA 1.24 3.99E-12 8.21E-10 8.21E-10
93  SNORA47 non-coding RNA 1.75 6.99E-12 1.42E-09 1.42E-09
94  SNORD38B non-coding RNA 0.76 9.27E-12 1.87E-09 1.87E-09
95  NCRNA00084 non-coding RNA 1.85 1.01E-11 2.00E-09 2.00E-09
96  SNORD125 non-coding RNA 1.16 1.08E-11 2.12E-09 2.12E-09
97  SNORD116-2_dup1 non-coding RNA 0.93 2.33E-11 4.54E-09 4.54E-09
98  SNORA26 non-coding RNA 0.81 5.52E-11 1.07E-08 1.07E-08
99  SNORD113-4 non-coding RNA 0.68 6.16E-11 1.18E-08 1.18E-08
100  SNORA37 non-coding RNA 1.26 6.49E-11 1.23E-08 1.23E-08
101  SNORD113-5 non-coding RNA 0.80 1.47E-10 2.75E-08 2.75E-08
102  SNORD121B non-coding RNA 0.48 1.60E-10 2.97E-08 2.97E-08
103  EIF4A2 coding RNA 0.81 2.16E-10 3.97E-08 3.97E-08
104  SNORD115-37 non-coding RNA 0.38 2.19E-10 3.99E-08 3.99E-08
105  SNORA74A non-coding RNA 0.58 3.05E-10 5.50E-08 5.50E-08




Num gene ID type fold change p-value q-value(Benjamini et al. 1995) q-value(Storey et al. 2003)
107  GAS5 non-coding RNA 0.69 2.15E-09 3.80E-07 3.80E-07
108  SNORD96A non-coding RNA 1.16 3.80E-09 6.65E-07 6.63E-07
109  SNORA35 non-coding RNA 0.60 3.82E-09 6.63E-07 6.63E-07
110  SNORA49 non-coding RNA 1.11 3.93E-09 6.76E-07 6.76E-07
111  SNORD114-14 non-coding RNA 1.19 4.62E-09 7.88E-07 7.88E-07
112  ACTB coding RNA 1.27 6.61E-09 1.12E-06 1.12E-06
113  SNORD91A non-coding RNA 0.79 7.47E-09 1.25E-06 1.25E-06
114  SNORD116-6 non-coding RNA 0.92 1.24E-08 2.04E-06 2.04E-06
115  SNORD116-2_dup2 non-coding RNA 0.92 1.24E-08 2.04E-06 2.04E-06
116  SNORD115-44 non-coding RNA 1.23 1.49E-08 2.43E-06 2.43E-06
117  NPAS4 coding RNA 20.37 3.08E-08 4.98E-06 4.98E-06
118  SNORD54 non-coding RNA 0.85 5.65E-08 9.05E-06 9.05E-06
119  SNORD116-21 non-coding RNA 0.87 6.09E-08 9.68E-06 9.68E-06
120  SNORA64 non-coding RNA 1.23 7.39E-08 1.17E-05 1.17E-05
121  SNORD12B non-coding RNA 0.35 1.25E-07 1.95E-05 1.95E-05
122  SERPINA3 coding RNA 11.45 1.35E-07 2.09E-05 2.09E-05
123  APLNR coding RNA 3.56 1.53E-07 2.36E-05 2.36E-05
124  SNORD123 non-coding RNA 0.31 1.76E-07 2.68E-05 2.68E-05
125  CLU coding RNA 1.39 1.89E-07 2.86E-05 2.86E-05
126  SNORD119 non-coding RNA 0.53 1.90E-07 2.86E-05 2.86E-05
127  SNHG1 non-coding RNA 0.79 2.30E-07 3.43E-05 3.43E-05
128  SNORD115-3 non-coding RNA 5.72 2.43E-07 3.60E-05 3.60E-05
129  SNORD63 non-coding RNA 0.69 2.81E-07 4.12E-05 4.12E-05
130  SNORD109B_dup1 non-coding RNA 0.36 3.33E-07 4.83E-05 4.81E-05
131  SNORD109A_dup1 non-coding RNA 0.36 3.33E-07 4.83E-05 4.81E-05
132  SCARNA18 non-coding RNA 0.56 4.53E-07 6.50E-05 6.50E-05
133  SNORD12 non-coding RNA 0.75 5.09E-07 7.24E-05 7.24E-05
134  SNORD93 non-coding RNA 0.52 8.28E-07 1.17E-04 1.17E-04
135  SNORA32 non-coding RNA 0.76 1.01E-06 1.41E-04 1.41E-04
136  SNORD107 non-coding RNA 0.78 1.20E-06 1.66E-04 1.66E-04
137  SNORD114-26 non-coding RNA 0.88 1.35E-06 1.86E-04 1.86E-04
138  SNORD79 non-coding RNA 0.67 1.48E-06 2.03E-04 2.03E-04
139  HIST1H4E coding RNA 1.29 1.81E-06 2.46E-04 2.46E-04
140  SNORD52 non-coding RNA 0.92 1.86E-06 2.52E-04 2.52E-04
141  SNORD115-35 non-coding RNA 0.89 1.94E-06 2.61E-04 2.61E-04
142  SNORA38B non-coding RNA 1.32 2.88E-06 3.84E-04 3.84E-04
143  SNORD127 non-coding RNA 0.62 2.94E-06 3.88E-04 3.88E-04
144  SNORA17 non-coding RNA 0.87 3.35E-06 4.40E-04 4.40E-04
145  SNORD75 non-coding RNA 0.74 3.82E-06 4.99E-04 4.99E-04
146  SNORD56 non-coding RNA 0.85 4.21E-06 5.46E-04 5.46E-04
147  SNORD24 non-coding RNA 0.83 4.80E-06 6.17E-04 6.17E-04
148  SNORA68 non-coding RNA 0.75 5.54E-06 7.08E-04 7.08E-04
149  TXNIP coding RNA 1.58 6.01E-06 7.63E-04 7.63E-04
150  SNORD29 non-coding RNA 0.72 6.50E-06 8.20E-04 8.20E-04
151  SNORD17 non-coding RNA 1.24 6.68E-06 8.37E-04 8.37E-04
152  SNORA3 non-coding RNA 0.74 7.43E-06 9.24E-04 9.24E-04
153  SNORA65 non-coding RNA 1.44 9.51E-06 1.18E-03 1.18E-03
154  SCARNA2 non-coding RNA 1.46 9.97E-06 1.23E-03 1.23E-03
155  SNORD114-23 non-coding RNA 0.80 1.24E-05 1.52E-03 1.52E-03
156  SNORD91B non-coding RNA 0.94 1.26E-05 1.52E-03 1.52E-03
157  SCARNA6 non-coding RNA 0.82 1.55E-05 1.87E-03 1.87E-03
158  SNORD115-16 non-coding RNA 1.05 1.69E-05 2.02E-03 2.02E-03
159  SNORD121A non-coding RNA 11.02 1.69E-05 2.02E-03 2.02E-03
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Table A.1 Significantly changed genes in alcoholic brains. 
Among all genes from the RefSeq Genes model, the most significantly changed genes in 
alcoholics found in the MA plot analysis using the DEGseq package (p-value < 0.001). 
Num gene ID type fold change p-value q-value(Benjamini et al. 1995) q-value(Storey et al. 2003)
160  SNORD88C non-coding RNA 1.39 2.09E-05 2.47E-03 2.47E-03
161  AQP1 coding RNA 2.95 2.14E-05 2.51E-03 2.51E-03
162  MT1X coding RNA 3.07 2.25E-05 2.63E-03 2.63E-03
163  SNORD30 non-coding RNA 0.84 2.56E-05 2.97E-03 2.97E-03
164  RNU4ATAC non-coding RNA 0.79 2.99E-05 3.45E-03 3.45E-03
165  SNORA62 non-coding RNA 0.86 3.83E-05 4.39E-03 4.39E-03
166  C7orf41 coding RNA 1.31 5.50E-05 6.27E-03 6.27E-03
167  SNORD114-18 non-coding RNA 4.66 5.87E-05 6.65E-03 6.65E-03
168  RPLP2 coding RNA 1.62 6.01E-05 6.77E-03 6.77E-03
169  VTRNA1-3 non-coding RNA 8.36 6.86E-05 7.68E-03 7.68E-03
170  NAP1L2 coding RNA 0.73 7.14E-05 7.94E-03 7.93E-03
171  SNORA27 non-coding RNA 0.90 7.17E-05 7.93E-03 7.93E-03
172  SNORD4B non-coding RNA 1.65 7.72E-05 8.49E-03 8.49E-03
173  SNORD1B non-coding RNA 18.99 8.27E-05 9.04E-03 9.04E-03
174  MARS2 coding RNA 2.90 1.00E-04 1.09E-02 1.09E-02
175  HBII-52-45 non-coding RNA 6.02 1.06E-04 1.14E-02 1.14E-02
176  SNORD36B non-coding RNA 0.36 1.09E-04 1.18E-02 1.18E-02
177  IFITM3 coding RNA 2.19 1.20E-04 1.28E-02 1.28E-02
178  HBII-52-28 non-coding RNA 0.28 1.41E-04 1.50E-02 1.50E-02
179  SCARNA14 non-coding RNA 0.75 1.51E-04 1.60E-02 1.60E-02
180  FAM107A coding RNA 1.38 1.63E-04 1.72E-02 1.72E-02
181  SNORD115-31 non-coding RNA 0.91 1.66E-04 1.73E-02 1.73E-02
182  SNORD114-20 non-coding RNA 0.65 1.67E-04 1.74E-02 1.74E-02
183  C7orf68 coding RNA 3.26 1.70E-04 1.76E-02 1.76E-02
184  HIST1H2AE coding RNA 0.52 1.86E-04 1.91E-02 1.91E-02
185  SNORA43 non-coding RNA 1.50 2.13E-04 2.17E-02 2.17E-02
186  SNORA61 non-coding RNA 0.64 2.15E-04 2.19E-02 2.19E-02
187  RPS2 coding RNA 1.42 2.18E-04 2.21E-02 2.21E-02
188  SNORD114-13 non-coding RNA 0.53 2.27E-04 2.28E-02 2.28E-02
189  UNC45B coding RNA 0.56 3.09E-04 3.09E-02 3.09E-02
190  SNORD92 non-coding RNA 0.95 3.17E-04 3.16E-02 3.16E-02
191  ACTG1 coding RNA 1.17 3.26E-04 3.23E-02 3.23E-02
192  SPP1 coding RNA 1.51 3.47E-04 3.42E-02 3.42E-02
193  SNORD65 non-coding RNA 0.65 3.63E-04 3.56E-02 3.56E-02
194  ATP5EP2 non-coding RNA 0.64 4.06E-04 3.96E-02 3.96E-02
195  XIST non-coding RNA 3.53 4.58E-04 4.44E-02 4.44E-02
196  MBP coding RNA 1.75 4.84E-04 4.67E-02 4.67E-02
197  NAP1L3 coding RNA 0.79 5.11E-04 4.91E-02 4.91E-02
198  SNORD116-24 non-coding RNA 0.84 5.43E-04 5.18E-02 5.18E-02
199  SNORD21 non-coding RNA 0.90 5.49E-04 5.22E-02 5.22E-02
200  SNORD116-4 non-coding RNA 1.44 6.06E-04 5.73E-02 5.73E-02
201  SNORA21 non-coding RNA 1.11 6.27E-04 5.90E-02 5.90E-02
202  HIST1H4C coding RNA 0.70 6.44E-04 6.03E-02 6.03E-02
203  SNORD18B non-coding RNA 0.43 7.10E-04 6.61E-02 6.61E-02
204  SNORD43 non-coding RNA 0.83 8.08E-04 7.49E-02 7.49E-02
205  SNORD16 non-coding RNA 0.73 8.30E-04 7.66E-02 7.66E-02
206  SNORA44 non-coding RNA 0.85 8.52E-04 7.82E-02 7.81E-02
207  SNORD115-43_dup1 non-coding RNA 0.15 8.67E-04 7.87E-02 7.81E-02
208  SNORD115-36_dup1 non-coding RNA 0.15 8.67E-04 7.87E-02 7.81E-02
209  SNORD115-29_dup1 non-coding RNA 0.15 8.67E-04 7.87E-02 7.81E-02
210  SNORD115-11_dup1 non-coding RNA 0.15 8.67E-04 7.87E-02 7.81E-02
211  HIST1H2BH coding RNA 32.38 9.62E-04 8.63E-02 8.63E-02









Num junction location type fold change p-value q-value(Benjamini et al. 1995) q-value(Storey et al. 2003)
1 chrM:2169-7250 novel 11,849.87      0.00E+00 0.00E+00 0.00E+00
2 chrM:1753-9606 novel 5.73                 0.00E+00 0.00E+00 0.00E+00
3 chrM:2169-2908 novel 0.00                 0.00E+00 0.00E+00 0.00E+00
4 chrM:2169-2324 novel 0.36                 0.00E+00 0.00E+00 0.00E+00
5 chrM:2169-3006 novel 1.83                 0.00E+00 0.00E+00 0.00E+00
6 chrM:2883-2987 novel 7.04                 0.00E+00 0.00E+00 0.00E+00
7 chrM:3042-3284 novel 1.35                 0.00E+00 0.00E+00 0.00E+00
8 chrM:2300-10041 novel 0.80                 0.00E+00 0.00E+00 0.00E+00
9 chrM:3027-3307 novel 0.07                 0.00E+00 0.00E+00 0.00E+00
10 chrM:1717-10770 novel 11.68               0.00E+00 0.00E+00 0.00E+00
11 chrM:2779-3092 novel 0.46                 0.00E+00 0.00E+00 0.00E+00
12 chr11:10480107-10486672 novel 0.37                 0.00E+00 0.00E+00 0.00E+00
13 chrM:2169-5996 novel 0.40                 0.00E+00 0.00E+00 0.00E+00
14 chrM:2024-3000 novel 860.00            0.00E+00 0.00E+00 0.00E+00
15 chrM:2024-6268 novel 224.74            0.00E+00 0.00E+00 0.00E+00
16 chr17:40341044-40343508 known 2.31                 0.00E+00 0.00E+00 0.00E+00
17 chrM:2688-2851 novel 0.35                 0.00E+00 0.00E+00 0.00E+00
18 chrM:2692-2851 novel 5,618.06         0.00E+00 0.00E+00 0.00E+00
19 chrM:1896-7324 novel 0.06                 2.39E-305 1.52E-301 7.67E-302
20 chrM:1753-1932 novel 7.14                 1.17E-283 7.07E-280 3.57E-280
21 chr9:5083804-5084484 novel 3.01                 9.59E-280 5.51E-276 2.78E-276
22 chrM:1717-15939 novel 0.17                 2.03E-269 1.11E-265 5.62E-266
23 chrM:2169-2223 novel 0.14                 2.43E-258 1.28E-254 6.45E-255
24 chrM:2813-2968 novel 0.76                 2.44E-255 1.23E-251 6.21E-252
25 chrM:2169-8925 novel 0.00                 8.43E-251 4.07E-247 2.06E-247
26 chrM:2974-6806 novel 11.55               7.59E-249 3.52E-245 1.78E-245
27 chrM:3072-6899 novel 0.39                 3.75E-247 1.67E-243 8.46E-244
28 chrM:1784-2405 novel 0.00                 1.03E-231 4.45E-228 2.25E-228
29 chrM:2297-3048 novel 0.73                 3.07E-229 1.28E-225 6.45E-226
30 chrM:1717-2987 novel 3.63                 1.96E-225 7.87E-222 3.98E-222
31 chrM:2813-3883 novel 1.26                 4.40E-225 1.71E-221 8.65E-222
32 chrM:2961-3179 novel 0.25                 5.01E-225 1.89E-221 9.54E-222
33 chrM:2904-3006 novel 1.74                 1.39E-223 5.07E-220 2.56E-220
34 chrM:2753-3092 novel 0.42                 1.02E-220 3.61E-217 1.82E-217
35 chr17:21947572-21947942 novel 0.71                 5.34E-212 1.84E-208 9.30E-209
36 chrM:2796-6785 novel 232.30            2.01E-205 6.72E-202 3.40E-202
37 chrM:2169-2242 novel 0.00                 2.36E-202 7.70E-199 3.89E-199
38 chrM:1746-7783 novel 40.93               5.21E-202 1.66E-198 8.36E-199
39 chrM:2796-2849 novel 0.54                 1.85E-197 5.73E-194 2.90E-194
40 chrM:1753-2242 novel 0.36                 1.12E-191 3.38E-188 1.71E-188
41 chrM:2328-6487 novel 0.10                 1.47E-187 4.31E-184 2.18E-184
42 chr8:27517830-27518357 known 1.86                 1.59E-186 4.56E-183 2.30E-183
43 chrM:1717-5327 novel 342.81            1.47E-184 4.12E-181 2.08E-181
44 chrM:2675-2905 novel 29.35               8.99E-182 2.46E-178 1.25E-178
45 chrM:2169-2391 novel 0.74                 4.43E-175 1.19E-171 6.00E-172
46 chrM:1753-12225 novel 0.07                 1.90E-169 4.99E-166 2.52E-166
47 chrM:2800-2922 novel 0.37                 1.91E-165 4.90E-162 2.48E-162
48 chr8:27512070-27513213 known 1.77                 2.41E-165 6.05E-162 3.06E-162
49 chrM:3013-11952 novel 0.50                 8.64E-161 2.13E-157 1.07E-157





Table A.2 Top 100 most significantly changed splicing junctions in alcoholic brains. 
Among all splicing junction found from RNA-seq, the top 100 significantly changed 
junctions in alcoholics found from statistical analysis using the DEGseq package. 
  
Num junction location type fold change p-value q-value(Benjamini et al. 1995) q-value(Storey et al. 2003)
51 chr5:79876547-79981970 novel 0.58                 2.07E-156 4.90E-153 2.48E-153
52 chrM:3013-7230 novel 0.13                 2.46E-155 5.72E-152 2.89E-152
53 chrM:2306-2699 novel 0.00                 3.44E-155 7.82E-152 3.95E-152
54 chrM:1717-9533 novel 0.03                 1.14E-152 2.54E-149 1.28E-149
55 chrM:2328-15005 novel 2.98                 4.37E-152 9.58E-149 4.84E-149
56 chrM:2024-6361 novel 1.29                 7.86E-145 1.69E-141 8.56E-142
57 chr18:72829857-72830899 known 2.73                 5.36E-135 1.13E-131 5.73E-132
58 chrM:2100-2538 novel 0.17                 4.67E-128 9.72E-125 4.91E-125
59 chrM:1717-9365 novel 0.02                 1.10E-126 2.26E-123 1.14E-123
60 chrM:2798-11562 novel 0.00                 1.71E-126 3.44E-123 1.74E-123
61 chrM:721-6739 novel 5.23                 9.59E-125 1.90E-121 9.59E-122
62 chrM:2466-15931 novel 0.35                 9.09E-124 1.77E-120 8.94E-121
63 chrM:2331-14589 novel 1,611.32         1.67E-123 3.19E-120 1.61E-120
64 chrM:1784-7078 novel 7.39                 4.24E-122 7.99E-119 4.04E-119
65 chr2:70777037-70784960 known 2.85                 2.39E-121 4.43E-118 2.24E-118
66 chr11:10486130-10486790 novel 0.00                 1.10E-120 2.01E-117 1.01E-117
67 chrM:2172-15807 novel 0.56                 5.36E-120 9.66E-117 4.88E-117
68 chr17:21947905-21949761 novel 0.33                 1.44E-118 2.55E-115 1.29E-115
69 chrM:743-3520 novel 0.56                 1.92E-118 3.36E-115 1.70E-115
70 chrM:1890-2925 novel 1.94                 2.51E-118 4.33E-115 2.19E-115
71 chrM:1717-2485 novel 5.58                 1.34E-116 2.28E-113 1.15E-113
72 chrM:1925-2607 novel 0.15                 1.79E-115 3.00E-112 1.52E-112
73 chrM:2800-3006 novel 0.00                 1.93E-113 3.19E-110 1.61E-110
74 chrM:2100-5906 novel 1,428.42         1.07E-112 1.75E-109 8.85E-110
75 chrM:1842-2068 novel 1,414.85         7.04E-112 1.13E-108 5.73E-109
76 chrM:2058-2538 novel 0.71                 2.10E-110 3.34E-107 1.69E-107
77 chrM:2267-9349 novel 0.24                 5.84E-107 9.15E-104 4.62E-104
78 chrM:2100-4408 novel 0.67                 5.26E-106 8.14E-103 4.11E-103
79 chrM:1881-2450 novel 0.21                 4.04E-100 6.18E-97 3.12E-97
80 chr10:57029251-57030307 novel 5.15                 2.59E-98 3.90E-95 1.97E-95
81 chrM:1968-7063 novel 1,136.58         1.29E-94 1.91E-91 9.67E-92
82 chrM:1753-2063 novel 0.01                 8.92E-94 1.31E-90 6.63E-91
83 chrM:1784-8951 novel 0.00                 9.17E-93 1.33E-89 6.74E-90
84 chrM:1896-3077 novel 0.36                 1.56E-91 2.24E-88 1.13E-88
85 chrM:2169-2316 novel 1.11                 3.39E-90 4.81E-87 2.43E-87
86 chrM:1717-2626 novel 17.33               4.40E-90 6.17E-87 3.12E-87
87 chrM:2480-6133 novel 0.49                 6.89E-88 9.55E-85 4.83E-85
88 chrM:2024-7075 novel 1,025.39         2.08E-87 2.85E-84 1.44E-84
89 chrM:2779-2977 novel 0.05                 2.82E-87 3.82E-84 1.93E-84
90 chrM:1862-6275 novel 0.00                 3.25E-87 4.35E-84 2.20E-84
91 chrM:1759-3079 novel 980.84            1.84E-84 2.44E-81 1.23E-81
92 chrM:2297-2476 novel 2.91                 7.15E-84 9.38E-81 4.74E-81
93 chrM:2675-3092 novel 0.22                 3.96E-83 5.14E-80 2.60E-80
94 chrM:2904-3765 novel 1.23                 1.39E-81 1.78E-78 9.01E-79
95 chr11:2373327-2373674 known 2.29                 3.33E-80 4.23E-77 2.14E-77
96 chrM:2974-6808 novel 10.69               3.77E-78 4.74E-75 2.40E-75
97 chrM:1753-3158 novel 2.55                 6.11E-78 7.60E-75 3.84E-75
98 chr21:26276662-26294200 known 2.11                 4.98E-77 6.13E-74 3.10E-74
99 chrM:2312-3000 novel 0.00                 4.16E-76 5.06E-73 2.56E-73




Table A.3 Mapped read counts for not changed GABAB1 splicing junctions in 
alcoholics. 
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